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D
iabetes is a chronic illness that re-
quires continuing medical care and
ongoing patient self-management
education and support to prevent acute
complications and to reduce the risk of
long-term complications. Diabetes care is
complex and requires that many issues,
beyondglycemiccontrol,beaddressed.A
large body of evidence exists that sup-
ports a range of interventions to improve
diabetes outcomes.
These standards of care are intended
to provide clinicians, patients, research-
ers, payors, and other interested individ-
uals with the components of diabetes
care, general treatment goals, and tools to
evaluate the quality of care. While indi-
vidual preferences, comorbidities, and
other patient factors may require modiﬁ-
cation of goals, targets that are desirable
for most patients with diabetes are pro-
vided. These standards are not intended
to preclude clinical judgment or more ex-
tensiveevaluationandmanagementofthe
patient by other specialists as needed.
For more detailed information about
management of diabetes, refer to refer-
ences 1–3.
The recommendations included are
screening, diagnostic, and therapeutic ac-
tions that are known or believed to favor-
ably affect health outcomes of patients
withdiabetes.Agradingsystem(Table1),
developed by the American Diabetes As-
sociation (ADA) and modeled after exist-
ing methods, was utilized to clarify and
codify the evidence that forms the basis
for the recommendations. The level of ev-
idence that supports each recommenda-
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using the letters A, B, C, or E.
These standards of care are revised
annually by the ADA’s multidisciplinary
Professional Practice Committee, incor-
porating new evidence. Members of the
ProfessionalPracticeCommitteeandtheir
disclosed conﬂicts of interest are listed on
page S97. Subsequently, as with all Posi-
tion Statements, the standards of care are
reviewed and approved by the Executive
Committee of ADA’s Board of Directors.
I. CLASSIFICATION AND
DIAGNOSIS OF DIABETES
A. Classiﬁcation of diabetes
The classiﬁcation of diabetes includes
four clinical classes:
● Type 1 diabetes (results from -cell de-
struction, usually leading to absolute
insulin deﬁciency)
● Type2diabetes(resultsfromaprogres-
sive insulin secretory defect on the
background of insulin resistance)
● Other speciﬁc types of diabetes due to
other causes, e.g., genetic defects in
-cell function, genetic defects in insu-
lin action, diseases of the exocrine pan-
creas(suchascysticﬁbrosis),anddrug-
or chemical-induced (such as in the
treatment of HIV/AIDS or after organ
transplantation)
● Gestational diabetes mellitus (GDM)
(diabetes diagnosed during pregnancy
that is not clearly overt diabetes)
Some patients cannot be clearly classiﬁed
as having type 1 or type 2 diabetes. Clin-
ical presentation and disease progression
vary considerably in both types of diabe-
tes. Occasionally, patients who otherwise
havetype2diabetesmaypresentwithke-
toacidosis. Similarly, patients with type 1
diabetes may have a late onset and slow
(but relentless) progression of disease de-
spite having features of autoimmune dis-
ease. Such difﬁculties in diagnosis may
occur in children, adolescents, and
adults. The true diagnosis may become
more obvious over time.
B. Diagnosis of diabetes
Fordecades,thediagnosisofdiabeteswas
based on plasma glucose criteria, either
the fasting plasma glucose (FPG) or the
2-h value in the 75-g oral glucose toler-
ance test (OGTT) (4).
In 2009, an International Expert
Committee that included representatives
of the ADA, the International Diabetes
Federation (IDF), and the European As-
sociation for the Study of Diabetes
(EASD) recommended the use of the A1C
testtodiagnosediabetes,withathreshold
of 6.5% (5), and ADA adopted this cri-
terion in 2010 (4). The diagnostic test
should be performed using a method that
is certiﬁed by the National Glycohemo-
globin Standardization Program (NGSP)
and standardized or traceable to the Dia-
betes Control and Complications Trial
(DCCT) reference assay. Point-of-care
A1C assays are not sufﬁciently accurate at
this time to use for diagnostic purposes.
Epidemiologic datasets show a simi-
lar relationship between A1C and risk of
retinopathy as has been shown for the
corresponding FPG and 2-h plasma glu-
cose thresholds. The A1C has several ad-
vantagestotheFPGandOGTT,including
greater convenience, since fasting is not
required; evidence to suggest greater pre-
analytical stability; and less day-to-day
perturbationsduringperiodsofstressand
illness. These advantages must be bal-
anced by greater cost, the limited avail-
ability of A1C testing in certain regions of
thedevelopingworld,andtheincomplete
correlationbetweenA1Candaverageglu-
cose in certain individuals. In addition,
A1C levels can vary with patients’ ethnic-
ity (6) as well as with certain anemias and
hemoglobinopathies.Forpatientswithan
abnormalhemoglobinbutnormalredcell
turnover, such as sickle cell trait, an A1C
assaywithoutinterferencefromabnormal
hemoglobins should be used (an updated
list is available at www.ngsp.org/interf.
asp). For conditions with abnormal red
cell turnover, such as pregnancy, recent
blood loss or transfusion, or some ane-
mias, the diagnosis of diabetes must em-
ploy glucose criteria exclusively.
The established glucose criteria for
the diagnosis of diabetes (FPG and 2-h
PG) remain valid as well (Table 2). Just as
there is less than 100% concordance be-
tween the FPG and 2-h PG tests, there is
not perfect concordance between A1C
and either glucose-based test. Analyses of
National Health and Nutrition Examina-
tionSurvey(NHANES)dataindicatethat,
assuminguniversalscreeningoftheundi-
agnosed, the A1C cut point of 6.5%
identiﬁesone-thirdfewercasesofundiag-
nosed diabetes than a fasting glucose cut
point of 126 mg/dl (7.0 mmol/l) (7).
Table 1—ADA evidence grading system for clinical practice recommendations
Level of
evidence Description
A Clear evidence from well-conducted, generalizable, randomized controlled
trials that are adequately powered, including:
• Evidence from a well-conducted multicenter trial
• Evidence from a meta-analysis that incorporated quality ratings in the
analysis
Compelling nonexperimental evidence, i.e., “all or none” rule developed
by Center for Evidence Based Medicine at Oxford
Supportive evidence from well-conducted randomized controlled trials
that are adequately powered, including:
• Evidence from a well-conducted trial at one or more institutions
• Evidence from a meta-analysis that incorporated quality ratings in the
analysis
B Supportive evidence from well-conducted cohort studies
• Evidence from a well-conducted prospective cohort study or registry
• Evidence from a well-conducted meta-analysis of cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies
• Evidence from randomized clinical trials with one or more major or
three or more minor methodological ﬂaws that could invalidate the
results
• Evidence from observational studies with high potential for bias (such
as case series with comparison to historical controls)
• Evidence from case series or case reports
Conﬂicting evidence with the weight of evidence supporting the
recommendation
E Expert consensus or clinical experience
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the diabetic population remains unaware
of their condition. Thus, the lower sensi-
tivity of A1C at the designated cut point
may well be offset by the test’s greater
practicality, and wider application of a
more convenient test (A1C) may actually
increase the number of diagnoses made.
As with most diagnostic tests, a test
result diagnostic of diabetes should be re-
peated to rule out laboratory error, unless
the diagnosis is clear on clinical grounds,
such as a patient with a hyperglycemic
crisis or classic symptoms of hyperglyce-
mia and a random plasma glucose 200
mg/dl.Itispreferablethatthesametestbe
repeatedforconﬁrmation,sincetherewill
be a greater likelihood of concurrence in
this case. For example, if the A1C is 7.0%
and a repeat result is 6.8%, the diagnosis
of diabetes is conﬁrmed. However, if two
different tests (such as A1C and FPG) are
both above the diagnostic thresholds, the
diagnosis of diabetes is also conﬁrmed.
On the other hand, if two different
testsareavailableinanindividualandthe
results are discordant, the test whose re-
sult is above the diagnostic cut point
should be repeated, and the diagnosis is
made on the basis of the conﬁrmed test.
That is, if a patient meets the diabetes cri-
terionoftheA1C(tworesults6.5%)but
nottheFPG(126mg/dlor7.0mmol/l),
or vice versa, that person should be con-
sidered to have diabetes.
Since there is preanalytic and analytic
variabilityofallthetests,itisalsopossible
that when a test whose result was above
the diagnostic threshold is repeated, the
second value will be below the diagnostic
cut point. This is least likely for A1C,
somewhat more likely for FPG, and most
likely for the 2-h PG. Barring a laboratory
error, such patients are likely to have test
results near the margins of the threshold
for a diagnosis. The healthcare profes-
sional might opt to follow the patient
closely and repeat the testing in 3–6
months.
The current diagnostic criteria for di-
abetes are summarized in Table 2.
C. Categories of increased risk for
diabetes (prediabetes)
In1997and2003,TheExpertCommittee
on Diagnosis and Classiﬁcation of Diabe-
tes Mellitus (8,9) recognized an interme-
diate group of individuals whose glucose
levels, although not meeting criteria for
diabetes, are nevertheless too high to be
considered normal. These persons were
deﬁned as having impaired fasting glu-
cose (IFG) (FPG levels 100–125 mg/dl
[5.6–6.9 mmol/l]) or impaired glucose
tolerance (IGT) (2-h PG values in the
OGTT of 140–199 mg/dl [7.8–11.0
mmol/l]). It should be noted that the
WorldHealthOrganization(WHO)anda
number of other diabetes organizations
deﬁnethecutoffforIFGat110mg/dl(6.1
mmol/l).
IndividualswithIFGand/orIGThave
beenreferredtoashavingprediabetes,in-
dicating the relatively high risk for the fu-
ture development of diabetes. IFG and
IGT should not be viewed as clinical en-
tities in their own right but rather risk
factors for diabetes as well as cardiovas-
cular disease (CVD). IFG and IGT are as-
sociated with obesity (especially
abdominal or visceral obesity), dyslipide-
mia with high triglycerides and/or low
HDL cholesterol, and hypertension.
As is the case with the glucose mea-
sures, several prospective studies that
used A1C to predict the progression to
diabetes demonstrated a strong, continu-
ous association between A1C and subse-
quent diabetes. In a systematic review of
44,203 individuals from 16 cohort stud-
ieswithafollow-upintervalaveraging5.6
years (range 2.8–12 years), those with an
A1C between 5.5 and 6.0% had a sub-
stantially increased risk of diabetes with
5-year incidences ranging from 9–25%.
An A1C range of 6.0–6.5% had a 5-year
risk of developing diabetes between 25–
50% and relative risk 20 times higher
compared with an A1C of 5.0% (10). In a
community-based study of black and
white adults without diabetes, baseline
A1C was a stronger predictor of subse-
quent diabetes and cardiovascular events
than fasting glucose (11). Other analyses
suggest that an A1C of 5.7% is associated
with diabetes risk similar to that of the
high-riskparticipantsintheDiabetesPre-
vention Program (DPP).
Hence, it is reasonable to consider an
A1C range of 5.7–6.4% as identifying in-
dividuals with high risk for future diabe-
tes, a state that may be referred to as
prediabetes (4). As is the case for individ-
uals found to have IFG and IGT, individ-
uals with an A1C of 5.7–6.4% should be
informedoftheirincreasedriskfordiabe-
tes as well as CVD and counseled about
effectivestrategiestolowertheirrisks(see
IV. PREVENTION/DELAY OF TYPE 2 DIABETES). As
with glucose measurements, the contin-
uum of risk is curvilinear—as A1C rises,
the risk of diabetes rises disproportion-
ately (10). Accordingly, interventions
should be most intensive and follow-up
particularly vigilant for those with A1Cs
above6.0%,whoshouldbeconsideredto
be at very high risk.
Table 3 summarizes the categories of
increased risk for diabetes.
II. TESTING FOR DIABETES
IN ASYMPTOMATIC
PATIENTS
Recommendations
● Testing to detect type 2 diabetes and
assessriskforfuturediabetesinasymp-
tomaticpeopleshouldbeconsideredin
adultsofanyagewhoareoverweightor
obese (BMI 25 kg/m
2) and who have
one or more additional risk factors for
diabetes (Table 4). In those without
these risk factors, testing should begin
at age 45 years. (B)
● If tests are normal, repeat testing car-
ried out at least at 3-year intervals is
reasonable. (E)
Table 2—Criteria for the diagnosis of
diabetes
A1C 6.5%. The test should be performed
in a laboratory using a method that is
NGSP certiﬁed and standardized to the
DCCT assay.*
or
FPG 126 mg/dl (7.0 mmol/l). Fasting is
deﬁned as no caloric intake for at least
8 h.*
or
2-h plasma glucose 200 mg/dl (11.1
mmol/l) during an OGTT. The test should
be performed as described by the World
Health Organization, using a glucose load
containing the equivalent of 75 g
anhydrous glucose dissolved in water.*
or
In a patient with classic symptoms of
hyperglycemia or hyperglycemic crisis, a
random plasma glucose 200 mg/dl (11.1
mmol/l)
*In the absence of unequivocal hyperglycemia, re-
sult should be conﬁrmed by repeat testing.
Table 3—Categories of increased risk for di-
abetes (prediabetes)*
FPG 100–125 mg/dl (5.6–6.9 mmol/l): IFG
or
2-h plasma glucose in the 75-g OGTT 140–
199 mg/dl (7.8–11.0 mmol/l): IGT
or
A1C 5.7–6.4%
*For all three tests, risk is continuous, extending
below the lower limit of the range and becoming
disproportionately greater at higher ends of the
range.
Position Statement
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future diabetes, A1C, FPG, or 2-h 75-g
OGTT is appropriate. (B)
● In those identiﬁed with increased risk
for future diabetes, identify and, if ap-
propriate, treat other CVD risk factors.
(B)
For many illnesses, there is a major dis-
tinction between screening and diagnos-
tic testing. However, for diabetes, the
same tests would be used for “screening”
as for diagnosis. Diabetes may be identi-
ﬁedanywherealongaspectrumofclinical
scenarios ranging from a seemingly low-
risk individual who happens to have glu-
cose testing, to a higher-risk individual
whom the provider tests because of high
suspicion of diabetes, to the symptomatic
patient. The discussion herein is primar-
ily framed as testing for diabetes in those
without symptoms. Testing for diabetes
will also detect individuals at increased
future risk for diabetes, herein referred to
as having prediabetes.
A. Testing for type 2 diabetes and
risk of future diabetes in adults
Type 2 diabetes is frequently not diag-
nosed until complications appear, and
approximately one-fourth of all people
with diabetes in the U.S. may be undiag-
nosed. The effectiveness of early identiﬁ-
cation of prediabetes and diabetes
through mass testing of asymptomatic in-
dividuals has not been proven deﬁni-
tively, and rigorous trials to provide such
proof are unlikely to occur. However,
mathematical modeling studies suggest
that screening independent of risk factors
beginning at age 30 or 45 years is highly
cost-effective ($11,000 per quality-
adjusted life-year gained) (12). Prediabe-
tes and diabetes meet established criteria
for conditions in which early detection is
appropriate. Both conditions are com-
monandincreasinginprevalenceandim-
pose signiﬁcant public health burdens.
There is a long presymptomatic phase be-
fore the diagnosis of type 2 diabetes is
usually made. Relatively simple tests are
available to detect preclinical disease. Ad-
ditionally, the duration of glycemic bur-
den is a strong predictor of adverse
outcomes, and effective interventions ex-
ist to prevent progression of prediabetes
todiabetes(see IV. PREVENTION/DELAY OF TYPE
2 DIABETES) and to reduce risk of compli-
cations of diabetes (see VI. PREVENTION AND
MANAGEMENT OF DIABETES COMPLICATIONS).
Recommendations for testing for dia-
betes in asymptomatic, undiagnosed
adultsarelistedinTable4.Testingshould
be considered in adults of any age with
BMI 25 kg/m
2 and one or more of the
known risk factors for diabetes. Because
ageisamajorriskfactorfordiabetes,test-
ing of those without other risk factors
should begin no later than age 45 years.
Either A1C, FPG, or the 2-h OGTT is
appropriate for testing. The 2-h OGTT
identiﬁes people with either IFG or IGT
andthusmorepeopleatincreasedriskfor
the development of diabetes and CVD. It
should be noted that the two tests do not
necessarily detect the same individuals.
The efﬁcacy of interventions for primary
prevention of type 2 diabetes (13–19)
haveprimarilybeendemonstratedamong
individuals with IGT, not for individuals
with IFG (who do not also have IGT) or
for individuals with speciﬁc A1C levels.
The appropriate interval between
tests is not known (20). The rationale for
the 3-year interval is that false negatives
will be repeated before substantial time
elapses, and there is little likelihood that
an individual will develop signiﬁcant
complications of diabetes within 3 years
of a negative test result. In the modeling
study, repeat screening every 3 or 5 years
was cost-effective (12).
Becauseoftheneedforfollow-upand
discussion of abnormal results, testing
should be carried out within the health
care setting. Community screening out-
side a health care setting is not recom-
mended because people with positive
tests may not seek, or have access to, ap-
propriate follow-up testing and care.
Conversely,theremaybefailuretoensure
appropriate repeat testing for individuals
who test negative. Community screening
may also be poorly targeted, i.e., it may
fail to reach the groups most at risk and
inappropriately test those at low risk (the
worried well) or even those already diag-
nosed.
B. Testing for type 2 diabetes in
children
The incidence of type 2 diabetes in ado-
lescents has increased dramatically in the
last decade, especially in minority popu-
lations (21), although the disease remains
rare in the general pediatric population
(22). Consistent with recommendations
for adults, children and youth at in-
creased risk for the presence or the devel-
opment of type 2 diabetes should be
tested within the health care setting. The
recommendations of the ADA Consensus
StatementonType2DiabetesinChildren
andYouth(23),withsomemodiﬁcations,
are summarized in Table 5.
C. Screening for type 1 diabetes
Generally, people with type 1 diabetes
present with acute symptoms of diabetes
and markedly elevated blood glucose lev-
els, and most cases are diagnosed soon
after the onset of hyperglycemia. How-
ever,evidencefromtype1preventionstud-
ies suggests that measurement of islet
autoantibodies identiﬁes individuals who
are at risk for developing type 1 diabetes.
Such testing may be appropriate in high-
risk individuals, such as those with prior
transient hyperglycemia or those who have
relativeswithtype1diabetes,inthecontext
of clinical research studies (see, for ex-
ample, http://www2.diabetestrialnet.org).
Widespreadclinicaltestingofasymptom-
atic low-risk individuals cannot currently
be recommended, as it would identify
very few individuals in the general popu-
lation who are at risk. Individuals who
screen positive should be counseled
about their risk of developing diabetes.
Clinical studies are being conducted to
Table 4—Criteria for testing for diabetes in
asymptomatic adult individuals
1. Testing should be considered in all adults
who are overweight (BMI 25 kg/m
2*)
and have additional risk factors:
• physical inactivity
• ﬁrst-degree relative with diabetes
• high-risk race/ethnicity (e.g., African
American, Latino, Native American,
Asian American, Paciﬁc Islander)
• women who delivered a baby weighing
9 lb or were diagnosed with GDM
• hypertension (140/90 mmHg or on
therapy for hypertension)
• HDL cholesterol level 35 mg/dl (0.90
mmol/l) and/or a triglyceride level 250
mg/dl (2.82 mmol/l)
• women with polycystic ovarian
syndrome (PCOS)
• A1C 5.7%, IGT, or IFG on previous
testing
• other clinical conditions associated with
insulin resistance (e.g., severe obesity,
acanthosis nigricans)
• history of CVD
2. In the absence of the above criteria, testing
for diabetes should begin at age 45
years.
3. If results are normal, testing should be
repeated at least at 3-year intervals, with
consideration of more frequent testing
depending on initial results and risk
status.
*At-risk BMI may be lower in some ethnic groups.
Standards of Medical Care
S14 DIABETES CARE, VOLUME 34, SUPPLEMENT 1, JANUARY 2011 care.diabetesjournals.orgtest various methods of preventing type 1
diabetes, or reversing early type 1 diabe-
tes, in those with evidence of autoimmu-
nity.
III. DETECTION AND
DIAGNOSIS OF
GESTATIONAL DIABETES
MELLITUS
Recommendations
● Screen for undiagnosed type 2 diabetes
at the ﬁrst prenatal visit in those with
risk factors, using standard diagnostic
criteria. (B)
● In pregnant women not known to have
diabetes, screen for GDM at 24–28
weeks of gestation, using a 75-g 2-h
OGTT and the diagnostic cut points in
Table 6. (B)
● ScreenwomenwithGDMforpersistent
diabetes 6–12 weeks postpartum. (E)
● Women with a history of GDM should
have lifelong screening for the develop-
ment of diabetes or prediabetes at least
every 3 years. (E)
For many years, GDM was deﬁned as any
degree of glucose intolerance with onset
or ﬁrst recognition during pregnancy (8),
whether or not the condition persisted af-
terpregnancy,andnotexcludingthepos-
sibility that unrecognized glucose
intolerance may have antedated or begun
concomitantly with the pregnancy. This
deﬁnition facilitated a uniform strategy
for detection and classiﬁcation of GDM,
but its limitations were recognized for
many years. As the ongoing epidemic of
obesity and diabetes has led to more type
2 diabetes in women of childbearing age,
the number of pregnant women with un-
diagnosed type 2 diabetes has increased
(24). Because of this, it is reasonable to
screen women with risk factors for type 2
diabetes(Table4)fordiabetesattheirini-
tialprenatalvisit,usingstandarddiagnos-
tic criteria (Table 2). Women with
diabetes found at this visit should receive
a diagnosis of overt, not gestational, dia-
betes.
GDM carries risks for the mother and
neonate.TheHyperglycemiaandAdverse
PregnancyOutcomes(HAPO)study(25),
a large-scale (25,000 pregnant women)
multinational epidemiologic study, dem-
onstrated that risk of adverse maternal,
fetal, and neonatal outcomes continu-
ously increased as a function of maternal
glycemia at 24–28 weeks, even within
ranges previously considered normal for
pregnancy.Formostcomplications,there
was no threshold for risk. These results
have led to careful reconsideration of the
diagnostic criteria for GDM. After delib-
erations in 2008–2009, the International
Association of Diabetes and Pregnancy
Study Groups (IADPSG), an international
consensus group with representatives
from multiple obstetrical and diabetes or-
ganizations, including ADA, developed
revised recommendations for diagnosing
GDM. The group recommended that all
women not known to have diabetes un-
dergo a 75-g OGTT at 24–28 weeks of
gestation. Additionally, the group devel-
oped diagnostic cut points for the fasting,
1-h, and 2-h plasma glucose measure-
ments that conveyed an odds ratio for ad-
verse outcomes of at least 1.75 compared
withthemeanglucoselevelsintheHAPO
study. Current screening and diagnostic
strategies, based on the IADPSG state-
ment (26), are outlined in Table 6.
These new criteria will signiﬁcantly
increase the prevalence of GDM, primar-
ily because only one abnormal value, not
two, is sufﬁcient to make the diagnosis.
The ADA recognizes the anticipated sig-
niﬁcant increase in the incidence of GDM
to be diagnosed by these criteria and is
sensitive to concerns about the “medical-
ization”ofpregnanciespreviouslycatego-
rized as normal. These diagnostic criteria
changes are being made in the context of
worrisome worldwide increases in obe-
sity and diabetes rates, with the intent of
optimizing gestational outcomes for
women and their babies.
Admittedly, there are few data from
randomized clinical trials regarding ther-
apeutic interventions in women who will
now be diagnosed with GDM based on
only one blood glucose value above the
speciﬁed cut points (in contrast to the
older criteria that stipulated at least two
abnormal values.) Expected beneﬁts to
theirpregnanciesandoffspringisinferred
from intervention trials that focused on
women with more mild hyperglycemia
thanidentiﬁedusingolderGDMdiagnos-
ticcriteriaandthatfoundmodestbeneﬁts
(27,28). The frequency of their follow-up
and blood glucose monitoring is not yet
clear, but likely to be less intensive than
women diagnosed by the older criteria.
Additional well-designed clinical studies
are needed to determine the optimal in-
tensity of monitoring and treatment of
women with GDM diagnosed by the new
criteria(thatwouldnothavemettheprior
deﬁnitionofGDM).Itisimportanttonote
that 80–90% of women in both of the
mild GDM studies (whose glucose values
overlapped with the thresholds recom-
mended herein) could be managed with
lifestyle therapy alone.
Because some cases of GDM may rep-
resent preexisting undiagnosed type 2 di-
abetes, women with a history of GDM
should be screened for diabetes 6–12
weeks postpartum, using nonpregnant
OGTT criteria. Women with a history of
GDMhaveagreatlyincreasedsubsequent
risk for diabetes (29) and should be fol-
lowed up with subsequent screening for
the development of diabetes or prediabe-
tes, as outlined in II. TESTING FOR DIABETES IN
ASYMPTOMATIC PATIENTS.
Table 6—Screening for and diagnosis of
GDM
Perform a 75-g OGTT, with plasma glucose
measurement fasting and at 1 and 2 h,
at 24–28 weeks of gestation in women
not previously diagnosed with overt
diabetes.
The OGTT should be performed in the
morning after an overnight fast of at
least 8 h.
The diagnosis of GDM is made when any of
the following plasma glucose values are
exceeded:
• Fasting 92 mg/dl (5.1 mmol/l)
• 1h180 mg/dl (10.0 mmol/l)
• 2h153 mg/dl (8.5 mmol/l)
Table 5—Testing for type 2 diabetes in
asymptomatic children
Criteria
• Overweight (BMI 85th percentile for
age and sex, weight for height 85th
percentile, or weight 120% of ideal for
height)
Plus any two of the following risk factors:
• Family history of type 2 diabetes in ﬁrst-
or second-degree relative
• Race/ethnicity (Native American, African
American, Latino, Asian American,
Paciﬁc Islander)
• Signs of insulin resistance or conditions
associated with insulin resistance
(acanthosis nigricans, hypertension,
dyslipidemia, PCOS, or small-for-
gestational-age birth weight)
• Maternal history of diabetes or GDM
during the child’s gestation
Age of initiation: age 10 years or at onset of
puberty, if puberty occurs at a younger
age
Frequency: every 3 years
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OF TYPE 2 DIABETES
Recommendations
● Patients with IGT (A), IFG (E), or an
A1C of 5.7–6.4% (E) should be re-
ferred to an effective ongoing support
program targeting weight loss of 7% of
body weight and increasing physical
activity to at least 150 min/week of
moderate activity such as walking.
● Follow-upcounselingappearstobeim-
portant for success. (B)
● Based on potential cost savings of diabe-
tes prevention, such programs should be
covered by third-party payors. (E)
● Metformin therapy for prevention of
type 2 diabetes may be considered in
those at the highest risk for developing
diabetes, such as those with multiple
risk factors, especially if they demon-
strate progression of hyperglycemia
(e.g., A1C 6%) despite lifestyle inter-
ventions. (B)
● Monitoring for the development of di-
abetes in those with prediabetes should
be performed every year. (E)
Randomized controlled trials have shown
that individuals at high risk for develop-
ing diabetes (those with IFG, IGT, or
both) can be given interventions that sig-
niﬁcantly decrease the rate of onset of di-
abetes (13–19). These interventions
include intensive lifestyle modiﬁcation
programsthathavebeenshowntobevery
effective (58% reduction after 3 years)
and use of the pharmacologic agents met-
formin, -glucosidase inhibitors, orlistat,
and thiazolidinediones (TZDs), each of
which has been shown to decrease inci-
dent diabetes to various degrees. A sum-
maryofmajordiabetespreventiontrialsis
shown in Table 7.
Follow-up of all three large studies of
lifestyleinterventionhasshownsustained
reductionintherateofconversiontotype
2 diabetes, with 43% reduction at 20
years in the Da Qing study (30), 43% re-
duction at 7 years in the Finnish Diabetes
Prevention Study (DPS) (31) and 34% re-
duction at 10 years in the U.S. Diabetes
Prevention Program Outcomes Study
(DPPOS) (32). A cost-effectiveness analy-
sissuggestedthatlifestyleinterventionsas
delivered in the DPP are cost-effective
(33). Group delivery of the DPP interven-
tionincommunitysettingshasthepoten-
tialtobesigniﬁcantlylessexpensivewhile
still achieving similar weight loss (34).
Based on the results of clinical trials
and the known risks of progression of
prediabetes to diabetes, persons with an
A1C of 5.7–6.4%, IGT, or IFG should be
counseled on lifestyle changes with goals
similar to those of the DPP (7% weight
loss and moderate physical activity of at
least 150 min/week). Regarding the more
difﬁcult issue of drug therapy for diabetes
prevention, a consensus panel felt that
metformin should be the only drug con-
sidered(39).Forotherdrugs,theissuesof
cost, side effects, and lack of persistence
of effect in some studies led the panel to
notrecommendtheirusefordiabetespre-
vention. Metformin, which was signiﬁ-
cantly less effective than lifestyle in the
DPP and DPPOS, reasonably may be rec-
ommended for very-high-risk individuals
(thosewithriskfactorsfordiabetesand/or
those with more severe or progressive hy-
perglycemia). Of note, in the DPP met-
formin was most effective compared to
lifestyle in those with BMI of at least 35
kg/m
2 and was not signiﬁcantly better
than placebo in those over age 60 years.
V. DIABETES CARE
A. Initial evaluation
A complete medical evaluation should be
performed to classify the diabetes, detect
the presence of diabetes complications,
review previous treatment and glycemic
controlinpatientswithestablisheddiabe-
tes, assist in formulating a management
plan, and provide a basis for continuing
care. Laboratory tests appropriate to the
evaluation of each patient’s medical con-
Table 7—Therapies proven effective in diabetes prevention trials
Study (ref.) n Population
Mean
age
(years)
Duration
(years)
Intervention
(daily dose)
Incidence in
control
subjects
(%/year)
Relative risk
reduction (%)
(95% CI)
3-Year
number
needed to
treat
Lifestyle
Finnish DPS (14) 522 IGT, BMI 25 kg/m
2 55 3.2 I-D&E 6 58 (30–70) 8.5
DPP (13) 2,161* IGT, BMI 24 kg/m
2,
FPG 5.3 mmol/l
51 3 I-D&E 10.4 58 (48–66) 6.9
Da Qing (15) 259* IGT (randomized groups) 45 6 G-D&E 14.5 38 (14–56) 7.9
Toranomon Study
(35)
458 IGT (men), BMI  24
kg/m
2
55 4 I-D&E 2.4 67 (P  0.043)† 20.6
Indian DPP (19) 269* IGT 46 2.5 I-D&E 23 29 (21–37) 6.4
Medications
DPP (13) 2,155* IGT, BMI 24 kg/m
2,
FPG 5.3 mmol/l
51 2.8 Metformin (1,700
mg)
10.4 31 (17–43) 13.9
Indian DPP (19) 269* IGT 46 2.5 Metformin (500 mg) 23 26 (19–35) 6.9
STOP-NIDDM (17) 1,419 IGT, FPG 5.6 mmol/l 54 3.2 Acarbose (300 mg) 12.4 25 (10–37) 9.6
XENDOS (36) 3,277 BMI 30 kg/m
2 43 4 Orlistat (360 mg) 2.4 37 (14–54) 45.5
DREAM (18) 5,269 IGT or IFG 55 3.0 Rosiglitazone (8 mg) 9.1 60 (54–65) 6.9
Voglibose Ph-3
(37)
1,780 IGT 56 3.0 (1-year
Rx)
Vogliobose (0.2 mg) 12.0 40 (18–57) 21 (1-year
Rx)
Modiﬁed and reprinted with permission (38). Percentage points: Number needed to treat to prevent 1 case of diabetes, standardized for a 3-year period to improve
comparisonsacrossstudies.*Numberofparticipantsintheindicatedcomparisons,notnecessarilyinentirestudy.†Calculatedfrominformationinthearticle.DPP,Diabetes
Prevention Program; DPS, Diabetes Prevention Study; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; STOP-NIDDM, Study to
Prevent Non-Insulin Dependent Diabetes; XENDOS, Xenical in the prevention of Diabetes in Obese Subjects. I, individual; G, group; D&E, diet and exercise.
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the components of comprehensive care
(Table8)willassistthehealthcareteamto
ensure optimal management of the pa-
tient with diabetes.
B. Management
People with diabetes should receive med-
ical care from a physician-coordinated
team. Such teams may include, but are
notlimitedto,physicians,nursepractitio-
ners, physician’s assistants, nurses, dieti-
tians, pharmacists, and mental health
professionals with expertise and a special
interest in diabetes. It is essential in this
collaborative and integrated team ap-
proach that individuals with diabetes as-
sume an active role in their care.
The management plan should be
formulated as a collaborative therapeu-
tic alliance among the patient and fam-
ily,thephysician,andothermembersof
the health care team. A variety of strat-
egies and techniques should be used to
provide adequate education and devel-
opment of problem-solving skills in the
various aspects of diabetes manage-
ment. Implementation of the manage-
ment plan requires that each aspect is
understood and agreed to by the patient
andthecareprovidersandthatthegoals
and treatment plan are reasonable. Any
plan should recognize diabetes self-
management education (DSME) and
ongoing diabetes support as an integral
component of care. In developing the
plan, consideration should be given to
the patient’s age, school or work sched-
ule and conditions, physical activity,
eating patterns, social situation and
cultural factors, and presence of com-
plications of diabetes or other medical
conditions.
C. Glycemic control
1. Assessment of glycemic control
Two primary techniques are available for
healthprovidersandpatientstoassessthe
effectiveness of the management plan on
glycemic control: patient self-monitoring
of blood glucose (SMBG) or interstitial
glucose, and A1C.
a. Glucose monitoring
Recommendations
● SMBG should be carried out three or
moretimesdailyforpatientsusingmul-
tiple insulin injections or insulin pump
therapy. (A)
● For patients using less-frequent insulin
injections, noninsulin therapies, or
medical nutrition therapy (MNT)
alone,SMBGmaybeusefulasaguideto
the success of therapy. (E)
● To achieve postprandial glucose tar-
gets,postprandialSMBGmaybeappro-
priate. (E)
● When prescribing SMBG, ensure that
patients receive initial instruction in,
and routine follow-up evaluation of,
SMBGtechniqueandtheirabilitytouse
data to adjust therapy. (E)
● Continuousglucosemonitoring(CGM)
in conjunction with intensive insulin
regimens can be a useful tool to lower
A1C in selected adults (age 25 years)
with type 1 diabetes. (A)
● Although the evidence for A1C-
lowering is less strong in children,
teens, and younger adults, CGM may
be helpful in these groups. Success cor-
relates with adherence to ongoing use
of the device. (C)
● CGM may be a supplemental tool to
SMBG in those with hypoglycemia un-
awareness and/or frequent hypoglyce-
mic episodes. (E)
Table 8—Components of the comprehensive diabetes evaluation
Medical history
• Age and characteristics of onset of diabetes (e.g., DKA, asymptomatic laboratory ﬁnding)
• Eating patterns, physical activity habits, nutritional status, and weight history; growth
and development in children and adolescents
• Diabetes education history
• Review of previous treatment regimens and response to therapy (A1C records)
• Current treatment of diabetes, including medications, meal plan, physical activity
patterns, and results of glucose monitoring and patient’s use of data
• DKA frequency, severity, and cause
• Hypoglycemic episodes
• Hypoglycemia awareness
• Any severe hypoglycemia: frequency and cause
• History of diabetes-related complications
• Microvascular: retinopathy, nephropathy, neuropathy (sensory, including history of
foot lesions; autonomic, including sexual dysfunction and gastroparesis)
• Macrovascular: CHD, cerebrovascular disease, PAD
• Other: psychosocial problems*, dental disease*
Physical examination
• Height, weight, BMI
• Blood pressure determination, including orthostatic measurements when indicated
• Fundoscopic examination*
• Thyroid palpation
• Skin examination (for acanthosis nigricans and insulin injection sites)
• Comprehensive foot examination:
• Inspection
• Palpation of dorsalis pedis and posterior tibial pulses
• Presence/absence of patellar and Achilles reﬂexes
• Determination of proprioception, vibration, and monoﬁlament sensation
Laboratory evaluation
• A1C, if results not available within past 2–3 months
• If not performed/available within past year:
• Fasting lipid proﬁle, including total, LDL and HDL cholesterol and triglycerides
• Liver function tests
• Test for urine albumin excretion with spot urine albumin-to-creatinine ratio
• Serum creatinine and calculated GFR
• Thyroid-stimulating hormone in type 1 diabetes, dyslipidemia, or women over age 50
years
Referrals
• Annual dilated eye exam
• Family planning for women of reproductive age
• Registered dietitian for MNT
• DSME
• Dental examination
• Mental health professional, if needed
*See appropriate referrals for these categories.
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tients that demonstrated the beneﬁts of
intensive glycemic control on diabetes
complications have included SMBG as
part of multifactorial interventions, sug-
gesting that SMBG is a component of ef-
fective therapy. SMBG allows patients to
evaluatetheirindividualresponsetother-
apy and assess whether glycemic targets
are being achieved. Results of SMBG can
beusefulinpreventinghypoglycemiaand
adjusting medications (particularly pran-
dialinsulindoses),MNT,andphysicalac-
tivity.
The frequency and timing of SMBG
shouldbedictatedbytheparticularneeds
and goals of the patient. SMBG is espe-
cially important for patients treated with
insulintomonitorforandpreventasymp-
tomatic hypoglycemia and hyperglyce-
mia. For most patients with type 1
diabetes and pregnant women taking in-
sulin, SMBG is recommended three or
more times daily. For these populations,
signiﬁcantlymorefrequenttestingmaybe
required to reach A1C targets safely with-
outhypoglycemia.Theoptimalfrequency
andtimingofSMBGforpatientswithtype
2 diabetes on noninsulin therapy is un-
clear. A meta-analysis of SMBG in non–
insulin-treated patients with type 2
diabetes concluded that some regimen of
SMBG was associated with a reduction in
A1Cof0.4%.However,manyofthestud-
ies in this analysis also included patient
education with diet and exercise counsel-
ingand,insomecases,pharmacologicin-
tervention,makingitdifﬁculttoassessthe
contribution of SMBG alone to improved
control (40). Several recent trials have
calledintoquestiontheclinicalutilityand
cost-effectiveness of routine SMBG in
non–insulin-treated patients (41–43).
Because the accuracy of SMBG is in-
strument and user dependent (44), it is
important to evaluate each patient’s mon-
itoring technique, both initially and at
regular intervals thereafter. In addition,
optimal use of SMBG requires proper in-
terpretation of the data. Patients should
be taught how to use the data to adjust
food intake, exercise, or pharmacological
therapytoachievespeciﬁcglycemicgoals,
and these skills should be reevaluated pe-
riodically.
CGMthroughthemeasurementofin-
terstitial glucose (which correlates well
with plasma glucose) is available. These
sensors require calibration with SMBG,
and the latter are still recommended for
making acute treatment decisions. CGM
devices also have alarms for hypo- and
hyperglycemic excursions. Small studies
in selected patients with type 1 diabetes
have suggested that CGM use reduces the
time spent in hypo- and hyperglycemic
ranges and may modestly improve glyce-
mic control. A larger 26-week random-
ized trial of 322 type 1 patients showed
that adults age 25 years and older using
intensive insulin therapy and CGM expe-
rienced a 0.5% reduction in A1C (from
7.6% to 7.1%) compared to usual in-
tensive insulin therapy with SMBG (45).
Sensor use in children, teens, and adults
up to age 24 years did not result in signif-
icant A1C lowering, and there was no sig-
niﬁcantdifferenceinhypoglycemiainany
group.Importantly,thegreatestpredictor
of A1C-lowering in this study for all age-
groups was frequency of sensor use,
which was lower in younger age-groups.
Inasmallerrandomizedcontrolledtrialof
129 adults and children with baseline
A1C 7.0%, outcomes combining A1C
and hypoglycemia favored the group uti-
lizing CGM, suggesting that CGM is also
beneﬁcial for individuals with type 1 dia-
beteswhohavealreadyachievedexcellent
control with A1C 7.0 (46). Although
CGMisanevolvingtechnology,emerging
data suggest that, in appropriately se-
lected patients who are motivated to wear
it most of the time, it may offer beneﬁt.
CGM may be particularly useful in those
with hypoglycemia unawareness and/or
frequent episodes of hypoglycemia, and
studies in this area are ongoing.
b. A1C
Recommendations
● Perform the A1C test at least two times
ayearinpatientswhoaremeetingtreat-
ment goals (and who have stable glyce-
mic control). (E)
● Perform the A1C test quarterly in pa-
tients whose therapy has changed or
whoarenotmeetingglycemicgoals.(E)
● Use of point-of-care testing for A1C al-
lows for timely decisions on therapy
changes, when needed. (E)
Because A1C is thought to reﬂect average
glycemia over several months (44), and
has strong predictive value for diabetes
complications (47,48), A1C testing
should be performed routinely in all pa-
tients with diabetes, at initial assessment
and then as part of continuing care. Mea-
surement approximately every 3 months
determines whether a patient’s glycemic
targets have been reached and main-
tained.Foranyindividualpatient,thefre-
quency of A1C testing should be
dependent on the clinical situation, the
treatment regimen used, and the judg-
ment of the clinician. Some patients with
stable glycemia well within target may do
well with testing only twice per year,
while unstable or highly intensively man-
aged patients (e.g., pregnant type 1
women) may be tested more frequently
than every 3 months. The availability of
the A1C result at the time that the patient
isseen(point-of-caretesting)hasbeenre-
ported to result in increased intensiﬁca-
tion of therapy and improvement in
glycemic control (49,50).
The A1C test is subject to certain lim-
itations. Conditions that affect erythro-
cyte turnover (hemolysis, blood loss) and
hemoglobin variants must be considered,
particularlywhentheA1Cresultdoesnot
correlate with the patient’s clinical situa-
tion (44). In addition, A1C does not pro-
vide a measure of glycemic variability or
hypoglycemia. For patients prone to gly-
cemic variability (especially type 1 pa-
tients, or type 2 patients with severe
insulin deﬁciency), glycemic control is
best judged by the combination of results
of SMBG testing and the A1C. The A1C
may also serve as a check on the accuracy
of the patient’s meter (or the patient’s re-
portedSMBGresults)andtheadequacyof
the SMBG testing schedule.
Table 9 contains the correlation be-
tween A1C levels and mean plasma glu-
cose levels based on data from the
international A1C-Derived Average Glu-
cose (ADAG) trial utilizing frequent
SMBGandCGMin507adults(83%Cau-
casian) with type 1, type 2, and no diabe-
Table 9—Correlation of A1C with average
glucose
A1C (%)
Mean plasma glucose
mg/dl mmol/l
6 126 7.0
7 154 8.6
8 183 10.2
9 212 11.8
10 240 13.4
11 269 14.9
12 298 16.5
These estimates are based on ADAG data of 2,700
glucosemeasurementsover3monthsperA1Cmea-
surement in 507 adults with type 1, type 2, and no
diabetes. The correlation between A1C and average
glucose was 0.92 (51). A calculator for converting
A1Cresultsintoestimatedaverageglucose(eAG),in
either mg/dl or mmol/l, is available at http://
professional.diabetes.org/eAG.
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Association and American Association of
Clinical Chemists have determined that
the correlation (r  0.92) is strong
enough to justify reporting both an A1C
result and an estimated average glucose
(eAG) result when a clinician orders the
A1Ctest.Thetableinpreviousversionsof
the Standards of Medical Care in Diabetes
describing the correlation between A1C
and mean glucose was derived from rela-
tively sparse data (one 7-point proﬁle
over 1 day per A1C reading) in the pri-
marily Caucasian type 1 diabetic partici-
pants in the DCCT (52). Clinicians
should note that the numbers in the table
are now different, as they are based on
2,800 readings per A1C in the ADAG
trial.
In the ADAG trial, there were no sig-
niﬁcant differences among racial and eth-
nicgroupsintheregressionlinesbetween
A1C and mean glucose, although there
was a trend toward a difference between
African/African American participants
and Caucasian ones that might have been
signiﬁcant had more African/African
Americanparticipantsbeenstudied.Are-
cent study comparing A1C with CGM
data in 48 type 1 diabetic children found
a highly statistically signiﬁcant correla-
tion between A1C and mean blood glu-
cose, although the correlation (r  0.7)
was signiﬁcantly lower than in the ADAG
trial (53). Whether there are signiﬁcant
differences in how A1C relates to average
glucose in children or in African Ameri-
can patients is an area for further study.
For the time being, the question has not
led to different recommendations about
testing A1C or to different interpretations
of the clinical meaning of given levels of
A1C in those populations.
For patients in whom A1C/eAG and
measured blood glucose appear discrep-
ant, clinicians should consider the possi-
bilities of hemoglobinopathy or altered
redcellturnover,andtheoptionsofmore
frequent and/or different timing of SMBG
oruseofCGM.Othermeasuresofchronic
glycemia such as fructosamine are avail-
able, but their linkage to average glucose
and their prognostic signiﬁcance are not
as clear as is the case for A1C.
2. Glycemic goals in adults
Recommendations
● Lowering A1C to below or around 7%
has been shown to reduce microvascu-
lar and neuropathic complications of
diabetesand,ifimplementedsoonafter
the diagnosis of diabetes, is associated
with long-term reduction in macrovas-
cular disease. Therefore, a reasonable
A1C goal for many nonpregnant adults
is 7%. (B)
● Because additional analyses from sev-
eral randomized trials suggest a small
but incremental beneﬁt in microvascu-
lar outcomes with A1C values closer to
normal, providers might reasonably
suggest more stringent A1C goals for
selected individual patients, if this can
be achieved without signiﬁcant hypo-
glycemia or other adverse effects of
treatment. Such patients might include
those with short duration of diabetes,
long life expectancy, and no signiﬁcant
CVD. (B)
● Conversely, less stringent A1C goals
may be appropriate for patients with a
history of severe hypoglycemia, limited
life expectancy, advanced microvascu-
larormacrovascularcomplications,ex-
tensivecomorbidconditions,andthose
with longstanding diabetes in whom
the general goal is difﬁcult to attain de-
spite DSME, appropriate glucose mon-
itoring, and effective doses of multiple
glucose-lowering agents including in-
sulin. (C)
Glycemic control is fundamental to the
management of diabetes. The DCCT (47)
(in patients with type 1 diabetes), the Ku-
mamoto study (54), and the UK Prospec-
tive Diabetes Study (UKPDS) (55,56)
(both in patients with type 2 diabetes)
wereprospective,randomized,controlled
trials of intensive versus standard glyce-
mic control in patients with relatively re-
cently diagnosed diabetes. These trials
showed deﬁnitively that improved glyce-
mic control is associated with signiﬁ-
cantly decreased rates of microvascular
(retinopathy and nephropathy) and neu-
ropathic complications. Follow up of the
DCCT cohorts in the Epidemiology of Di-
abetes Interventions and Complications
(EDIC) study (57,58) and of the UKPDS
cohort (59) has shown persistence of
thesemicrovascularbeneﬁtsinpreviously
intensively treated subjects, even though
their glycemic control has been equiva-
lent to that of previous standard arm sub-
jects during follow-up.
Subsequent trials in patients with
more long-standing type 2 diabetes, de-
signed primarily to look at the role of
intensive glycemic control on cardiovas-
cular outcomes also conﬁrmed a beneﬁt,
although more modest, on onset or pro-
gression of microvascular complications.
The Veterans Affairs Diabetes Trial
(VADT) showed signiﬁcant reductions in
albuminuriawithintensive(achievedme-
dian A1C 6.9%) compared to standard
glycemic control, but no difference in ret-
inopathy and neuropathy (60,61). The
Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modiﬁed Release
ControlledEvaluation(ADVANCE)study
of intensive versus standard glycemic
control in type 2 diabetes found a statis-
tically signiﬁcant reduction in albumin-
uria with an A1C target of 6.5%
(achieved median A1C 6.3%) compared
to standard therapy achieving a median
A1C of 7.0% (62). Recent analyses from
theActiontoControlCardiovascularRisk
in Diabetes (ACCORD) trial have shown
lower rates of measures of microvascular
complications in the intensive glycemic
control arm compared with the standard
arm (63,64).
Epidemiological analyses of the
DCCTandUKPDS(47,48)demonstratea
curvilinearrelationshipbetweenA1Cand
microvascular complications. Such anal-
yses suggest that, on a population level,
the greatest number of complications will
be averted by taking patients from very
poorcontroltofairorgoodcontrol.These
analysesalsosuggestthatfurtherlowering
of A1C from 7 to 6% is associated with
further reduction in the risk of microvas-
cular complications, albeit the absolute
risk reductions become much smaller.
Given the substantially increased risk of
hypoglycemia (particularly in those with
type1diabetes,butalsointherecenttype
2 trials), the concerning mortality ﬁnd-
ings in the ACCORD trial (65), and the
relatively much greater effort required to
achieve near-normoglycemia, the risks of
lower targets may outweigh the potential
beneﬁts on microvascular complications
on a population level. However, selected
individual patients, especially those with
little comorbidity and long life expect-
ancy (who may reap the beneﬁts of fur-
therloweringofglycemiabelow7%)may,
at patient and provider judgment, adopt
glycemictargetsasclosetonormalaspos-
sible as long as signiﬁcant hypoglycemia
does not become a barrier.
Whereas many epidemiologic studies
and meta-analyses (66,67) have clearly
shown a direct relationship between A1C
andCVD,thepotentialofintensiveglyce-
mic control to reduce CVD has been less
clearly deﬁned. In the DCCT, there was a
trend toward lower risk of CVD events
with intensive control. However, 9-year
post-DCCT follow-up of the cohort has
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domized to the intensive arm had a 42%
reduction (P  0.02) in CVD outcomes
and a 57% reduction (P  0.02) in the
risk of nonfatal myocardial infarction
(MI), stroke, or CVD death compared
with those previously in the standard arm
(68). The beneﬁt of intensive glycemic
control in this type 1 cohort has recently
been shown to persist for several decades
(69).
The UKPDS trial of type 2 diabetes
observeda16%reductionincardiovascu-
larcomplications(combinedfatalornon-
fatal MI and sudden death) in the
intensive glycemic control arm, although
this difference was not statistically signif-
icant (P  0.052), and there was no sug-
gestionofbeneﬁtonotherCVDoutcomes
such as stroke. However, 10 years of fol-
low-up of the UKPDS cohort demon-
strated, for participants originally
randomized to intensive glycemic control
compared with those randomized to con-
ventional glycemic control, long-term re-
ductions in MI (15% with sulfonylurea or
insulin as initial pharmacotherapy, 33%
with metformin as initial pharmacother-
apy, both statistically signiﬁcant) and in
all-cause mortality (13 and 27%, respec-
tively, both statistically signiﬁcant) (59).
Results of three large trials
(ACCORD, ADVANCE, and VADT) sug-
gested no signiﬁcant reduction in CVD
outcomeswithintensiveglycemiccontrol
in these populations, who had more ad-
vanced diabetes than UKPDS partici-
pants. Details of these three studies are
reviewed extensively in a recent ADA po-
sition statement (70).
The glycemic control arm of
ACCORD was halted early due to the
ﬁndingofanincreasedrateofmortalityin
theintensivearmcomparedwiththestan-
dard arm (1.41% vs. 1.14% per year; HR
1.22 [95% CI 1.01 to 1.46]); with a sim-
ilarincreaseincardiovasculardeaths.The
primary outcome of ACCORD (MI,
stroke, or cardiovascular death) was
lower in the intensive glycemic control
group, due to a reduction in nonfatal MI,
butthisreductionwasnotstatisticallysig-
niﬁcant when the study was terminated
(65).
The potential cause of excess deaths
in the intensive group of the ACCORD
has been difﬁcult to pinpoint. Explor-
atory analyses of the mortality ﬁndings of
ACCORD (evaluating variables including
weight gain, use of any speciﬁc drug or
drug combination, and hypoglycemia)
were reportedly unable to identify a clear
explanationfortheexcessmortalityinthe
intensive arm. The ACCORD investiga-
tors subsequently published additional
analyses showing no increase in mortality
in the intensive arm participants who
achievedA1Clevels7%orinthosewho
lowered their A1C quickly after trial en-
rollment. In fact, the converse was ob-
served—thoseathighestriskformortality
were participants in the intensive arm
with the highest A1C levels (71).
The primary outcome of ADVANCE
was a combination of microvascular
events (nephropathy and retinopathy)
and major adverse cardiovascular events
(MI, stroke, and cardiovascular death).
Intensive glycemic control signiﬁcantly
reduced the primary end point, although
this was due to a signiﬁcant reduction in
the microvascular outcome, primarily de-
velopment of macroalbuminuria, with no
signiﬁcant reduction in the macrovascu-
lar outcome. There was no difference in
overall or cardiovascular mortality be-
tween the intensive compared with the
standard glycemic control arms (62).
The VADT randomized participants
with type 2 diabetes uncontrolled on in-
sulin or maximal dose oral agents (me-
dian entry A1C 9.4%) to a strategy of
intensive glycemic control (goal A1C
6.0%) or standard glycemic control,
with a planned A1C separation of at least
1.5%. The primary outcome of the VADT
was a composite of CVD events. The cu-
mulative primary outcome was nonsig-
niﬁcantly lower in the intensive arm (60).
UnliketheUKPDS,whichwascarried
out in patients with newly diagnosed di-
abetes, all three of the recent type 2 car-
diovascular trials were conducted in
participants with established diabetes
(mean duration 8–11 years) and either
known CVD or multiple risk factors, sug-
gesting the presence of established ath-
erosclerosis. Subset analyses of the three
trials suggested a signiﬁcant beneﬁt of in-
tensive glycemic control on CVD in par-
ticipants with shorter duration of
diabetes, lower A1C at entry, and/or or
absenceofknownCVD.TheDCCT-EDIC
study and the long-term follow-up of the
UKPDScohortbothsuggestthatintensive
glycemic control initiated soon after diag-
nosis of diabetes in patients with a lower
level of CVD risk may impart long-term
protection from CVD events. As is the
case with microvascular complications, it
may be that glycemic control plays a
greater role before macrovascular disease
is well developed and minimal or no role
when it is advanced. Consistent with this
concept, data from an ancillary study of
the VADT demonstrated that intensive
glycemic control was quite effective in re-
ducing CVD events in individuals with
less atherosclerosis at baseline (assessed
by coronary calcium) but not in persons
with more extensive baseline atheroscle-
rosis (72).
The evidence for a cardiovascular
beneﬁt of intensive glycemic control pri-
marily rests on long-term follow-up of
study cohorts treated early in the course
of type 1 and type 2 diabetes and subset
analyses of ACCORD, ADVANCE, and
VADT. A recent group-level meta-
analysis of the latter three trials suggests
that glucose lowering has a modest (9%)
but statistically signiﬁcant reduction in
major CVD outcomes, primarily nonfatal
MI,withnosigniﬁcanteffectonmortality.
A prespeciﬁed subgroup analysis sug-
gested that major CVD outcome reduc-
tion occurred in patients without known
CVD at baseline (HR 0.84 [95% CI 0.74–
0.94]) (73). Conversely, the mortality
ﬁndings in ACCORD and subgroup anal-
yses of VADT suggest that the potential
risks of very intensive glycemic control
may outweigh its beneﬁts in some pa-
tients, such as those with very long dura-
tion of diabetes, known history of severe
hypoglycemia, advanced atherosclerosis,
and advanced age/frailty. Certainly, pro-
vidersshouldbevigilantinpreventingse-
vere hypoglycemia in patients with
advanced disease and should not aggres-
sively attempt to achieve near-normal
A1C levels in patients in whom such a
target cannot be reasonably easily and
safely achieved.
Recommended glycemic goals for
many nonpregnant adults are shown in
Table 10. The recommendations are
basedonthoseforA1Cvalues,withlisted
blood glucose levels that appear to corre-
late with achievement of an A1C of 7%.
Less-stringent treatment goals may be ap-
propriate for adults with limited life ex-
pectancies or advanced vascular disease.
Glycemic goals for children are provided
in VII.A.1.a. Glycemic control. Severe or
frequent hypoglycemia is an absolute in-
dication for the modiﬁcation of treatment
regimens, including setting higher glyce-
mic goals.
The issue of pre- versus postprandial
SMBG targets is complex (74). Elevated
postchallenge (2-h OGTT) glucose values
have been associated with increased car-
diovascular risk independent of FPG in
some epidemiological studies. In diabetic
subjects, some surrogate measures of vas-
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function, are negatively affected by
postprandial hyperglycemia (75). It is
clear that postprandial hyperglycemia,
like preprandial hyperglycemia, contrib-
utes to elevated A1C levels, with its rela-
tive contribution being higher at A1C
levelsthatarecloserto7%.However,out-
come studies have clearly shown A1C to
be the primary predictor of complica-
tions, and landmark glycemic control tri-
als such as the DCCT and UKPDS relied
overwhelmingly on preprandial SMBG.
Additionally, a randomized controlled
trial in patients with known CVD found
no CVD beneﬁt of insulin regimens tar-
geting postprandial glucose compared
withtargetingpreprandialglucose(76).A
reasonable recommendation for post-
prandial testing and targets is that for in-
dividuals who have premeal glucose
values within target but have A1C values
above target, monitoring postprandial
plasmaglucose(PPG)1–2hafterthestart
ofthemealandtreatmentaimedatreduc-
ing PPG values to 180 mg/dl may help
lower A1C.
As regards goals for glycemic control
for women with GDM, recommendations
from the Fifth International Workshop-
Conference on Gestational Diabetes (77)
were to target maternal capillary glucose
concentrations of:
• Preprandial 95 mg/dl (5.3 mmol/l)
and either
• 1-h postmeal 140 mg/dl (7.8
mmol/l)
or
• 2-h postmeal 120 mg/dl (6.7
mmol/l)
For women with preexisting type 1 or
type 2 diabetes who become pregnant, a
recent consensus statement (78) recom-
mended the following as optimal glyce-
mic goals, if they can be achieved without
excessive hypoglycemia:
● premeal, bedtime, and overnight glu-
cose 60–99 mg/dl (3.3–5.4 mmol/l)
● peak postprandial glucose 100–129
mg/dl (5.4–7.1mmol/l)
● A1C 6.0%
D. Pharmacologic and overall
approaches to treatment
1. Therapy for type 1 diabetes
The DCCT clearly showed that intensive
insulin therapy (three or more injections
per day of insulin, or continuous subcu-
taneous insulin infusion (CSII) (insulin
pump therapy) was a key part of im-
proved glycemia and better outcomes
(47,68). At the time of the study, therapy
was carried out with short- and interme-
diate-acting human insulins. Despite bet-
ter microvascular outcomes, intensive
insulintherapywasassociatedwithahigh
rate in severe hypoglycemia (62 episodes
per 100 patient-years of therapy). Since
the time of the DCCT, a number of rapid-
acting and long-acting insulin analogs
have been developed. These analogs are
associated with less hypoglycemia with
equal A1C-lowering in type 1 diabetes
(79,80).
Therefore, recommended therapy for
type 1 diabetes consists of the following
components: 1) use of multiple dose in-
sulin injections (three to four injections
per day of basal and prandial insulin) or
CSII therapy; 2) matching of prandial in-
sulin to carbohydrate intake, premeal
blood glucose, and anticipated activity;
and 3) for many patients (especially if hy-
poglycemia is a problem), use of insulin
analogs.Thereareexcellentreviewsavail-
able that guide the initiation and manage-
mentofinsulintherapytoachievedesired
glycemic goals (3,79,81).
Because of the increased frequency of
other autoimmune diseases in type 1 dia-
betes, screening for thyroid dysfunction,
vitamin B12 deﬁciency, or celiac disease
should be considered based on signs and
symptoms. Periodic screening in absence
ofsymptomshasbeenrecommended,but
the effectiveness and optimal frequency
are unclear.
2. Therapy for type 2 diabetes
The ADA and the EASD published an ex-
pertconsensusstatementontheapproach
to management of hyperglycemia in indi-
viduals with type 2 diabetes (82). High-
lightsofthisapproachare:interventionat
the time of diagnosis with metformin in
combination with lifestyle changes (MNT
and exercise) and continuing timely aug-
mentation of therapy with additional
agents (including early initiation of insu-
lin therapy) as a means of achieving and
maintaining recommended levels of gly-
cemic control (i.e., A1C 7% for most
patients).AsA1Ctargetsarenotachieved,
treatment intensiﬁcation is based on the
addition of another agent from a different
class. The overall objective is to achieve
and maintain glycemic control and to
change interventions when therapeutic
goals are not being met.
The algorithm took into account the
evidenceforA1C-loweringoftheindivid-
ual interventions, their additive effects,
andtheirexpense.Theprecisedrugsused
and their exact sequence may not be as
important as achieving and maintaining
glycemic targets safely. Medications not
included in the consensus algorithm, ow-
ing to less glucose-lowering effectiveness,
limited clinical data, and/or relative ex-
pense, still may be appropriate choices in
individual patients to achieve glycemic
goals.Initiationofinsulinattimeofdiagno-
sisisrecommendedforindividualspresent-
ing with weight loss or other severe
hyperglycemic symptoms or signs.
Table 10—Summary of glycemic recommendations for many nonpregnant adults with
diabetes
A1C 7.0%*
Preprandial capillary plasma glucose 70–130 mg/dl* (3.9–7.2 mmol/l)
Peak postprandial capillary plasma glucose† 180 mg/dl* (10.0 mmol/l)
• Goals should be individualized based on*:
• duration of diabetes
• age/life expectancy
• comorbid conditions
• known CVD or advanced microvascular
complications
• hypoglycemia unawareness
• individual patient considerations
• More or less stringent glycemic goals may
be appropriate for individual patients.
• Postprandial glucose may be targeted if
A1C goals are not met despite reaching
preprandial glucose goals.
Postprandial glucose measurements should be made 1–2 h after the beginning of the meal, generally peak
levels in patients with diabetes.
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Recommendations
● People with diabetes should receive di-
abetes self-management education
(DSME) according to national stan-
dards when their diabetes is diagnosed
and as needed thereafter. (B)
● Effective self-management and quality
of life are the key outcomes of DSME
and should be measured and moni-
tored as part of care. (C)
● DSME should address psychosocial is-
sues, since emotional well-being is as-
sociated with positive diabetes
outcomes. (C)
● Because DSME can result in cost-
savings and improved outcomes (B),
DSME should be adequately reim-
bursed by third-party payors. (E)
DSME is an essential element of diabetes
care (83–88), and national standards for
DSME (89) are based on evidence for its
beneﬁts. Education helps people with di-
abetes initiate effective self-management
andcopewithdiabeteswhentheyareﬁrst
diagnosed. Ongoing DSME and support
also help people with diabetes maintain
effective self-management throughout a
lifetime of diabetes as they face new chal-
lenges and treatment advances become
available. DSME helps patients optimize
metabolic control, prevent and manage
complications, and maximize quality of
life in a cost-effective manner (90).
DSME is the ongoing process of facil-
itating the knowledge, skill, and ability
necessary for diabetes self-care. This pro-
cessincorporatestheneeds,goals,andlife
experiences of the person with diabetes.
TheoverallobjectivesofDSMEaretosup-
port informed decision-making, self-care
behaviors, problem-solving, and active
collaboration with the health care team to
improve clinical outcomes, health status,
and quality of life in a cost-effective man-
ner (89).
Current best practice of DSME is a
skills-based approach that focuses on
helping those with diabetes to make in-
formed self-management choices. DSME
has changed from a didactic approach fo-
cusing on providing information to more
theoreticallybasedempowermentmodels
that focus on helping those with diabetes
make informed self-management deci-
sions. Care of diabetes has shifted to an
approach that is more patient centered
and places the person with diabetes and
his or her family at the center of the care
model working in collaboration with
health care professionals. Patient-
centered care is respectful of and respon-
sive to individual patient preferences,
needs,andvaluesandensuresthatpatient
values guide all decision making (91).
Evidence for the beneﬁts of DSME
Multiple studies have found that DSME is
associated with improved diabetes
knowledgeandimprovedself-carebehav-
ior(83),improvedclinicaloutcomessuch
as lower A1C (84,85,87,88,92), lower
self-reportedweight(83),improvedqual-
ity of life (86,93), healthy coping (94),
and lower costs (95). Better outcomes
were reported for DSME interventions
that were longer and included follow-up
support (83,96–99), that were culturally
(100,101) and age appropriate (102,103)
and tailored to individual needs and pref-
erences, and that addressed psychosocial
issues and incorporated behavioral strat-
egies (83,87,104–106). Both individual
and group approaches have been found
effective (107–110). There is growing ev-
idence for the role of community health
workers and peer (111,112) and lay lead-
ers(113)indeliveringDSMEandsupport
in addition to the core team (114).
Diabetes education is associated with
increased use of primary and preventive
services and lower use of acute, inpatient
hospital services (95). Patients who par-
ticipate in diabetes education are more
likely to follow best practice treatment
recommendations, particularly among
the Medicare population, and have lower
Medicare and commercial claim costs
(115).
National standards for DSME
National standards for DSME are de-
signed to deﬁne quality DSME and to as-
sist diabetes educators in a variety of
settingstoprovideevidence-basededuca-
tion (89). The standards, most recently
revised in 2007, are reviewed and up-
dated every 5 years by a task force repre-
senting key organizations involved in the
ﬁeld of diabetes education and care.
Reimbursement for DSME
DSME, when provided by a program that
meets the national standards for DSME and
is recognized by the ADA or other approval
bodies,isreimbursedaspartoftheMedicare
programasoverseenbytheCentersforMedi-
care and Medicaid Services (CMS) (www.
cms.hhs.gov/DiabetesSelfManagement).
DSMEisalsocoveredbyagrowingnumber
of other health insurance plans.
F. Medical nutrition therapy
General recommendations
● Individualswhohaveprediabetesordi-
abetes should receive individualized
medical nutrition therapy (MNT) as
neededtoachievetreatmentgoals,pref-
erablyprovidedbyaregistereddietitian
familiar with the components of diabe-
tes MNT. (A)
● Because MNT can result in cost-savings
and improved outcomes (B), MNT
should be adequately covered by insur-
ance and other payors. (E)
Energy balance, overweight, and
obesity
● In overweight and obese insulin-
resistant individuals, modest weight
loss has been shown to reduce insulin
resistance. Thus, weight loss is recom-
mended for all overweight or obese in-
dividuals who have or are at risk for
diabetes. (A)
● Forweightloss,eitherlow-carbohydrate,
low-fat calorie-restricted, or Mediterra-
nean diets may be effective in the short-
term (up to 2 years). (A)
● Forpatientsonlow-carbohydratediets,
monitor lipid proﬁles, renal function,
and protein intake (in those with ne-
phropathy), and adjust hypoglycemic
therapy as needed. (E)
● Physical activity and behavior modiﬁ-
cation are important components of
weight loss programs and are most
helpful in maintenance of weight loss.
(B)
Recommendations for primary
prevention of diabetes
● Amongindividualsathighriskforde-
veloping type 2 diabetes, structured
programs that emphasize lifestyle
changesthatincludemoderateweight
loss (7% body weight) and regular
physical activity (150 min/week),
with dietary strategies including re-
duced calories and reduced intake of
dietary fat, can reduce the risk for de-
veloping diabetes and are therefore
recommended. (A)
● Individuals at high risk for type 2 dia-
betes should be encouraged to achieve
the U.S. Department of Agriculture
(USDA) recommendation for dietary ﬁ-
ber (14 g ﬁber/1,000 kcal) and foods
containing whole grains (one-half of
grain intake). (B)
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Macronutrients in diabetes
management
● The best mix of carbohydrate, protein,
and fat may be adjusted to meet the
metabolic goals and individual prefer-
ences of the person with diabetes. (E)
● Monitoring carbohydrate, whether by
carbohydrate counting, choices, or ex-
perience-based estimation, remains a
key strategy in achieving glycemic con-
trol. (A)
● Forindividualswithdiabetes,theuseof
the glycemic index and glycemic load
may provide a modest additional bene-
ﬁt for glycemic control over that ob-
served when total carbohydrate is
considered alone. (B)
● Saturated fat intake should be 7% of
total calories. (A)
● Reducing intake of trans fat lowers LDL
cholesterol and increases HDL choles-
terol (A), therefore intake of trans fat
should be minimized. (E)
Other nutrition recommendations
● If adults with diabetes choose to use
alcohol, daily intake should be limited
to a moderate amount (one drink per
day or less for adult women and two
drinks per day or less for adult men).
(E)
● Routine supplementation with antioxi-
dants, such as vitamins E and C and
carotene, is not advised because of lack
of evidence of efﬁcacy and concern re-
lated to long-term safety. (A)
● Individualized meal planning should
include optimization of food choices to
meet recommended dietary allowance
(RDA)/dietary reference intake (DRI)
for all micronutrients. (E)
MNTisanintegralcomponentofdiabetes
prevention, management, and self-
management education. In addition to its
role in preventing and controlling diabe-
tes, ADA recognizes the importance of
nutrition as an essential component of an
overall healthy lifestyle. A full review of
the evidence regarding nutrition in pre-
venting and controlling diabetes and its
complications and additional nutrition-
relatedrecommendationscanbefoundin
the ADA position statement, “Nutrition
Recommendations and Interventions for
Diabetes,” published in 2007 and up-
dated for 2008 (116). Achieving nutri-
tion-related goals requires a coordinated
team effort that includes the active in-
volvement of the person with prediabetes
or diabetes. Because of the complexity of
nutrition issues, it is recommended that a
registered dietitian who is knowledgeable
and skilled in implementing nutrition
therapy into diabetes management and
education be the team member who pro-
vides MNT.
Clinical trials/outcome studies of
MNT have reported decreases in A1C at
3–6 months ranging from 0.25% to 2.9%
with higher reductions seen in type 2 di-
abetes of shorter duration. Multiple stud-
ies have demonstrated sustained
improvements in A1C at 12 months and
longer when an Registered Dietitian pro-
vided follow-up visits ranging from
monthly to three sessions per year (117–
124). Studies in nondiabetic people sug-
gestthatMNTreducesLDLcholesterolby
15–25 mg/dl up to 16% (125) and sup-
port a role for lifestyle modiﬁcation in
treating hypertension (125,126).
Because of the effects of obesity on
insulin resistance, weight loss is an im-
portant therapeutic objective for over-
weight or obese individuals with
prediabetes or diabetes (127). Short-term
studies have demonstrated that moderate
weight loss (5% of body weight) in sub-
jects with type 2 diabetes is associated
with decreased insulin resistance, im-
provedmeasuresofglycemiaandlipemia,
and reduced blood pressure (128); long-
er-termstudies(52weeks)showedmixed
effects on A1C in adults with type 2 dia-
betes (129–131), and in some studies re-
sults were confounded by pharmacologic
weight loss therapy. A systematic review
of 80 weight loss studies of 1 year in
duration demonstrated that moderate
weight loss achieved through diet alone,
diet and exercise, and meal replacements
canbeachievedandmaintained(4.8–8%
weightlossat12months)(132).Themul-
tifactorial intensive lifestyle intervention
employed in the DPP, which included re-
duced intake of fat and calories, led to
weightlossaveraging7%at6monthsand
maintenance of 5% weight loss at 3 years,
associated with a 58% reduction in inci-
dence of type 2 diabetes (13). A recent
randomized controlled trial looking at
high-riskindividualsinSpainshowedthe
Mediterranean dietary pattern reduced
theincidenceofdiabetesintheabsenceof
weight loss by 52% compared to the low-
fat control group (133). Look AHEAD
(Action for Health in Diabetes) is a large
clinical trial designed to determine
whether long-term weight loss will im-
prove glycemia and prevent cardiovascu-
lareventsinsubjectswithtype2diabetes.
One-year results of the intensive lifestyle
intervention in this trial show an average
8.6% weight loss, signiﬁcant reduction of
A1C, and reduction in several CVD risk
factors (134), with beneﬁts sustained at 4
years (135). When completed, the Look
AHEADstudyshouldprovideinsightinto
theeffectsoflong-termweightlossonim-
portant clinical outcomes.
The optimal macronutrient distribu-
tion of weight loss diets has not been es-
tablished. Although low-fat diets have
traditionally been promoted for weight
loss, several randomized controlled trials
found that subjects on low-carbohydrate
diets (130 g/day of carbohydrate) lost
moreweightat6monthsthansubjectson
low-fat diets (136,137); however, at 1
year, the difference in weight loss be-
tween the low-carbohydrate and low-fat
diets was not signiﬁcant, and weight loss
wasmodestwithbothdiets.Astudycom-
paring low-fat to low-carbohydrate diets,
both combined with a comprehensive
lifestyle program, showed the same
amount of weight loss (7%) at 2 years in
bothgroups(138).Anotherstudyofover-
weight women randomized to one of four
diets showed signiﬁcantly more weight
loss at 12 months with the Atkins low-
carbohydrate diet than with higher-
carbohydrate diets (139). Changes in
serum triglyceride and HDL cholesterol
were more favorable with the low-
carbohydrate diets. In one study, those
subjects with type 2 diabetes demon-
strated a greater decrease in A1C with a
low-carbohydrate diet than with a low-fat
diet(137).Arecentmeta-analysisshowed
that at 6 months, low-carbohydrate diets
were associated with greater improve-
mentsintriglycerideandHDLcholesterol
concentrations than low-fat diets; how-
ever, LDL cholesterol was signiﬁcantly
higher on the low-carbohydrate diets
(140). In a 2-year dietary intervention
study, Mediterranean and low-carbohy-
drate diets were found to be effective and
safe alternatives to a low-fat diet for
weight reduction in moderately obese
participants (141).
The RDA for digestible carbohydrate
is 130 g/day and is based on providing
adequate glucose as the required fuel for
the central nervous system without reli-
anceonglucoseproductionfromingested
protein or fat. Although brain fuel needs
can be met on lower-carbohydrate diets,
long term metabolic effects of very-low-
carbohydrate diets are unclear, and such
diets eliminate many foods that are im-
Position Statement
care.diabetesjournals.org DIABETES CARE, VOLUME 34, SUPPLEMENT 1, JANUARY 2011 S23portant sources of energy, ﬁber, vitamins,
and minerals and are important in dietary
palatability (142).
Although numerous studies have at-
tempted to identify the optimal mix of
macronutrients for meal plans of people
with diabetes, it is unlikely that one such
combination of macronutrients exists.
The best mix of carbohydrate, protein,
and fat appears to vary depending on in-
dividual circumstances. It must be clearly
recognized that regardless of the macronu-
trient mix, total caloric intake must be ap-
propriate to weight management goal.
Further, individualization of the macronu-
trient composition will depend on the met-
abolic status of the patient (e.g., lipid
proﬁle, renal function) and/or food prefer-
ences. Plant-based diets (vegan or vegetar-
ian) that are well planned and nutritionally
adequate have also been shown to improve
metabolic control (143,144).
The primary goal with respect to di-
etary fat in individuals with diabetes is to
limit saturated fatty acids, trans fatty acids,
and cholesterol intake so as to reduce risk
for CVD. Saturated and trans fatty acids are
the principal dietary determinants of
plasma LDL cholesterol. There is a lack of
evidenceontheeffectsofspeciﬁcfattyacids
on people with diabetes, so the recom-
mended goals are consistent with those for
individuals with CVD (125,145).
Reimbursement for MNT
MNT,whendeliveredbyaregistereddietitian
according to nutrition practice guidelines, is
reimbursedaspartoftheMedicareprogramas
overseen by the Centers for Medicare and
MedicaidServices(CMS)(www.cms.hhs.gov/
medicalnutritiontherapy).
G. Physical activity
Recommendations
● People with diabetes should be advised
to perform at least 150 min/week of
moderate-intensity aerobic physical ac-
tivity (50–70% of maximum heart
rate). (A)
● In the absence of contraindications,
people with type 2 diabetes should be
encouragedtoperformresistancetrain-
ing three times per week. (A)
Exerciseisanimportantpartofthediabe-
tes management plan. Regular exercise
hasbeenshowntoimprovebloodglucose
control, reduce cardiovascular risk fac-
tors, contribute to weight loss, and im-
prove well-being. Furthermore, regular
exercise may prevent type 2 diabetes in
high-riskindividuals(13–15).Structured
exercise interventions of at least 8 weeks’
duration have been shown to lower A1C
by an average of 0.66% in people with
type 2 diabetes, even with no signiﬁcant
change in BMI (146). Higher levels of ex-
erciseintensityareassociatedwithgreater
improvements in A1C and in ﬁtness
(147). A new joint position statement of
the American Diabetes Association and
the American College of Sports Medicine
summarizes the evidence for the beneﬁts
of exercise in people with type 2 diabetes
(148).
Frequency and type of exercise
The U.S. Department of Health and Hu-
man Services’ Physical Activity Guide-
lines for Americans (149) suggest that
adultsoverage18yearsdo150min/week
of moderate-intensity, or 75 min/week of
vigorous aerobic physical activity, or an
equivalent combination of the two. In ad-
dition, the guidelines suggest that adults
also do muscle-strengthening activities
that involve all major muscle groups two
or more days per week. The guidelines
suggest that adults over age 65 years, or
those with disabilities, follow the adult
guidelines if possible or (if this is not pos-
sible) be as physically active as they are
able. Studies included in the meta-
analysisofeffectsofexerciseinterventions
on glycemic control (146) had a mean
number of sessions per week of 3.4, with
a mean of 49 min/session. The DPP life-
style intervention, which included 150
min/week of moderate intensity exercise,
had a beneﬁcial effect on glycemia in
those with prediabetes. Therefore, it
seemsreasonabletorecommendthatpeo-
plewithdiabetestrytofollowthephysical
activity guidelines for the general popula-
tion.
Progressive resistance exercise im-
proves insulin sensitivity in older men
with type 2 diabetes to the same or even a
greater extent as aerobic exercise (150).
Clinical trials have provided strong evi-
dence for the A1C-lowering value of re-
sistance training in older adults with type
2 diabetes (151,152) and for an additive
beneﬁt of combined aerobic and resis-
tanceexerciseinadultswithtype2diabe-
tes (153).
Evaluation of the diabetic patient
before recommending an exercise
program
Priorguidelinessuggestedthatbeforerec-
ommending a program of physical activ-
ity, the provider should assess patients
with multiple cardiovascular risk factors
for coronary artery disease (CAD). As dis-
cussed more fully in VI.A.5. Coronary
heartdiseasescreeningandtreatment,the
area of screening asymptomatic diabetic
patients for CAD remains unclear, and a
recent ADA consensus statement on this
issue concluded that routine screening is
not recommended (154). Providers
should use clinical judgment in this area.
Certainly,highriskpatientsshouldbeen-
couraged to start with short periods of
low intensity exercise and increase the in-
tensity and duration slowly.
Providers should assess patients for
conditions that might contraindicate cer-
tain types of exercise or predispose to in-
jury, such as uncontrolled hypertension,
severe autonomic neuropathy, severe pe-
ripheral neuropathy or history of foot
lesions, and unstable proliferative reti-
nopathy. The patient’s age and previous
physical activity level should be consid-
ered.
Exercise in the presence of
nonoptimal glycemic control
Hyperglycemia. When people with type
1 diabetes are deprived of insulin for
12–48 h and are ketotic, exercise can
worsen hyperglycemia and ketosis (155);
therefore, vigorous activity should be
avoided in the presence of ketosis. How-
ever, it is not necessary to postpone exer-
cise based simply on hyperglycemia,
provided the patient feels well and urine
and/or blood ketones are negative.
Hypoglycemia. In individuals taking in-
sulin and/or insulin secretagogues, phys-
ical activity can cause hypoglycemia if
medication dose or carbohydrate con-
sumption is not altered. For individuals
on these therapies, added carbohydrate
should be ingested if pre-exercise glucose
levels are 100 mg/dl (5.6 mmol/l). Hy-
poglycemia is rare in diabetic individuals
whoarenottreatedwithinsulinorinsulin
secretagogues, and no preventive mea-
sures for hypoglycemia are usually ad-
vised in these cases.
Exercise in the presence of speciﬁc
long-term complications of diabetes
Retinopathy. In the presence of prolifer-
ativediabeticretinopathy(PDR)orsevere
nonproliferative diabetic retinopathy
(NPDR), vigorous aerobic or resistance
exercise may be contraindicated because
of the risk of triggering vitreous hemor-
rhage or retinal detachment (156).
Peripheral neuropathy. Decreased pain
sensation in the extremities results in in-
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tion and of Charcot joint destruction.
Prior recommendations have advised
non–weight-bearing exercise for patients
with severe peripheral neuropathy. How-
ever, studies have shown that moderate-
intensity walking may not lead to
increased risk of foot ulcers or re-
ulceration in those with peripheral neu-
ropathy (157). All individuals with
peripheral neuropathy should wear
proper footwear and examine their feet
daily to detect lesions early. Anyone with
a foot injury or open sore should be re-
stricted to non–weight-bearing activities.
Autonomicneuropathy. Autonomicneu-
ropathy can increase the risk of exercise-
induced injury or adverse event through
decreased cardiac responsiveness to exer-
cise, postural hypotension, impaired
thermoregulation, impaired night vision
due to impaired papillary reaction, and
unpredictablecarbohydratedeliveryfrom
gastroparesis predisposing to hypoglyce-
mia (158). Autonomic neuropathy is also
strongly associated with CVD in people
with diabetes (159,160). People with di-
abetic autonomic neuropathy should un-
dergo cardiac investigation before
beginning physical activity more intense
than that to which they are accustomed.
Albuminuria and nephropathy. Physical
activity can acutely increase urinary pro-
tein excretion. However, there is no evi-
dence that vigorous exercise increases the
rate of progression of diabetic kidney dis-
ease, and there is likely no need for any
speciﬁc exercise restrictions for people
with diabetic kidney disease (161).
H. Psychosocial assessment and care
Recommendations
● Assessment of psychological and social
situation should be included as an on-
going part of the medical management
of diabetes. (E)
● Psychosocial screening and follow-up
should include, but is not limited to,
attitudes about the illness, expectations
for medical management and out-
comes, affect/mood, general and diabe-
tes-related quality of life, resources
(ﬁnancial, social, and emotional), and
psychiatric history. (E)
● Screen for psychosocial problems such
as depression and diabetes-related dis-
tress, anxiety, eating disorders, and
cognitive impairment when self-
management is poor. (C)
Psychological and social problems can
impairtheindividual’s(162–165)orfam-
ily’sabilitytocarryoutdiabetescaretasks
and therefore compromise health status.
There are opportunities for the clinician
to assess psychosocial status in a timely
and efﬁcient manner so that referral for
appropriate services can be accom-
plished.
Key opportunities for screening of
psychosocial status occur at diagnosis,
during regularly scheduled management
visits, during hospitalizations, at discov-
ery of complications, or when problems
withglucosecontrol,qualityoflife,orad-
herence are identiﬁed. Patients are likely
to exhibit psychological vulnerability at
diagnosis and when their medical status
changes, e.g., the end of the honeymoon
period, when the need for intensiﬁed
treatment is evident, and when complica-
tions are discovered (164).
Issues known to impact self-
management and health outcomes in-
clude but are not limited to: attitudes
abouttheillness,expectationsformedical
management and outcomes, affect/mood,
general and diabetes-related quality of
life, diabetes-related distress (166), re-
sources (ﬁnancial, social, and emotional)
(167), and psychiatric history (168–
170). Screening tools are available for a
number of these areas (105). Indications
for referral to a mental health specialist
familiar with diabetes management may
include: gross noncompliance with med-
ical regimen (by self or others) (170), de-
pression with the possibility of self-harm,
debilitatinganxiety(aloneorwithdepres-
sion), indications of an eating disorder
(171), or cognitive functioning that
signiﬁcantly impairs judgment. It is
preferable to incorporate psychological
assessment and treatment into routine
care rather than waiting for identiﬁcation
of a speciﬁc problem or deterioration in
psychological status (105). Although the
clinician may not feel qualiﬁed to treat
psychological problems, utilizing the pa-
tient-provider relationship as a founda-
tionforfurthertreatmentcanincreasethe
likelihood that the patient will accept re-
ferral for other services. It is important to
establishthatemotionalwell-beingispart
of diabetes management.
I. When treatment goals are not met
Foravarietyofreasons,somepeoplewith
diabetes and their health care providers
do not achieve the desired goals of treat-
ment (Table 10). Re-thinking the treat-
ment regimen may require assessment of
barriersincludingincome,healthliteracy,
diabetes distress, depression, and com-
peting demands, including those related
to family responsibilities and dynamics.
Other strategies may include culturally
appropriate and enhanced DSME, co-
management with a diabetes team, refer-
ral to a medical social worker for
assistance with insurance coverage, or
change in pharmacological therapy. Initi-
ation of or increase in SMBG, utilization
of CGM, frequent contact with the pa-
tient,orreferraltoamentalhealthprofes-
sional or physician with special expertise
in diabetes may be useful. Providing pa-
tients with an algorithm for self-titration
of insulin doses based on SMBG results
may be helpful for type 2 patients who
take insulin (172).
J. Hypoglycemia
Recommendations
● Glucose (15–20 g) is the preferred
treatment for the conscious individual
with hypoglycemia, although any form
of carbohydrate that contains glucose
may be used. If SMBG 15 min after
treatment shows continued hypoglyce-
mia, the treatment should be repeated.
Once SMBG glucose returns to normal,
the individual should consume a meal
orsnacktopreventrecurrenceofhypo-
glycemia. (E)
● Glucagon should be prescribed for all
individuals at signiﬁcant risk of severe
hypoglycemia, and caregivers or family
membersoftheseindividualsshouldbe
instructed in its administration. Gluca-
gon administration is not limited to
health care professionals. (E)
● Individuals with hypoglycemia un-
awareness or one or more episodes of
severehypoglycemiashouldbeadvised
to raise their glycemic targets to strictly
avoid further hypoglycemia for at least
severalweeks,topartiallyreversehypo-
glycemia unawareness and reduce risk
of future episodes. (B)
Hypoglycemia is the leading limiting fac-
tor in the glycemic management of type 1
and insulin-treated type 2 diabetes (173).
Mild hypoglycemia may be inconvenient
or frightening to patients with diabetes,
and more severe hypoglycemia can cause
acute harm to the person with diabetes or
others, if it causes falls, motor vehicle ac-
cidents, or other injury. A large cohort
study suggested that among older adults
with type 2 diabetes, a history of severe
hypoglycemiawasassociatedwithgreater
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dence from the DCCT/EDIC trial, which
involved younger type 1 patients, sug-
gested no association of frequency of se-
vere hypoglycemia with cognitive decline
(175). Treatment of hypoglycemia
(plasma glucose 70 mg/dl) requires in-
gestion of glucose- or carbohydrate-
containing foods. The acute glycemic
response correlates better with the glu-
cose content than with the carbohydrate
content of the food. Although pure glu-
cose is the preferred treatment, any form
ofcarbohydratethatcontainsglucosewill
raise blood glucose. Added fat may retard
and then prolong the acute glycemic re-
sponse. Ongoing activity of insulin or in-
sulin secretagogues may lead to
recurrence of hypoglycemia unless fur-
ther food is ingested after recovery.
Severehypoglycemia(wheretheindi-
vidual requires the assistance of another
person and cannot be treated with oral
carbohydrate due to confusion or uncon-
sciousness)shouldbetreatedusingemer-
gency glucagon kits, which require a
prescription. Those in close contact with,
or having custodial care of, people with
hypoglycemia-prone diabetes (family
members, roommates, school personnel,
child care providers, correctional institu-
tion staff, or coworkers), should be in-
structed in use of such kits. An individual
does not need to be a health care profes-
sional to safely administer glucagon. Care
should be taken to ensure that unexpired
glucagon kits are available.
Prevention of hypoglycemia is a crit-
ical component of diabetes management.
Teaching people with diabetes to balance
insulin use, carbohydrate intake, and ex-
ercise is a necessary but not always sufﬁ-
cient strategy. In type 1 diabetes and
severely insulin-deﬁcient type 2 diabetes,
the syndrome of hypoglycemia unaware-
ness, or hypoglycemia-associated auto-
nomic failure, can severely compromise
stringent diabetes control and quality of
life. The deﬁcient counterregulatory hor-
monereleaseandautonomicresponsesin
this syndrome are both risk factors for,
andcausedby,hypoglycemia.Acorollary
tothis“viciouscycle”isthatseveralweeks
of avoidance of hypoglycemia has been
demonstrated to improve counterregula-
tion and awareness to some extent in
manypatients(176).Hence,patientswith
one or more episodes of severe hypogly-
cemia may beneﬁt from at least short-
term relaxation of glycemic targets.
K. Intercurrent illness
The stress of illness, trauma, and/or sur-
gery frequently aggravates glycemic con-
trol and may precipitate diabetic
ketoacidosis (DKA) or nonketotic hyper-
osmolar state, life-threatening conditions
that require immediate medical care to
prevent complications and death. Any
condition leading to deterioration in gly-
cemic control necessitates more frequent
monitoring of blood glucose and (in ke-
tosis-prone patients) urine or blood ke-
tones. Marked hyperglycemia requires
temporary adjustment of the treatment
program and, if accompanied by ketosis,
vomiting, or alteration in level of con-
sciousness, immediate interaction with
thediabetescareteam.Thepatienttreated
with noninsulin therapies or MNT alone
may temporarily require insulin. Ade-
quate ﬂuid and caloric intake must be as-
sured. Infection or dehydration are more
likely to necessitate hospitalization of the
person with diabetes than the person
without diabetes.
The hospitalized patient should be
treated by a physician with expertise in
the management of diabetes. For further
information on management of patients
with hyperglycemia in the hospital, see
VIII.A. Diabetes care in the hospital. For
further information on management of
DKA or nonketotic hyperosmolar state,
refer to the ADA consensus statement on
hyperglycemic crises (172).
L. Bariatric surgery
Recommendations
● Bariatric surgery may be considered for
adults with BMI 35 kg/m
2 and type 2
diabetes,especiallyifthediabetesoras-
sociated comorbidities are difﬁcult to
control with lifestyle and pharmaco-
logic therapy. (B)
● Patients with type 2 diabetes who have
undergone bariatric surgery need life-
long lifestyle support and medical
monitoring. (E)
● Although small trials have shown gly-
cemic beneﬁt of bariatric surgery in pa-
tients with type 2 diabetes and BMI of
30–35 kg/m
2, there is currently insuf-
ﬁcient evidence to generally recom-
mendsurgeryinpatientswithBMI35
kg/m
2 outside of a research protocol.
(E)
● The long-term beneﬁts, cost-
effectiveness, and risks of bariatric sur-
gery in individuals with type 2 diabetes
should be studied in well-designed
controlled trials with optimal medical
and lifestyle therapy as the comparator.
(E)
Gastric reduction surgery, either gastric
banding or procedures that involve by-
passing,transposing,orresectingsections
ofthesmallintestine,whenpartofacom-
prehensive team approach, can be an ef-
fective weight loss treatment for severe
obesity, and national guidelines support
its consideration for people with type 2
diabetes who have BMI exceeding 35 kg/
m
2. Bariatric surgery has been shown to
leadtonear-orcompletenormalizationof
glycemia in 55–95% of patients with
type2diabetes,dependingonthesurgical
procedure. A meta-analysis of studies of
bariatric surgery involving 3,188 patients
with diabetes reported that 78% had re-
mission of diabetes (normalization of
blood glucose levels in the absence of
medications),andthattheremissionrates
were sustained in studies that had fol-
low-up exceeding 2 years (177). Remis-
sion rates tend to be lower with
procedures that only constrict the stom-
ach, and higher with those that bypass
portions of the small intestine. Addition-
ally, there is a suggestion that intestinal
bypass procedures may have glycemic ef-
fects that are independent of their effects
on weight, perhaps involving the incretin
axis.
One randomized controlled trial
compared adjustable gastric banding to
“best available” medical and lifestyle ther-
apy in subjects with type 2 diabetes diag-
nosed less than 2 years before
randomization and BMI 30–40 kg/m
2
(178). In this trial, 73% of surgically
treated patients achieved “remission” of
their diabetes, compared with 13% of
those treated medically. The latter group
lost only 1.7% of body weight, suggesting
that their therapy was not optimal. Over-
all the trial had 60 subjects, and only 13
had a BMI under 35 kg/m
2, making it dif-
ﬁcult to generalize these results widely to
diabetic patients who are less severely
obese or with longer duration of diabetes.
In a more recent study involving 110 pa-
tients with type 2 diabetes and a mean
BMI of 47 kg/m
2, Roux-en-Y gastric by-
pass resulted in a mean loss of excess
weight of 63% at 1 year and 84% at 2
years (179).
Bariatric surgery is costly in the short
termandhassomerisks.Ratesofmorbid-
ity and mortality directly related to the
surgery have been reduced considerably
in recent years, with 30-day mortality
rates now 0.28%, similar to those of lapa-
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term concerns include vitamin and
mineral deﬁciencies, osteoporosis, and
rare but often severe hypoglycemia from
insulinhypersecretion.Cohortstudiesat-
tempting to match subjects suggest that
the procedure may reduce longer-term
mortality rates (181), and it is reasonable
to postulate that there may be recouping
of costs over the long run. Recent retro-
spective analyses and modeling studies
suggestthattheseproceduresmaybecost
effective, when one considers reduction
in subsequent health care costs (182–
184). However, studies of the mecha-
nisms of glycemic improvement and
long-term beneﬁts and risks of bariatric
surgery in individuals with type 2 diabe-
tes, especially those who are not severely
obese, will require well-designed clinical
trials, with optimal medical and lifestyle
therapy of diabetes and cardiovascular
risk factors as the comparator.
M. Immunization
Recommendations
● Annually provide an inﬂuenza vaccine
to all diabetic patients at least 6 months
of age. (C)
● Administer pneumococcal polysaccha-
ride vaccine to all diabetic patients 2
yearsofage.Aone-timerevaccinationis
recommended for individuals 64
years of age previously immunized
when they were 65 years of age if the
vaccine was administered 5 years
ago. Other indications for repeat vacci-
nation include nephrotic syndrome,
chronic renal disease, and other immu-
nocompromised states, such as after
transplantation. (C)
Inﬂuenza and pneumonia are common,
preventable infectious diseases associated
with high mortality and morbidity in the
elderly and in people with chronic dis-
eases. Though there are limited studies
reporting the morbidity and mortality of
inﬂuenza and pneumococcal pneumonia
speciﬁcally in people with diabetes, ob-
servational studies of patients with a vari-
ety of chronic illnesses, including
diabetes, show that these conditions are
associatedwithanincreaseinhospitaliza-
tions for inﬂuenza and its complications.
People with diabetes may be at increased
risk of the bacteremic form of pneumo-
coccal infection and have been reported
to have a high risk of nosocomial bactere-
mia, which has a mortality rate as high as
50% (185).
Safe and effective vaccines are avail-
able that can greatly reduce the risk of
serious complications from these diseases
(186,187). In a case-control series, inﬂu-
enza vaccine was shown to reduce diabe-
tes-relatedhospitaladmissionbyasmuch
as79%duringﬂuepidemics(186).There
is sufﬁcient evidence to support that peo-
ple with diabetes have appropriate sero-
logic and clinical responses to these
vaccinations. The Centers for Disease
Control and Prevention (CDC) Advisory
Committee on Immunization Practices
recommends inﬂuenza and pneumococ-
calvaccinesforallindividualswithdiabe-
tes (http://www.cdc.gov/vaccines/recs/).
VI. PREVENTION AND
MANAGEMENT OF
DIABETES COMPLICATIONS
A. CVD
CVD is the major cause of morbidity and
mortality for individuals with diabetes,
and the largest contributor to the direct
and indirect costs of diabetes. The com-
mon conditions coexisting with type 2
diabetes (e.g., hypertension and dyslipi-
demia) are clear risk factors for CVD, and
diabetes itself confers independent risk.
Numerous studies have shown the efﬁ-
cacy of controlling individual cardiovas-
cular risk factors in preventing or slowing
CVD in people with diabetes. Large ben-
eﬁts are seen when multiple risk factors
areaddressedglobally(188,189).Riskfor
coronary heart disease (CHD) and for
CVD in general can be estimated using
multivariable risk factor approaches, and
suchastrategymaybedesirabletounder-
take in adult patients prior to instituting
preventive therapy.
1. Hypertension/blood pressure
control
Recommendations
Screening and diagnosis
● Blood pressure should be measured at
every routine diabetes visit. Patients
found to have systolic blood pressure
130 mmHg or diastolic blood pres-
sure 80 mmHg should have blood
pressure conﬁrmed on a separate day.
Repeat systolic blood pressure 130
mmHgordiastolicbloodpressure80
mmHg conﬁrms a diagnosis of hyper-
tension. (C)
Goals
● A goal systolic blood pressure 130
mmHg is appropriate for most patients
with diabetes. (C)
● Based on patient characteristics and re-
sponse to therapy, higher or lower sys-
tolic blood pressure targets may be
appropriate. (B)
● Patientswithdiabetesshouldbetreated
to a diastolic blood pressure 80
mmHg. (B)
Treatment
● Patients with a systolic blood pressure
of 130–139 mmHg or a diastolic blood
pressureof80–89mmHgmaybegiven
lifestyle therapy alone for a maximum
of 3 months and then, if targets are not
achieved, be treated with addition of
pharmacological agents. (E)
● Patients with more severe hypertension
(systolic blood pressure 140 or dia-
stolic blood pressure 90 mmHg) at
diagnosis or follow-up should receive
pharmacologic therapy in addition to
lifestyle therapy. (A)
● Lifestyle therapy for hypertension con-
sists of: weight loss, if overweight; Di-
etaryApproachestoStopHypertension
(DASH)-style dietary pattern including
reducing sodium and increasing potas-
sium intake; moderation of alcohol in-
take; and increased physical activity.
(B)
● Pharmacologic therapy for patients
with diabetes and hypertension should
be with a regimen that includes either
anACEinhibitororanARB.Ifoneclass
is not tolerated, the other should be
substituted. If needed to achieve blood
pressure targets, a thiazide diuretic
should be added to those with an esti-
mated GFR (eGFR) (see below) 30
ml/min/1.73 m
2 and a loop diuretic for
those with an eGFR 30 ml/min/1.73
m
2. (C)
● Multiple drug therapy (two or more
agents at maximal doses) is generally
required to achieve blood pressure tar-
gets. (B)
● IfACEinhibitors,ARBs,ordiureticsare
used,kidneyfunctionandserumpotas-
sium levels should be monitored. (E)
● In pregnant patients with diabetes and
chronic hypertension, blood pressure
target goals of 110–129/65–79 mmHg
are suggested in the interest of long-
term maternal health and minimizing
impaired fetal growth. ACE inhibitors
and ARBs are contraindicated during
pregnancy. (E)
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of diabetes, affecting the majority of pa-
tients,withprevalencedependingontype
of diabetes, age, obesity, and ethnicity.
Hypertension is a major risk factor for
both CVD and microvascular complica-
tions. In type 1 diabetes, hypertension is
often the result of underlying nephropa-
thy, while in type 2 diabetes it usually
coexists with other cardiometabolic risk
factors.
Screening and diagnosis
Measurement of blood pressure in the of-
ﬁce should be done by a trained individ-
ual and should follow the guidelines
established for nondiabetic individuals:
measurement in the seated position, with
feet on the ﬂoor and arm supported at
heart level, after 5 min of rest. Cuff size
should be appropriate for the upper arm
circumference. Elevated values should be
conﬁrmed on a separate day. Because of
the clear synergistic risks of hypertension
and diabetes, the diagnostic cut-off for a
diagnosis of hypertension is lower in peo-
ple with diabetes (blood pressure 130/
80) than those without diabetes (blood
pressure 140/90 mmHg) (190).
Homebloodpressureself-monitoring
and 24-h ambulatory blood pressure
monitoring may provide additional evi-
dence of “white coat” and masked hyper-
tension and other discrepancies between
ofﬁce and “true” blood pressure, and in
studies in nondiabetic populations, home
measurements may better correlate with
CVD risk than ofﬁce measurements
(191,192). However, the preponderance
of the clear evidence of beneﬁts of treat-
ment of hypertension in people with dia-
betes is based on ofﬁce measurements.
Treatment goals
Epidemiologic analyses show that blood
pressurevalues115/75mmHgareasso-
ciated with increased cardiovascular
event rates and mortality in individuals
with diabetes (190,193,194). Random-
ized clinical trials have demonstrated the
beneﬁt (reduction in CHD events, stroke,
and nephropathy) of lowering blood
pressure to 140 mmHg systolic and
80 mmHg diastolic in individuals with
diabetes (190,195–197). The ACCORD
trial examined whether lowering blood
pressure to a systolic 120 mmHg pro-
vides greater cardiovascular protection
than a systolic blood pressure level of
130–140 mmHg in patients with type 2
diabetes at high risk for CVD (198). The
blood pressure achieved was 119/64
mmHg in the intensive group and 133/70
mmHg in the standard group; the differ-
ence achieved was attained with an aver-
age of 3.4 medications per participant in
the intensive group and 2.1 in the stan-
dard therapy group. The primary out-
come was a composite of nonfatal MI,
nonfatal stroke, and CVD death; the haz-
ard ratio for the primary end point in the
intensive group was 0.88 (95% CI 0.73–
1.06; P  0.20). Of the prespeciﬁed sec-
ondary end points, only stroke and
nonfatal stroke were statistically signiﬁ-
cantly reduced by intensive blood pres-
suretreatment,withahazardratioof0.59
(95% CI 0.39–0.89, P  0.01) and 0.63
(95% CI 0.41–0.96, P  0.03), respec-
tively. If this ﬁnding is real, the number
needed to treat to prevent one stroke over
the course of 5 years with intensive blood
pressure management is 89.
In predeﬁned subgroup analyses,
there was a suggestion of heterogeneity
(P  0.08) based on whether participants
wererandomizedtostandardorintensive
glycemia intervention. In those random-
ized to standard glycemic control, the
event rate for the primary end point was
1.89 per year in the intensive blood pres-
sure arm and 2.47 in the standard blood
pressurearm,whiletherespectiveratesin
the intensive glycemia arm were 1.85 and
1.73.Ifthisobservationistrue,itsuggests
that intensive management to a systolic
blood pressure target of 120 mmHg
may be of beneﬁt in those who are not
targeting an A1C of 6% and/or that the
beneﬁt of intensive blood pressure man-
agement is diminished by more intensive
glycemia management targeting an A1C
of 6%.
Other recent randomized trial data
include those from ADVANCE, in which
treatmentwithanangiotensin-converting
enzyme inhibitor and a thiazide-type di-
uretic reduced the rate of death but not
the composite macrovascular outcome.
However, the ADVANCE trial had no
speciﬁed targets for the randomized com-
parison, and the mean systolic blood
pressure in the intensive group (135
mmHg) was not as low as the mean sys-
tolicbloodpressureintheACCORDstan-
dard therapy group (199). A post hoc
analysis of blood pressure control in
6,400 patients with diabetes and CAD
enrolled in the International Verapamil-
Trandolapril (INVEST) trial demonstrated
that “tight control” (130 mmHg) was
not associated with improved CV out-
comes compared with “usual care” (130–
140 mmHg) (200).
Only the ACCORD blood pressure
trial formally has examined treatment tar-
gets 130 mmHg in diabetes. It is possi-
ble that lowering systolic blood pressure
fromthelow-130stolessthan120mmHg
does not further reduce coronary events
ordeath,andthatmostofthebeneﬁtfrom
lowering blood pressure is achieved by
targeting a goal of 140 mmHg. How-
ever, this has not been formally assessed.
The absence of signiﬁcant harm, the
trends toward beneﬁt in stroke, and the
potentialheterogeneitywithrespecttoin-
tensive glycemia management suggests
that previously recommended targets are
reasonable pending further analyses and
results. Systolic blood pressure targets
more or less stringent than 130 mmHg
may be appropriate for individual pa-
tients, based on response to therapy,
medication tolerance, and individual
characteristics,keepinginmindthatmost
analyses have suggested that outcomes
are worse if the systolic blood pressure is
140 mmHg.
Treatment strategies
Although there are no well-controlled
studies of diet and exercise in the treat-
ment of hypertension in individuals with
diabetes, the Dietary Approaches to
Stop Hypertension (DASH) study in
nondiabetic individuals has shown anti-
hypertensive effects similar to pharmaco-
logic monotherapy. Lifestyle therapy
consists of reducing sodium intake (to
1,500mg/day)andexcessbodyweight;
increasing consumption of fruits, vegeta-
bles (8–10 servings/day), and low-fat
dairy products (2–3 servings/day); avoid-
ing excessive alcohol consumption (no
more than 2 servings/day in men and no
more than 1 serving/day in women)
(201); and increasing activity levels
(190). These nonpharmacological strate-
gies may also positively affect glycemia
and lipid control. Their effects on cardio-
vasculareventshavenotbeenestablished.
An initial trial of nonpharmacologic ther-
apymaybereasonableindiabeticindivid-
uals with mild hypertension (systolic
blood pressure 130–139 mmHg or dia-
stolic blood pressure 80–89 mmHg). If
systolic blood pressure is 140 mmHg
and/or diastolic is 90 mmHg at the time
of diagnosis, pharmacologic therapy
should be initiated along with nonphar-
macologic therapy (190).
Lowering of blood pressure with reg-
imens based on a variety of antihyperten-
sive drugs, including ACE inhibitors,
ARBs, -blockers, diuretics, and calcium
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effective in reducing cardiovascular
events. Several studies suggested that
ACE inhibitors may be superior to dihy-
dropyridine calcium channel blockers in
reducing cardiovascular events (202–
204). However, a variety of other studies
have shown no speciﬁc advantage to ACE
inhibitorsasinitialtreatmentofhyperten-
sion in the general hypertensive popula-
tion, but rather an advantage on
cardiovascularoutcomesofinitialtherapy
with low-dose thiazide diuretics
(190,205,206).
In people with diabetes, inhibitors of
the renin-angiotensin system (RAS) may
haveuniqueadvantagesforinitialorearly
therapy of hypertension. In a nonhyper-
tension trial of high-risk individuals, in-
cluding a large subset with diabetes, an
ACE inhibitor reduced CVD outcomes
(207). In patients with congestive heart
failure (CHF), including diabetic sub-
groups, ARBs have been shown to reduce
major CVD outcomes (208–211), and in
type 2 patients with signiﬁcant nephrop-
athy, ARBs were superior to calcium
channel blockers for reducing heart fail-
ure (212). Though evidence for distinct
advantagesofRASinhibitorsonCVDout-
comes in diabetes remains conﬂicting
(195,206), the high CVD risks associated
with diabetes, and the high prevalence of
undiagnosed CVD, may still favor recom-
mendations for their use as ﬁrst-line hy-
pertension therapy in people with
diabetes (190). Recently, the blood pres-
sure arm of the ADVANCE trial demon-
strated that routine administration of a
ﬁxed combination of the ACE inhibitor
perindopril and the diuretic indapamide
signiﬁcantly reduced combined micro-
vascular and macrovascular outcomes, as
well as CVD and total mortality. The im-
proved outcomes could also have been
due to lower achieved blood pressure in
the perindopril-indapamide arm (199).
In addition, the Avoiding Cardiovascular
Events through Combination Therapy in
Patients Living with Systolic Hyperten-
sion (ACCOMPLISH) trial showed a de-
creaseinmorbidityandmortalityinthose
receiving benazapril and amlodipine ver-
sus benazapril and hydrochlorothiazide.
ThecompellingbeneﬁtsofRASinhibitors
in diabetic patients with albuminuria or
renal insufﬁciency provide additional ra-
tionale for use of these agents (see VI.B.
Nephropathy screening and treatment).
An important caveat is that most pa-
tients with hypertension require multi-
drug therapy to reach treatment goals,
especially diabetic patients whose targets
are lower. Many patients will require
three or more drugs to reach target goals
(190). If blood pressure is refractory to
optimal doses of at least three antihyper-
tensive agents of different classiﬁcations,
one of which should be a diuretic, clini-
cians should consider an evaluation for
secondary forms of hypertension.
During pregnancy in diabetic women
with chronic hypertension, target blood
pressure goals of systolic blood pressure
110–129 mmHg and diastolic blood
pressure 65–79 mmHg are reasonable, as
they contribute to long-term maternal
health. Lower blood pressure levels may
be associated with impaired fetal growth.
During pregnancy, treatment with ACE
inhibitors and ARBs is contraindicated,
since they can cause fetal damage. Anti-
hypertensive drugs known to be effective
and safe in pregnancy include methyl-
dopa, labetalol, diltiazem, clonidine, and
prazosin. Chronic diuretic use during
pregnancy has been associated with re-
stricted maternal plasma volume, which
might reduce uteroplacental perfusion
(213).
2. Dyslipidemia/lipid management
Recommendations
Screening
● In most adult patients, measure fasting
lipid proﬁle at least annually. In adults
with low-risk lipid values (LDL choles-
terol 100 mg/dl, HDL cholesterol
50 mg/dl, and triglycerides 150
mg/dl), lipid assessments may be re-
peated every 2 years. (E)
Treatment recommendations and
goals
● Lifestyle modiﬁcation focusing on the
reduction of saturated fat, trans fat, and
cholesterol intake; increase of omega-3
fatty acids, viscous ﬁber, and plant
stanols/sterols; weight loss (if indi-
cated); and increased physical activity
should be recommended to improve
the lipid proﬁle in patients with diabe-
tes. (A)
● Statin therapy should be added to life-
style therapy, regardless of baseline
lipid levels, for diabetic patients:
● with overt CVD. (A)
● without CVD who are over age 40
years and have one or more other
CVD risk factors. (A)
● For patients at lower risk than above
(e.g., without overt CVD and under age
40years),statintherapyshouldbecon-
sideredinadditiontolifestyletherapyif
LDL cholesterol remains above 100
mg/dl or in those with multiple CVD
risk factors. (E)
● In individuals without overt CVD, the
primary goal is an LDL cholesterol
100 mg/dl (2.6 mmol/l). (A)
● In individuals with overt CVD, a lower
LDLcholesterolgoalof70mg/dl(1.8
mmol/l),usingahighdoseofastatin,is
an option. (B)
● Ifdrug-treatedpatientsdonotreachthe
above targets on maximal tolerated sta-
tin therapy, a reduction in LDL choles-
terol of 30–40% from baseline is an
alternative therapeutic goal. (A)
● Triglyceride levels 150 mg/dl (1.7
mmol/l) and HDL cholesterol 40
mg/dl (1.0 mmol/l) in men and 50
mg/dl (1.3 mmol/l) in women, are de-
sirable. However, LDL cholesterol–
targeted statin therapy remains the
preferred strategy. (C)
● If targets are not reached on maximally
tolerated doses of statins, combination
therapy using statins and other lipid-
lowering agents may be considered to
achieve lipid targets but has not been
evaluated in outcome studies for either
CVD outcomes or safety. (E)
● Statin therapy is contraindicated in
pregnancy. (E)
Evidence for beneﬁts of lipid-
lowering therapy
Patients with type 2 diabetes have an in-
creased prevalence of lipid abnormalities,
contributing to their high risk of CVD.
For the past decade or more, multiple
clinical trials demonstrated signiﬁcant ef-
fects of pharmacologic (primarily statin)
therapy on CVD outcomes in subjects
with CHD and for primary CVD preven-
tion (214). Sub-analyses of diabetic sub-
groups of larger trials (215–219) and
trials speciﬁcally in subjects with diabetes
(220,221) showed signiﬁcant primary
and secondary prevention of CVD
events  CHD deaths in diabetic popula-
tions. As shown in Table 11, and similar
to ﬁndings in nondiabetic subjects, re-
duction in “hard” CVD outcomes (CHD
death and nonfatal MI) can be more
clearly seen in diabetic subjects with high
baseline CVD risk (known CVD and/or
very high LDL cholesterol levels), but
overall the beneﬁts of statin therapy in
people with diabetes at moderate or high
risk for CVD are convincing.
Low levels of HDL cholesterol, often
associated with elevated triglyceride lev-
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lipidemia in persons with type 2 diabetes.
However,theevidencebasefordrugsthat
target these lipid fractions is signiﬁcantly
less robust than that for statin therapy
(222). Nicotinic acid has been shown to
reduce CVD outcomes (223), although
the study was done in a nondiabetic co-
hort. Gemﬁbrozil has been shown to de-
crease rates of CVD events in subjects
without diabetes (224,225) and in the di-
abetic subgroup in one of the larger trials
(224). However, in a large trial speciﬁc to
diabetic patients, fenoﬁbrate failed to re-
duce overall cardiovascular outcomes
(226).
Dyslipidemia treatment and target
lipid levels
For most patients with diabetes, the ﬁrst
priority of dyslipidemia therapy (unless
severe hypertriglyceridemia is the imme-
diate issue) is to lower LDL cholesterol to
atargetgoalof100mg/dl(2.60mmol/l)
(227). Lifestyle intervention, including
MNT, increased physical activity, weight
loss, and smoking cessation, may allow
some patients to reach lipid goals. Nutri-
tion intervention should be tailored ac-
cording to each patient’s age, type of
diabetes, pharmacological treatment,
lipid levels, and other medical conditions
and should focus on the reduction of sat-
urated fat, cholesterol, and trans unsatur-
ated fat intake and increases in omega-3
fatty acids, viscous ﬁber (such as in oats,
legumes, citrus), and plant stanols/
sterols. Glycemic control can also beneﬁ-
cially modify plasma lipid levels,
particularly in patients with very high
triglycerides and poor glycemic control.
InthosewithclinicalCVDoroverage
40 years with other CVD risk factors,
pharmacological treatment should be
added to lifestyle therapy regardless of
baseline lipid levels. Statins are the drugs
of choice for LDL cholesterol lowering.
Inpatientsotherthanthosedescribed
above, statin treatment should be consid-
ered if there is an inadequate LDL choles-
terol response to lifestyle modiﬁcations
and improved glucose control, or if the
patient has increased cardiovascular risk
(e.g., multiple cardiovascular risk factors
or long duration of diabetes). Very little
clinical trial evidence exists for type 2 di-
abetic patients under age 40 years or for
type 1 patients of any age. In the Heart
Protection Study (lower age limit 40
years), the subgroup of 600 patients with
type1diabeteshadaproportionatelysim-
ilar reduction in risk as patients with type
2 diabetes, although not statistically sig-
niﬁcant (216). Although the data are not
deﬁnitive, consideration should be given
to similar lipid-lowering goals in type 1
diabetic patients as in type 2 diabetic pa-
tients, particularly if they have other car-
diovascular risk factors.
Alternative LDL cholesterol goals
Virtually all trials of statins and CVD out-
comes tested speciﬁc doses of statins
against placebo, other doses of statin, or
other statins, rather than aiming for spe-
ciﬁc LDL cholesterol goals (228). As can
be seen in Table 11, placebo-controlled
trials generally achieved LDL cholesterol
reductions of 30–40% from baseline.
Hence, LDL cholesterol lowering of this
magnitude is an acceptable outcome for
patients who cannot reach LDL choles-
terol goals due to severe baseline eleva-
tions in LDL cholesterol and/or
intolerance of maximal, or any, statin
doses. Additionally for those with base-
lineLDLcholesterolminimallyabove100
mg/dl, prescribing statin therapy to lower
LDL cholesterol about 30–40% from
baseline is probably more effective than
prescribing just enough to get LDL cho-
lesterol slightly below 100 mg/dl.
Recent clinical trials in high-risk pa-
tients, such as those with acute coronary
syndromes or previous cardiovascular
events (229–231), have demonstrated
that more aggressive therapy with high
doses of statins to achieve an LDL choles-
terol of 70 mg/dl led to a signiﬁcant re-
Table 11—Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or substudies of major trials,
in diabetic subjects (n  16,032)
Study (ref.) CVD
Statin dose and
comparator
Risk
reduction (%)
Relative risk
reduction (%)
Absolute risk
reduction (%)
LDL cholesterol
reduction (mg/dl)
LDL cholesterol
reduction (%)
4S-DM (215) 2° Simvastatin 20–40 mg
vs. placebo
85.7 to 43.2 50 42.5 186 to 119 36
ASPEN 2° (220) 2° Atorvastatin 10 mg vs.
placebo
39.5 to 24.5 34 15 112 to 79 29
HPS-DM (216) 2° Simvastatin 40 mg vs.
placebo
43.8 to 36.3 17 7.5 123 to 84 31
CARE-DM (217) 2° Pravastatin 40 mg vs.
placebo
40.8 to 35.4 13 5.4 136 to 99 27
TNT-DM (218) 2° Atorvastatin 80 mg vs.
10 mg
26.3 to 21.6 18 4.7 99 to 77 22
HPS-DM (216) 1° Simvastatin 40 mg vs.
placebo
17.5 to 11.5 34 6.0 124 to 86 31
CARDS (221) 1° Atorvastatin 10 mg vs.
placebo
11.5 to 7.5 35 4 118 to 71 40
ASPEN 1° (220) 1° Atorvastatin 10 mg vs.
placebo
9.8 to 7.9 19 1.9 114 to 80 30
ASCOT-DM (219) 1° Atorvastatin 10 mg vs.
placebo
11.1 to 10.2 8 0.9 125 to 82 34
Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and nonfatal MI. In this tabulation,
results of the statin on 10-year risk of major CVD endpoints (CHD death/nonfatal MI) are listed for comparison between studies. Correlation between 10-year CVD
riskofthecontrolgroupandtheabsoluteriskreductionwithstatintherapyishighlysigniﬁcant(P0.0007).AnalysesprovidedbyCraigWilliams,PharmD,Oregon
Health & Science University, 2007.
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reduction in LDL cholesterol to a goal of
70 mg/dl is an option in very-high-risk
diabetic patients with overt CVD (232).
In individual patients, LDL choles-
terol lowering with statins is highly vari-
able, and this variable response is poorly
understood (233). Reduction of CVD
events with statins correlates very closely
with LDL cholesterol lowering (214).
When maximally tolerated doses of st-
atins fail to signiﬁcantly lower LDL cho-
lesterol (30% reduction from patients
baseline),theprimaryaimofcombination
therapy should be to achieve additional
LDL cholesterol lowering. Niacin, fenoﬁ-
brate, ezetimibe, and bile acid seques-
trants all offer additional LDL cholesterol
lowering. The evidence that combination
therapy provides a signiﬁcant increment
in CVD risk reduction over statin therapy
alone is still elusive.
In 2008, a consensus panel convened
bytheAmericanDiabetesAssociationand
the American College of Cardiology rec-
ommended a greater focus on non-HDL
cholesterol and apo lipoprotein B (apo B)
in patients who are likely to have small
LDL particles, such as people with diabe-
tes (234). The consensus panel suggested
that for statin-treated patients in whom
the LDL cholesterol goal would be 70
mg/dl (non-HDL cholesterol 100 mg/
dl),apoBshouldbemeasuredandtreated
to80mg/dl.Forpatientsonstatinswith
an LDL cholesterol goal of 100 mg/dl
(non-HDL cholesterol 130 mg/dl), apo
Bshouldbemeasuredandtreatedto90
mg/dl.
Treatment of other lipoprotein
fractions or targets
Severe hypertriglyceridemia may warrant
immediate therapy of this abnormality
with lifestyle and usually pharmacologic
therapy (ﬁbric acid derivative, niacin, or
ﬁsh oil) to reduce the risk of acute pan-
creatitis. In the absence of severe hyper-
triglyceridemia, therapy targeting HDL
cholesterol or triglycerides has intuitive
appeal but lacks the evidence base of sta-
tintherapy.IftheHDLcholesterolis40
mg/dl and the LDL cholesterol between
100 and 129 mg/dl, gemﬁbrozil or niacin
might be used, especially if a patient is
intolerant to statins. Niacin is the most
effectivedrugforraisingHDLcholesterol.
It can signiﬁcantly increase blood glucose
at high doses, but recent studies demon-
strate that at modest doses (750–2,000
mg/day), signiﬁcant improvements in
LDL cholesterol, HDL cholesterol, and
triglyceride levels are accompanied by
only modest changes in glucose that are
generally amenable to adjustment of dia-
betes therapy (235,236).
Combination therapy
Combination therapy, with a statin and a
ﬁbrate or statin and niacin, may be efﬁca-
cious for treatment for all three lipid frac-
tions, but this combination is associated
with an increased risk for abnormal
transaminase levels, myositis, or rhabdo-
myolysis. The risk of rhabdomyolysis is
higher with higher doses of statins and
with renal insufﬁciency and seems to be
lower when statins are combined with fe-
noﬁbrate than gemﬁbrozil (237). In the
recent ACCORD study, the combination
of fenoﬁbrate and simvastatin did not re-
duce the rate of fatal cardiovascular
events, nonfatal myocardial infarction, or
nonfatal stroke, as compared with simva-
statin alone, in patients with type 2 dia-
betes who were at high risk for CVD.
However, prespeciﬁed subgroup analyses
suggested heterogeneity in treatment ef-
fects according to sex, with a beneﬁt for
men and possible harm for women, and a
possible beneﬁt of combination therapy
for patients with both triglyceride level
204 mg/dl and HDL cholesterol level
34 mg/dl (238). Other ongoing trials
may provide much-needed evidence for
the effects of combination therapy on car-
diovascular outcomes.
Table 12 summarizes common treatment
goals for A1C, blood pressure, and HDL
cholesterol.
3. Antiplatelet agents
Recommendations
● Consider aspirin therapy (75–162 mg/
day)asaprimarypreventionstrategyin
those with type 1 or type 2 diabetes at
increased cardiovascular risk (10-year
risk 10%). This includes most men
50 years of age or women 60 years
of age who have at least one additional
major risk factor (family history of
CVD, hypertension, smoking, dyslipi-
demia, or albuminuria). (C)
● Aspirin should not be recommended
for CVD prevention for adults with di-
abetes at low CVD risk (10-year CVD
risk 5%, such as in men 50 and
women60yearsofagewithnomajor
additional CVD risk factors), since the
potential adverse effects from bleeding
likely offset the potential beneﬁts. (C)
● In patients in these age-groups with
multipleotherriskfactors(e.g.,10-year
risk 5–10%), clinical judgment is re-
quired. (E)
● Use aspirin therapy (75–162 mg/day)
as a secondary prevention strategy in
those with diabetes with a history of
CVD. (A)
● For patients with CVD and docu-
mented aspirin allergy, clopidogrel (75
mg/day) should be used. (B)
● Combination therapy with ASA (75–
162 mg/day) and clopidogrel (75 mg/
day) is reasonable for up to a year after
an acute coronary syndrome. (B)
ADA and the American Heart Association
(AHA) have, in the past, jointly recom-
mended that low-dose aspirin therapy be
used as a primary prevention strategy in
those with diabetes at increased cardio-
vascular risk, including those who are
over 40 years of age or those with addi-
tional risk factors (family history of CVD,
hypertension, smoking, dyslipidemia, or
albuminuria) (188). These recommenda-
tions were derived from several older tri-
als that included small numbers of
patients with diabetes.
Aspirin has been shown to be effec-
tive in reducing cardiovascular morbidity
and mortality in high-risk patients with
previous myocardial infarction or stroke
(secondary prevention). Its net beneﬁt in
primary prevention among patients with
nopreviouscardiovasculareventsismore
controversial, both for patients with and
without a history of diabetes (239). Two
recent randomized controlled trials of as-
pirin speciﬁcally in patients with diabetes
failed to show a signiﬁcant reduction in
CVDendpoints,raisingfurtherquestions
about the efﬁcacy of aspirin for primary
Table 12—Summary of recommendations
for glycemic blood pressure and lipid control
for most adults with diabetes
A1C 7.0%*
Blood pressure 130/80 mmHg†
Lipids
LDL cholesterol 100 mg/dl
(2.6 mmol/l)‡
*More or less stringent glycemic goals may be ap-
propriate for individual patients. Goals should be
individualized based on: duration of diabetes, age/
life expectancy, comorbid conditions, known CVD
or advanced microvascular complications, hypogly-
cemia unawareness, and individual patient consid-
erations. †Based on patient characteristics and
response to therapy, higher or lower systolic blood
pressuretargetsmaybeappropriate.‡Inindividuals
with overt CVD, a lower LDL cholesterol goal of
70 mg/dl (1.8 mmol/l), using a high dose of a
statin, is an option.
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(240,241).
The Anti-thrombotic Trialists’ (ATT)
collaborators recently published an indi-
vidual patient-level meta-analysis of the
six large trials of aspirin for primary pre-
vention in the general population. These
trials collectively enrolled over 95,000
participants, including almost 4,000 with
diabetes. Overall, they found that aspirin
reduced the risk of vascular events by
12% (RR 0.88 [95% CI 0.82– 0.94]). The
largest reduction was for nonfatal myo-
cardialinfarctionwithlittleeffectonCHD
death (RR 0.95 [95% CI 0.78–1.15]) or
totalstroke.Therewassomeevidenceofa
difference in aspirin effect by sex. Aspirin
signiﬁcantly reduced CHD events in men
but not in women. Conversely, aspirin
had no effect on stroke in men but signif-
icantly reduced stroke in women. Nota-
bly, sex differences in aspirin’s effects
have not been observed in studies of sec-
ondary prevention (239). In the six trials
examined by the ATT collaborators, the
effects of aspirin on major vascular events
were similar for patients with or without
diabetes: RR 0.88 (95% CI 0.67–1.15)
and 0.87 (0.79–0.96), respectively. The
CI was wider for those with diabetes be-
cause of their smaller number.
Based on the currently available evi-
dence, aspirin appears to have a modest
effect on ischemic vascular events with
theabsolutedecreaseineventsdepending
on the underlying CVD risk. The main
adverse effects appear to be an increased
risk of gastrointestinal bleeding. The ex-
cess risk may be as high as 1–5 per 1,000
per year in real-world settings. In adults
with CVD risk greater than 1% per year,
the number of CVD events prevented will
besimilartoorgreaterthanthenumberof
episodes of bleeding induced, although
these complications do not have equal ef-
fects on long-term health (242).
In 2010, a position statement of the
ADA,AHA,andAmericanCollegeofCar-
diology Foundation (ACCF) updated
prior joint recommendations for primary
prevention (243). Low dose (75–162 mg/
day) aspirin use for primary prevention is
reasonableforadultswithdiabetesandno
previous history of vascular disease who
are at increased CVD risk (10-year risk of
CVDeventsover10%)andwhoarenotat
increasedriskforbleeding.Thisgenerally
includes most men over age 50 years and
women over age 60 years who also have
one or more of the following major risk
factors: smoking, hypertension, dyslipi-
demia, family history of premature CVD,
and albuminuria.
However, aspirin is no longer recom-
mended for those at low CVD risk
(women under age 60 years and men un-
der age 50 years with no major CVD risk
factors; 10-year CVD risk under 5%) as
the low beneﬁt is likely to be outweighed
by the risks of signiﬁcant bleeding. Clin-
ical judgment should be used for those at
intermediate risk (younger patients with
one or more risk factors, or older patients
with no risk factors; those with 10-year
CVDriskof5–10%)untilfurtherresearch
is available. Use of aspirin in patients un-
der the age of 21 years is contraindicated
due to the associated risk of Reye’s syn-
drome.
Average daily dosages used in most
clinical trials involving patients with dia-
betes ranged from 50 to 650 mg but were
mostlyintherangeof100to325mg/day.
Thereislittleevidencetosupportanyspe-
ciﬁc dose, but using the lowest possible
dosage may help reduce side effects
(244). Although platelets from patients
with diabetes have altered function, it is
unclear what, if any, impact that ﬁnding
has on the required dose of aspirin for
cardioprotective effects in the patient
with diabetes. Many alternate pathways
for platelet activation exist that are inde-
pendent of thromboxane A2 and thus not
sensitive to the effects of aspirin (245).
Therefore, while “aspirin resistance” ap-
pearshigherinthediabeticpatientswhen
measured by a variety of ex vivo and in
vitro methods (platelet aggrenometry,
measurement of thromboxane B2), these
observations alone are insufﬁcient to em-
pirically recommend higher doses of as-
pirinbeusedinthediabeticpatientatthis
time.
Clopidogrel has been demonstrated
to reduce CVD events in diabetic individ-
uals (246). It is recommended as adjunc-
tive therapy in the ﬁrst year after an acute
coronary syndrome or as alternative ther-
apy in aspirin-intolerant patients.
4. Smoking cessation
Recommendations
● Advise all patients not to smoke. (A)
● Include smoking cessation counseling
and other forms of treatment as a rou-
tine component of diabetes care. (B)
A large body of evidence from epidemio-
logical, case-control, and cohort studies
provides convincing documentation of
thecausallinkbetweencigarettesmoking
and health risks. Much of the work doc-
umenting the impact of smoking on
health did not separately discuss results
on subsets of individuals with diabetes,
butsuggeststhattheidentiﬁedrisksareat
leastequivalenttothosefoundinthegen-
eral population. Other studies of individ-
uals with diabetes consistently
demonstrate that smokers have a height-
ened risk of CVD, premature death, and
increased rate of microvascular complica-
tions of diabetes. Smoking may have a
role in the development of type 2 diabe-
tes.
The routine and thorough assess-
ment of tobacco use is important as a
means of preventing smoking or en-
couraging cessation. A number of large
randomized clinical trials have demon-
strated the efﬁcacy and cost-effective-
ness of brief counseling in smoking
cessation, including the use of quit
lines, in the reduction of tobacco use.
For the patient motivated to quit, the
addition of pharmacological therapy to
counseling is more effective than either
treatment alone. Special considerations
should include assessment of level of
nicotine dependence, which is associ-
ated with difﬁculty in quitting and re-
lapse (247).
5. CHD screening and treatment
Recommendations
Screening
● In asymptomatic patients, routine
screening for CAD is not recom-
mended, as it does not improve out-
comes as long as CVD risk factors are
treated. (A)
Treatment
● In patients with known CVD, ACE in-
hibitor (C) and aspirin and statin ther-
apy (A) (if not contraindicated) should
be used to reduce the risk of cardiovas-
cular events.
● In patients with a prior myocardial in-
farction, -blockers should be contin-
ued for at least 2 years after the event
(B).
● Longer term use of -blockers in the
absenceofhypertensionisreasonableif
well tolerated, but data are lacking. (E)
● Avoid TZD treatment in patients with
symptomatic heart failure. (C)
● Metforminmaybeusedinpatientswith
stable CHF if renal function is normal.
Itshouldbeavoidedinunstableorhos-
pitalized patients with CHF. (C)
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cently updated consensus statement
(154). To identify the presence of CAD
in diabetic patients without clear or
suggestive symptoms, a risk factor–
based approach to the initial diagnostic
evaluation and subsequent follow-up
has intuitive appeal. However, recent
studies concluded that using this ap-
proach fails to identify which patients
with type 2 diabetes will have silent
ischemia on screening tests (159,248).
Candidates for cardiac testing in-
clude those with 1) typical or atypical
cardiac symptoms and 2) an abnormal
resting ECG. The screening of asymp-
tomatic patients remains controversial,
especially as intensive medical therapy,
indicated in diabetic patients at high
riskforCVD,hasanincreasingevidence
base for providing equal outcomes to
invasive revascularization, including in
diabetic patients (249,250). There is
also some evidence that silent myocar-
dial ischemia may reverse over time,
adding to the controversy concerning
aggressive screening strategies (251).
Finally, a recent randomized observa-
tional trial demonstrated no clinical
beneﬁt to routine screening of asymp-
tomatic patients with type 2 diabetes
and normal ECGs (252). Despite abnor-
mal myocardial perfusion imaging in
more than one in ﬁve patients, cardiac
outcomes were essentially equal (and
very low) in screened versus un-
screened patients. Accordingly, the
overall effectiveness, especially the
cost-effectiveness,ofsuchanindiscrim-
inate screening strategy is now ques-
tioned.
Newer noninvasive CAD screening
methods, such as computed tomogra-
phy (CT) and CT angiography have
gained in popularity. These tests infer
thepresenceofcoronaryatherosclerosis
by measuring the amount of calcium in
coronary arteries and, in some circum-
stances, by direct visualization of lumi-
nal stenoses. Although asymptomatic
diabetic patients found to have a higher
coronary disease burden have more fu-
ture cardiac events (253–255), the role
of these tests beyond risk stratiﬁcation
is not clear. Their routine use leads to
radiation exposure and may result in
unnecessary invasive testing such as
coronary angiography and revascular-
ization procedures. The ultimate bal-
ance of beneﬁt, cost, and risks of such
an approach in asymptomatic patients
remains controversial, particularly in
the modern setting of aggressive CVD
risk factor control.
In all patients with diabetes, cardio-
vascular risk factors should be assessed
at least annually. These risk factors in-
clude dyslipidemia, hypertension,
smoking, a positive family history of
premature coronary disease, and the
presence of micro- or macroalbumin-
uria. Abnormal risk factors should be
treated as described elsewhere in these
guidelines. Patients at increased CHD
risk should receive aspirin and a statin
and ACE inhibitor or ARB therapy if hy-
pertensive, unless there are contraindi-
cations to a particular drug class. While
clear beneﬁt exists for ACE inhibitor
and ARB therapy in patients with ne-
phropathy or hypertension, the beneﬁts
in patients with CVD in the absence of
these conditions is less clear, especially
when LDL cholesterol is concomitantly
controlled (256,257).
B. Nephropathy screening and
treatment
Recommendations
General recommendations
● To reduce the risk or slow the progres-
sion of nephropathy, optimize glucose
control. (A)
● To reduce the risk or slow the progres-
sion of nephropathy, optimize blood
pressure control. (A)
Screening
● Perform an annual test to assess urine
albuminexcretionintype1diabeticpa-
tients with diabetes duration of 5 years
and in all type 2 diabetic patients start-
ing at diagnosis. (E)
● Measureserumcreatinineatleastannu-
ally in all adults with diabetes regard-
less of the degree of urine albumin
excretion. The serum creatinine should
be used to estimate GFR and stage the
level of chronic kidney disease (CKD),
if present. (E)
Treatment
● Inthetreatmentofthenonpregnantpa-
tientwithmicro-ormacroalbuminuria,
either ACE inhibitors or ARBs should
be used. (A)
● While there are no adequate head-to-
head comparisons of ACE inhibitors
and ARBs, there is clinical trial support
for each of the following statements:
● In patients with type 1 diabetes, with
hypertensionandanydegreeofalbu-
minuria, ACE inhibitors have been
showntodelaytheprogressionofne-
phropathy. (A)
● In patients with type 2 diabetes, hy-
pertension, and microalbuminuria,
both ACE inhibitors and ARBs have
been shown to delay the progression
to macroalbuminuria. (A)
● In patients with type 2 diabetes, hy-
pertension, macroalbuminuria, and
renal insufﬁciency (serum creatinine
1.5 mg/dl), ARBs have been shown
to delay the progression of nephrop-
athy. (A)
● If one class is not tolerated, the other
should be substituted. (E)
● Reduction of protein intake to 0.8–1.0
g   kg body wt
	1   day
	1 in individuals
with diabetes and the earlier stages of
CKD and to 0.8 g   kg body wt
	1  
day
	1 in the later stages of CKD may
improve measures of renal function
(urine albumin excretion rate, GFR)
and is recommended. (B)
● When ACE inhibitors, ARBs, or diuret-
ics are used, monitor serum creatinine
and potassium levels for the develop-
ment of acute kidney disease and hy-
perkalemia. (E)
● Continued monitoring of urine albu-
min excretion to assess both response
to therapy and progression of disease is
recommended. (E)
● When eGFR 60 ml/min/1.73 m
2,
evaluate and manage potential compli-
cations of CKD. (E)
● Consider referral to a physician experi-
enced in the care of kidney disease
when there is uncertainty about the eti-
ology of kidney disease (heavy protein-
uria, active urine sediment, absence of
retinopathy, rapid decline in GFR), dif-
ﬁcult management issues, or advanced
kidney disease. (B)
Diabetic nephropathy occurs in 20–40%
of patients with diabetes and is the single
leading cause of end-stage renal disease
(ESRD). Persistent albuminuria in the
range of 30–299 mg/24 h (microalbu-
minuria)hasbeenshowntobetheearliest
stage of diabetic nephropathy in type 1
diabetes and a marker for development of
nephropathy in type 2 diabetes. Mi-
croalbuminuria is also a well-established
marker of increased CVD risk (258,259).
Patients with microalbuminuria who
progress to macroalbuminuria (300
mg/24 h) are likely to progress to ESRD
(260,261). However, a number of inter-
ventions have been demonstrated to re-
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renal disease.
Intensive diabetes management with
the goal of achieving near-normoglyce-
mia has been shown in large prospective
randomized studies to delay the onset of
microalbuminuria and the progression of
micro- to macroalbuminuria in patients
with type 1 (262,263) and type 2 (55,56)
diabetes.TheUKPDSprovidedstrongev-
idence that control of blood pressure can
reduce the development of nephropathy
(195). In addition, large prospective ran-
domized studies in patients with type 1
diabetes have demonstrated that achieve-
ment of lower levels of systolic blood
pressure (140 mmHg) resulting from
treatmentusingACEinhibitorsprovidesa
selective beneﬁt over other antihyperten-
sive drug classes in delaying the progres-
sion from micro- to macroalbuminuria
and can slow the decline in GFR in pa-
tients with macroalbuminuria (264–
266). In type 2 diabetes with
hypertension and normoalbuminuria,
RAS inhibition has been demonstrated to
delay onset of microalbuminuria (267).
Inaddition,ACEinhibitorshavebeen
shown to reduce major CVD outcomes
(i.e.,myocardialinfarction,stroke,death)
in patients with diabetes (207), thus fur-
ther supporting the use of these agents in
patients with microalbuminuria, a CVD
risk factor. ARBs do not prevent mi-
croalbuminuria in normotensive patients
with type 1 or type 2 diabetes (268,269);
however, ARBs have been shown to re-
duce the rate of progression from micro-
to macroalbuminuria as well as ESRD in
patients with type 2 diabetes (270–272).
Some evidence suggests that ARBs have a
smaller magnitude of rise in potassium
compared with ACE inhibitors in people
with nephropathy (273,274). Combina-
tions of drugs that block the renin-
angiotensin-aldosterone system (e.g., an
ACE inhibitor plus an ARB, a mineralo-
corticoid antagonist, or a direct renin in-
hibitor) have been shown to provide
additionalloweringofalbuminuria(275–
278). However, the long-term effects of
such combinations on renal or cardiovas-
cular outcomes have not yet been evalu-
ated in clinical trials, and they are
associated with increased risk for hyper-
kalemia.
Other drugs, such as diuretics, cal-
cium channel blockers, and -blockers
should be used as additional therapy to
further lower blood pressure in patients
already treated with ACE inhibitors or
ARBs (212), or as alternate therapy in the
rare individual unable to tolerate ACE in-
hibitors or ARBs.
Studiesinpatientswithvaryingstages
of nephropathy have shown that protein
restriction of dietary protein helps slow
the progression of albuminuria, GFR de-
cline, and occurrence of ESRD (279–
282). Dietary protein restriction should
be considered particularly in patients
whosenephropathyseemstobeprogress-
ing despite optimal glucose and blood
pressure control and use of ACE inhibitor
and/or ARBs (282).
Assessment of albuminuria status
and renal function
Screening for microalbuminuria can be
performed by measurement of the albu-
min-to-creatinine ratio in a random spot
collection; 24-h or timed collections are
more burdensome and add little to pre-
diction or accuracy (283,284). Measure-
ment of a spot urine for albumin only,
whether by immunoassay or by using a
dipstick test speciﬁc for microalbumin,
without simultaneously measuring urine
creatinine,issomewhatlessexpensivebut
susceptible to false-negative and -positive
determinations as a result of variation in
urine concentration due to hydration and
other factors.
Abnormalities of albumin excretion
are deﬁned in Table 13. Because of vari-
ability in urinary albumin excretion, two
ofthreespecimenscollectedwithina3-to
6-month period should be abnormal be-
fore considering a patient to have crossed
one of these diagnostic thresholds. Exer-
cise within 24 h, infection, fever, CHF,
marked hyperglycemia, and marked hy-
pertension may elevate urinary albumin
excretion over baseline values.
Information on presence of abnormal
urine albumin excretion in addition to
level of GFR may be used to stage CKD.
The National Kidney Foundation classiﬁ-
cation (Table 14) is primarily based on
GFR levels and therefore differs from
other systems, in which staging is based
primarily on urinary albumin excretion
(285). Studies have found decreased GFR
in the absence of increased urine albumin
excretion in a substantial percentage of
adults with diabetes (286). Serum creati-
nineshouldthereforebemeasuredatleast
annually in all adults with diabetes, re-
gardless of the degree of urine albumin
excretion.
Serum creatinine should be used to
estimate GFR and to stage the level of
CKD, if present. eGFR is commonly co-
reported by laboratories or can be esti-
mated using formulae such as the
Modiﬁcation of Diet in Renal Disease
(MDRD)studyequation(287).Recentre-
ports have indicated that the MDRD is
more accurate for the diagnosis and strat-
iﬁcation of CKD in patients with diabetes
than the Cockcroft-Gault formula (288).
GFR calculators are available at http://
www.nkdep.nih.gov.
The role of continued annual quan-
titativeassessmentofalbuminexcretion
afterdiagnosisofmicroalbuminuriaand
institution of ACE inhibitor or ARB
therapy and blood pressure control is
unclear. Continued surveillance can as-
sess both response to therapy and pro-
gression of disease. Some suggest that
reducing abnormal albuminuria (30
mg/g) to the normal or near-normal
rangemayimproverenalandcardiovas-
cular prognosis, but this approach has
not been formally evaluated in prospec-
tive trials.
Table 14—Stages of CKD
Stage Description
GFR (ml/min per 1.73 m
2
body surface area)
1 Kidney damage* with normal or increased GFR 90
2 Kidney damage* with mildly decreased GFR 60–89
3 Moderately decreased GFR 30–59
4 Severely decreased GFR 15–29
5 Kidney failure 15 or dialysis
*Kidney damage deﬁned as abnormalities on pathologic, urine, blood, or imaging tests. Adapted from ref.
284.
Table13—Deﬁnitionsofabnormalitiesinal-
bumin excretion
Category
Spot collection
(
g/mg
creatinine)
Normal 30
Microalbuminuria 30–299
Macro (clinical)-albuminuria 300
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relatewithlevelofkidneyfunction.When
the eGFR is less than 60 ml/min/1.73 m
2,
screening for complications of CKD is in-
dicated (Table 15). Early vaccination
against hepatitis B is indicated in patients
likely to progress to end-stage kidney dis-
ease.
Consider referral to a physician ex-
perienced in the care of kidney disease
when there is uncertainty about the eti-
ology of kidney disease (heavy protein-
uria, active urine sediment, absence of
retinopathy, rapid decline in GFR, re-
sistant hypertension), difﬁcult manage-
ment issues, or advanced kidney
disease. The threshold for referral may
vary depending on the frequency with
which a provider encounters diabetic
patients with signiﬁcant kidney disease.
Consultation with a nephrologist when
stage 4 CKDdevelops has been found to
reduce cost, improve quality of care,
and keep people off dialysis longer
(289). However, nonrenal specialists
should not delay educating their pa-
tients about the progressive nature of
diabetic kidney disease; the renal pres-
ervation beneﬁts of aggressive treat-
ment of blood pressure, blood glucose,
and hyperlipidemia; and the potential
need for renal replacement therapy.
C. Retinopathy screening and
treatment
Recommendations
General recommendations
● To reduce the risk or slow the progres-
sion of retinopathy, optimize glycemic
control. (A)
● To reduce the risk or slow the progres-
sion of retinopathy, optimize blood
pressure control. (A)
Screening
● Adults and children aged 10 years or
older with type 1 diabetes should have
an initial dilated and comprehensive
eyeexaminationbyanophthalmologist
or optometrist within 5 years after the
onset of diabetes. (B)
● Patients with type 2 diabetes should
have an initial dilated and comprehen-
siveeyeexaminationbyanophthalmol-
ogist or optometrist shortly after the
diagnosis of diabetes. (B)
● Subsequent examinations for type 1
and type 2 diabetic patients should be
repeated annually by an ophthalmolo-
gistoroptometrist.Lessfrequentexams
(every 2–3 years) may be considered
following one or more normal eye ex-
ams. Examinations will be required
more frequently if retinopathy is pro-
gressing. (B)
● High-quality fundus photographs can
detect most clinically signiﬁcant dia-
betic retinopathy. Interpretation of the
images should be performed by a
trained eye care provider. While retinal
photography may serve as a screening
tool for retinopathy, it is not a substi-
tute for a comprehensive eye exam,
which should be performed at least ini-
tially and at intervals thereafter as rec-
ommendedbyaneyecareprofessional.
(E)
● Women with preexisting diabetes who
are planning a pregnancy or who have
become pregnant should have a com-
prehensiveeyeexaminationandshould
be counseled on the risk of develop-
mentand/orprogressionofdiabeticret-
inopathy. Eye examination should
occur in the ﬁrst trimester with close
follow-up throughout pregnancy and
for 1 year postpartum. (B)
Treatment
● Promptlyreferpatientswithanylevelof
macular edema, severe NPDR, or any
PDR to an ophthalmologist who is
knowledgeable and experienced in the
management and treatment of diabetic
retinopathy. (A)
● Laser photocoagulation therapy is indi-
cated to reduce the risk of vision loss in
patients with high-risk PDR, clinically
signiﬁcantmacularedema,andinsome
cases of severe NPDR. (A)
● The presence of retinopathy is not a
contraindication to aspirin therapy for
cardioprotection, as this therapy does
not increase the risk of retinal hemor-
rhage. (A)
Diabetic retinopathy is a highly speciﬁc
vascular complication of both type 1 and
type 2 diabetes, with prevalence strongly
related to the duration of diabetes. Dia-
betic retinopathy is the most frequent
cause of new cases of blindness among
adults aged 20–74 years. Glaucoma, cat-
aracts, and other disorders of the eye oc-
cur earlier and more frequently in people
with diabetes.
In addition to duration of diabetes,
other factors that increase the risk of, or
are associated with, retinopathy include
chronic hyperglycemia (290), the pres-
ence of nephropathy (291), and hyper-
tension (292). Intensive diabetes
management with the goal of achieving
near normoglycemia has been shown in
large prospective randomized studies to
prevent and/or delay the onset and pro-
gression of diabetic retinopathy (47,55,
56,64). Lowering blood pressure has
been shown to decrease the progression
of retinopathy (195). Several case series
and a controlled prospective study sug-
gest that pregnancy in type 1 diabetic pa-
tients may aggravate retinopathy
Table 15—Management of CKD in diabetes
GFR (ml/min/
1.73 m
2) Recommended
All patients Yearly measurement of creatinine, urinary albumin excretion, potassium
45–60 Referral to nephrology if possibility for nondiabetic kidney disease exists
(duration type 1 diabetes 10 years, heavy proteinuria, abnormal
ﬁndings on renal ultrasound, resistant hypertension, rapid fall in
GFR, or active urinary sediment)
Consider need for dose adjustment of medications
Monitor eGFR every 6 months
Monitor electrolytes, bicarbonate, hemoglobin, calcium, phosphorus,
parathyroid hormone at least yearly
Assure vitamin D sufﬁciency
Consider bone density testing
Referral for dietary counselling
30–44 Monitor eGFR every 3 months
Monitor electrolytes, bicarbonate, calcium, phosphorus, parathyroid
hormone, hemoglobin, albumin, weight every 3–6 months
Consider need for dose adjustment of medications
30 Referral to nephrologist
Adapted from http://www.kidney.org/professionals/KDOQI/guideline_diabetes/.
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gery can minimize this risk (294).
One of the main motivations for
screening for diabetic retinopathy is the
established efﬁcacy of laser photocoagu-
lation surgery in preventing vision loss.
Two large trials, the Diabetic Retinopathy
Study (DRS) and the Early Treatment Di-
abetic Retinopathy Study (ETDRS), pro-
vide the strongest support for the
therapeutic beneﬁts of photocoagulation
surgery.
The DRS (295) showed that panreti-
nalphotocoagulationsurgeryreducedthe
risk of severe vision loss from PDR from
15.9% in untreated eyes to 6.4% in
treated eyes, with greatest risk-to-beneﬁt
ratio in those with baseline disease (disc
neovascularization or vitreous hemor-
rhage).
The ETDRS (296) established the
beneﬁt of focal laser photocoagulation
surgery in eyes with macular edema, par-
ticularly those with clinically signiﬁcant
macular edema, with reduction of dou-
bling of the visual angle (e.g., 20/50 to
20/100) from 20% in untreated eyes to
8% in treated eyes. The ETDRS also veri-
ﬁed the beneﬁts of panretinal photocoag-
ulation for high-risk PDR and in older-
onset patients with severe NPDR or less-
than-high-risk PDR.
Laser photocoagulation surgery in
both trials was beneﬁcial in reducing the
risk of further vision loss, but generally
not beneﬁcial in reversing already dimin-
ished acuity. This preventive effect and
thefactthatpatientswithPDRormacular
edema may be asymptomatic provide
strongsupportforascreeningprogramto
detect diabetic retinopathy.
As retinopathy is estimated to take at
least 5 years to develop after the onset of
hyperglycemia, patients with type 1 dia-
betes should have an initial dilated and
comprehensive eye examination within 5
years after the onset of diabetes. Patients
with type 2 diabetes, who generally have
had years of undiagnosed diabetes and
who have a signiﬁcant risk of prevalent
DR at time of diabetes diagnosis, should
have an initial dilated and comprehensive
eye examination soon after diagnosis. Ex-
aminations should be performed by an
ophthalmologist or optometrist who is
knowledgeable and experienced in diag-
nosing the presence of diabetic retinopa-
thy and is aware of its management.
Subsequent examinations for type 1 and
type 2 diabetic patients are generally re-
peated annually. Less-frequent exams
(every 2–3 years) may be cost effective
after one or more normal eye exams,
whileexaminationswillberequiredmore
frequently if retinopathy is progressing
(297).
The use of retinal photography with
remote reading by experts has great po-
tential in areas where qualiﬁed eye care
professionals are not available, and may
also enhance efﬁciency and reduce costs
when the expertise of ophthalmologists
can be utilized for more complex exami-
nations and for therapy (298). In-person
exams are still necessary when the photos
are unacceptable and for follow-up of ab-
normalities detected. Photos are not a
substitute for a comprehensive eye exam,
which should be performed at least ini-
tially and at intervals thereafter as recom-
mended by an eye care professional.
Resultsofeyeexaminationsshouldbe
documented and transmitted to the refer-
ring health care professional. For a de-
tailed review of the evidence and further
discussionofdiabeticretinopathy,seethe
ADA’stechnicalreviewandpositionstate-
ment on this subject (297,300).
D. Neuropathy screening and
treatment (301)
Recommendations
● All patients should be screened for dis-
talsymmetricpolyneuropathy(DPN)at
diagnosis and at least annually thereaf-
ter, using simple clinical tests. (B)
● Electrophysiological testing is rarely
needed, except in situations where the
clinical features are atypical. (E)
● Screening for signs and symptoms of
autonomic neuropathy should be insti-
tutedatdiagnosisoftype2diabetesand
5 years after the diagnosis of type 1 di-
abetes. Special testing is rarely needed
and may not affect management or out-
comes. (E)
● Medications for the relief of speciﬁc
symptoms related to DPN and auto-
nomic neuropathy are recommended,
as they improve the quality of life of the
patient. (E)
The diabetic neuropathies are heteroge-
neous with diverse clinical manifesta-
tions. They may be focal or diffuse. Most
common among the neuropathies are
chronic sensorimotor DPN and auto-
nomicneuropathy.AlthoughDPNisadi-
agnosis of exclusion, complex
investigationstoexcludeotherconditions
are rarely needed.
The early recognition and appropri-
ate management of neuropathy in the pa-
tient with diabetes is important for a
number of reasons: 1) nondiabetic neu-
ropathies may be present in patients with
diabetes and may be treatable, 2) a num-
ber of treatment options exist for symp-
tomatic diabetic neuropathy, 3)u pt o
50% of DPN may be asymptomatic and
patients are at risk of insensate injury to
their feet, and 4) autonomic neuropathy
and particularly cardiovascular auto-
nomic neuropathy is associated with sub-
stantial morbidity and even mortality.
Speciﬁc treatment for the underlying
nerve damage is currently not available,
other than improved glycemic control,
which may modestly slow progression
(63) but not reverse neuronal loss. Effec-
tive symptomatic treatments are available
for some manifestations of DPN and au-
tonomic neuropathy.
Diagnosis of neuropathy
Distal symmetric polyneuropathy. Pa-
tients with diabetes should be screened
annually for DPN using tests such as pin-
prick sensation, vibration perception
(usinga128-Hztuningfork),10-gmono-
ﬁlament pressure sensation at the distal
plantar aspect of both great toes and
metatarsal joints, and assessment of ankle
reﬂexes. Combinations of more than one
test have 87% sensitivity in detecting
DPN. Loss of 10-g monoﬁlament percep-
tion and reduced vibration perception
predict foot ulcers (301). Importantly, in
patients with neuropathy, particularly
when severe, causes other than diabetes
should always be considered, such as
neurotoxic mediations, heavy metal poi-
soning, alcohol abuse, vitamin B12 deﬁ-
ciency (especially in those taking
metformin for prolonged periods (302),
renal disease, chronic inﬂammatory de-
myelinating neuropathy, inherited neu-
ropathies, and vasculitis (303).
Diabetic autonomic neuropathy (304).
The symptoms and signs of autonomic
dysfunction should be elicited carefully
during the history and physical examina-
tion. Major clinical manifestations of dia-
betic autonomic neuropathy include
resting tachycardia, exercise intolerance,
orthostatic hypotension, constipation,
gastroparesis, erectile dysfunction, sudo-
motor dysfunction, impaired neurovas-
cular function, and, potentially,
autonomicfailureinresponsetohypogly-
cemia.
Cardiovascular autonomic neuropa-
thy, a CVD risk factor (93), is the most
studied and clinically important form of
diabetic autonomic neuropathy. Cardio-
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indicated by resting tachycardia (100
bpm) or orthostasis (a fall in systolic
blood pressure 20 mmHg upon stand-
ing without an appropriate heart rate re-
sponse); it is also associated with
increased cardiac event rates.
Gastrointestinal neuropathies (e.g.,
esophageal enteropathy, gastroparesis,
constipation, diarrhea, fecal inconti-
nence) are common, and any section of
the gastrointestinal tract may be affected.
Gastroparesis should be suspected in in-
dividuals with erratic glucose control or
with upper gastrointestinal symptoms
without other identiﬁed cause. Evalua-
tionofsolid-phasegastricemptyingusing
double-isotope scintigraphy may be done
if symptoms are suggestive, but test re-
sults often correlate poorly with symp-
toms. Constipation is the most common
lower-gastrointestinal symptom but can
alternate with episodes of diarrhea.
Diabetic autonomic neuropathy is
also associated with genitourinary tract
disturbances.Inmen,diabeticautonomic
neuropathy may cause erectile dysfunc-
tion and/or retrograde ejaculation. Evalu-
ation of bladder dysfunction should be
performed for individuals with diabetes
who have recurrent urinary tract infec-
tions, pyelonephritis, incontinence, or a
palpable bladder.
Symptomatic treatments
DPN. Theﬁrststepinmanagementofpa-
tients with DPN should be to aim for sta-
ble and optimal glycemic control.
Althoughcontrolledtrialevidenceislack-
ing, several observational studies suggest
that neuropathic symptoms improve not
only with optimization of control, but
also with the avoidance of extreme blood
glucoseﬂuctuations.Patientswithpainful
DPN may beneﬁt from pharmacological
treatment of their symptoms: many
agents have efﬁcacy conﬁrmed in pub-
lished randomized controlled trials, sev-
eral of which are Food and Drug
Administration (FDA)-approved for the
management of painful DPN.
Treatment of autonomic neuropathy
Gastroparesis symptoms may improve
with dietary changes and prokinetic
agents such as metoclopramide or eryth-
romycin. Treatments for erectile dysfunc-
tion may include phosphodiesterase type
5 inhibitors, intracorporeal or intraure-
thral prostaglandins, vacuum devices, or
penile prostheses. Interventions for other
manifestations of autonomic neuropathy
are described in the ADA statement on
neuropathy (301). As with DPN treat-
ments, these interventions do not change
theunderlyingpathologyandnaturalhis-
toryofthediseaseprocess,butmayhavea
positiveimpactonthequalityoflifeofthe
patient.
E. Foot care
Recommendations
● For all patients with diabetes, perform
an annual comprehensive foot exami-
nationtoidentifyriskfactorspredictive
of ulcers and amputations. The foot ex-
amination should include inspection,
assessment of foot pulses, and testing
for loss of protective sensation (10-g
monoﬁlament plus testing any one of:
vibration using 128-Hz tuning fork,
pinprick sensation, ankle reﬂexes, or
vibration perception threshold). (B)
● Providegeneralfootself-careeducation
to all patients with diabetes. (B)
● A multidisciplinary approach is recom-
mendedforindividualswithfootulcers
andhigh-riskfeet,especiallythosewith
a history of prior ulcer or amputation.
(B)
● Refer patients who smoke, have loss of
protective sensation and structural ab-
normalities, or have history of prior
lower-extremity complications to foot
care specialists for ongoing preventive
care and life-long surveillance. (C)
● Initial screening for peripheral arterial
disease (PAD) should include a history
for claudication and an assessment of
thepedalpulses.Considerobtainingan
ankle-brachialindex(ABI),asmanypa-
tients with PAD are asymptomatic. (C)
● Referpatientswithsigniﬁcantclaudica-
tion or a positive ABI for further vascu-
lar assessment and consider exercise,
medications, and surgical options. (C)
Amputation and foot ulceration, conse-
quences of diabetic neuropathy and/or
PAD, are common and major causes of
morbidity and disability in people with
diabetes. Early recognition and manage-
ment of risk factors can prevent or delay
adverse outcomes.
The risk of ulcers or amputations is
increased in people who have the follow-
ing risk factors:
● Previous amputation
● Past foot ulcer history
● Peripheral neuropathy
● Foot deformity
● Peripheral vascular disease
● Visual impairment
● Diabetic nephropathy (especially pa-
tients on dialysis)
● Poor glycemic control
● Cigarette smoking
Many studies have been published pro-
posing a range of tests that might usefully
identify patients at risk of foot ulceration,
creatingconfusionamongpractitionersas
to which screening tests should be
adopted in clinical practice. An ADA task
force was therefore assembled in 2008 to
concisely summarize recent literature in
this area and then recommend what
should be included in the comprehensive
footexamforadultpatientswithdiabetes.
Their recommendations are summarized
below, but clinicians should refer to the
task force report (305) for further details
and practical descriptions of how to per-
form components of the comprehensive
foot examination.
At least annually, all adults with dia-
betes should undergo a comprehensive
foot examination to identify high risk
conditions. Clinicians should ask about
history of previous foot ulceration or am-
putation, neuropathic or peripheral vas-
cularsymptoms,impairedvision,tobacco
use, and foot care practices. A general in-
spection of skin integrity and musculo-
skeletal deformities should be done in a
well lit room. Vascular assessment would
include inspection and assessment of
pedal pulses.
The neurologic exam recommended
is designed to identify loss of protective
sensation (LOPS) rather than early neu-
ropathy.Theclinicalexaminationtoiden-
tify LOPS is simple and requires no
expensiveequipment.Fivesimpleclinical
tests (use of a 10-g monoﬁlament, vibra-
tion testing using a 128-Hz tuning fork,
tests of pinprick sensation, ankle reﬂex
assessment, and testing vibration percep-
tion threshold with a biothesiometer),
each with evidence from well-conducted
prospective clinical cohort studies, are
considered useful in the diagnosis of
LOPS in the diabetic foot. The task force
agreesthatanyoftheﬁvetestslistedcould
be used by clinicians to identify LOPS,
although ideally two of these should be
regularly performed during the screening
exam—normally the 10-g monoﬁlament
andoneothertest.Oneormoreabnormal
tests would suggest LOPS, while at least
two normal tests (and no abnormal test)
would rule out LOPS. The last test listed,
vibration assessment using a biothesiom-
eter or similar instrument, is widely used
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patient with LOPS can easily be carried
outwithoutthisorotherexpensiveequip-
ment.
Initial screening for PAD should in-
clude a history for claudication and an
assessmentofthepedalpulses.Adiagnos-
tic ABI should be performed in any pa-
tient with symptoms of PAD. Due to the
high estimated prevalence of PAD in pa-
tientswithdiabetesandthefactthatmany
patients with PAD are asymptomatic, an
ADA consensus statement on PAD (306)
suggested that a screening ABI be per-
formed in patients over 50 years of age
and be considered in patients under 50
years of age who have other PAD risk fac-
tors (e.g., smoking, hypertension, hyper-
lipidemia, or duration of diabetes 10
years). Refer patients with signiﬁcant
symptoms or a positive ABI for further
vascular assessment and consider exer-
cise, medications, and surgical options
(306).
Patients with diabetes and high-risk
foot conditions should be educated re-
garding their risk factors and appropriate
management. Patients at risk should un-
derstand the implications of the LOPS,
the importance of foot monitoring on a
daily basis, the proper care of the foot,
including nail and skin care, and the se-
lection of appropriate footwear. Patients
withLOPSshouldbeeducatedonwaysto
substitute other sensory modalities (hand
palpation, visual inspection) for surveil-
lance of early foot problems. Patients’ un-
derstanding of these issues and their
physical ability to conduct proper foot
surveillance and care should be assessed.
Patients with visual difﬁculties, physical
constraintspreventingmovement,orcog-
nitiveproblemsthatimpairtheirabilityto
assess the condition of the foot and to in-
stitute appropriate responses will need
other people, such as family members, to
assist in their care.
People with neuropathy or evidence
of increased plantar pressure (e.g., ery-
thema, warmth, callus, or measured pres-
sure) may be adequately managed with
well-ﬁttedwalkingshoesorathleticshoes
that cushion the feet and redistribute
pressure. Callus can be debrided with a
scalpel by a foot care specialist or other
health professional with experience and
training in foot care. People with bony
deformities (e.g., hammertoes, promi-
nent metatarsal heads, bunions) may
need extra-wide or -depth shoes. People
with extreme bony deformities (e.g.,
Charcot foot) who cannot be accommo-
dated with commercial therapeutic foot-
wear may need custom-molded shoes.
Foot ulcers and wound care may re-
quire care by a podiatrist, orthopedic or
vascular surgeon, or rehabilitation spe-
cialist experienced in the management of
individuals with diabetes.
VII. DIABETES CARE IN
SPECIFIC POPULATIONS
A. Children and adolescents
1. Type 1 diabetes
Three-quarters of all cases of type 1 dia-
betes are diagnosed in individuals 18
years of age. It is appropriate to consider
the unique aspects of care and manage-
ment of children and adolescents with
type 1 diabetes. Children with diabetes
differ from adults in many respects, in-
cluding changes in insulin sensitivity re-
lated to sexual maturity and physical
growth,abilitytoprovideself-care,super-
vision in child care and school, and
unique neurological vulnerability to hy-
poglycemia and DKA. Attention to such
issues as family dynamics, developmental
stages, and physiological differences re-
lated to sexual maturity are all essential in
developing and implementing an optimal
diabetes regimen. Although recommen-
dations for children and adolescents are
less likely to be based on clinical trial ev-
idence, expert opinion and a review of
available and relevant experimental data
are summarized in the ADA statement on
careofchildrenandadolescentswithtype
1 diabetes (307).
Ideally, the care of a child or adoles-
cent with type 1 diabetes should be pro-
vided by a multidisciplinary team of
specialists trained in the care of children
with pediatric diabetes. At the very least,
education of the child and family should
be provided by health care providers
trained and experienced in childhood di-
abetes and sensitive to the challenges
posed by diabetes in this age-group. At
the time of initial diagnosis, it is essential
that diabetes education be provided in a
timely fashion, with the expectation that
the balance between adult supervision
and self-care should be deﬁned by, and
will evolve according to, physical, psy-
chological,andemotionalmaturity.MNT
andpsychologicalsupportshouldbepro-
vided at diagnosis, and regularly thereaf-
ter, by individuals experienced with the
nutritional and behavioral needs of the
growing child and family.
a. Glycemic control
Recommendations
● Consider age when setting glycemic
goals in children and adolescents with
type 1 diabetes. (E)
While current standards for diabetes
management reﬂect the need to maintain
glucosecontrolasneartonormalassafely
possible, special consideration should be
giventotheuniquerisksofhypoglycemia
in young children. Glycemic goals may
need to be modiﬁed to take into account
the fact that most children 6 or 7 years
of age have a form of “hypoglycemic un-
awareness,” including immaturity of and
a relative inability to recognize and re-
spond to hypoglycemic symptoms, plac-
ing them at greater risk for severe
hypoglycemia and its sequelae. In addi-
tion, and unlike the case in adults, young
children under the age of 5 years may be
at risk for permanent cognitive impair-
ment after episodes of severe hypoglyce-
mia (308–310). Furthermore, ﬁndings
from the DCCT demonstrated that near-
normalization of blood glucose levels was
more difﬁcult to achieve in adolescents
than adults. Nevertheless, the increased
frequency of use of basal-bolus regimens
and insulin pumps in youth from infancy
through adolescence has been associated
with more children reaching ADA blood
glucose targets (311,312) in those fami-
lies in which both parents and the child
with diabetes participate jointly to per-
form the required diabetes-related tasks.
Furthermore, recent studies document-
ing neurocognitive sequelae of hypergly-
cemia in children provide another
compelling motivation for achieving gly-
cemic targets (313,314).
In selecting glycemic goals, the bene-
ﬁts on long-term health outcomes of
achieving a lower A1C should be bal-
anced against the risks of hypoglycemia
and the developmental burdens of inten-
sive regimens in children and youth. Age-
speciﬁc glycemic and A1C goals are
presented in Table 16.
b. Screening and management of
chronic complications in children
and adolescents with type 1 diabetes
i. Nephropathy
Recommendations
● Annual screening for microalbumin-
uria,witharandomspoturinesample
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tio, should be considered once the
child is 10 years of age and has had
diabetes for 5 years. (E)
● Conﬁrmed, persistently elevated ACR
on two additional urine specimens
from different days should be treated
withanACEinhibitor,titratedtonor-
malization of albumin excretion if
possible. (E)
ii. Hypertension
Recommendations
● Treatment of high-normal blood
pressure (systolic or diastolic blood
pressure consistently above the 90th
percentile for age, sex, and height)
should include dietary intervention
and exercise aimed at weight control
and increased physical activity, if ap-
propriate. If target blood pressure is
not reached with 3–6 months of life-
style intervention, pharmacologic
treatment should be considered. (E)
● Pharmacologic treatment of hyper-
tension (systolic or diastolic blood
pressure consistently above the 95th
percentile for age, sex, and height or
consistently greater than 130/80
mmHg, if 95% exceeds that value)
should be initiated as soon as the di-
agnosis is conﬁrmed. (E)
● ACE inhibitors should be considered
for the initial treatment of hyperten-
sion, following appropriate reproduc-
tive counseling due to its potential
teratogenic effects. (E)
● The goal of treatment is a blood pres-
sureconsistently130/80orbelowthe
90thpercentileforage,sex,andheight,
whichever is lower. (E)
It is important that blood pressure mea-
surements are determined correctly, us-
ing the appropriate size cuff, and with
the child seated and relaxed. Hyperten-
sion should be conﬁrmed on at least
three separate days. Normal blood pres-
sure levels for age, sex, and height and
appropriate methods for determina-
tions are available online at www.nhlbi.
nih.gov/health/prof/heart/hbp/hbp_
ped.pdf.
iii. Dyslipidemia
Recommendations
Screening
● If there is a family history of hypercho-
lesterolemia (total cholesterol 240
mg/dl) or a cardiovascular event before
age 55 years, or if family history is un-
known, then a fasting lipid proﬁle
should be performed on children 2
years of age soon after diagnosis (after
glucose control has been established).
If family history is not of concern, then
the ﬁrst lipid screening should be con-
sideredatpuberty(10years).Allchil-
dren diagnosed with diabetes at or after
pubertyshouldhaveafastinglipidpro-
ﬁle performed soon after diagnosis
(after glucose control has been estab-
lished). (E)
● Forbothage-groups,iflipidsareabnor-
mal, annual monitoring is recom-
mended. If LDL cholesterol values are
within the accepted risk levels (100
mg/dl [2.6 mmol/l]), a lipid proﬁle
should be repeated every 5 years. (E)
Table 16—Plasma blood glucose and A1C goals for type 1 diabetes by age-group
Plasma blood glucose goal range
(mg/dl)
A1C (%) Rationale Before meals Bedtime/overnight
Toddlers and preschoolers
(0–6 years)
100–180 110–200 8.5 • Vulnerability to hypoglycemia
• Insulin sensitivity
• Unpredictability in dietary intake and
physical activity
• A lower goal (8.0%) is reasonable if
it can be achieved without excessive
hypoglycemia
School age (6–12 years) 90–180 100–180 8 • Vulnerability to hypoglycemia
• A lower goal (7.5%) is reasonable if
it can be achieved without excessive
hypoglycemia
Adolescents and young adults
(13–19 years)
90–130 90–150 7.5 • A lower goal (7.0%) is reasonable if
it can be achieved without excessive
hypoglycemia
Key concepts in setting glycemic goals
• Goals should be individualized and lower goals may be reasonable based on beneﬁt-risk
assessment.
• Blood glucose goals should be modiﬁed in children with frequent hypoglycemia or
hypoglycemia unawareness.
• Postprandial blood glucose values should be measured when there is a discrepancy
between pre-prandial blood glucose values and A1C levels and to help assess glycemia in
those on basal/bolus regimens.
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● Initialtherapyshouldconsistofoptimi-
zation of glucose control and MNT us-
ing a Step 2 AHA diet aimed at a
decrease in the amount of saturated fat
in the diet. (E)
● Aftertheageof10years,theadditionof
a statin in patients who, after MNT and
lifestyle changes, have LDL cholesterol
160 mg/dl (4.1 mmol/l), or LDL cho-
lesterol 130 mg/dl (3.4 mmol/l) and
oneormoreCVDriskfactors,isreason-
able. (E)
● The goal of therapy is an LDL choles-
terol value 100 mg/dl (2.6 mmol/l).
(E)
People diagnosed with type 1 diabetes in
childhood have a high risk of early sub-
clinical (315–317) and clinical (318)
CVD. Although intervention data are
lacking, the AHA categorizes children
with type 1 diabetes in the highest tier for
cardiovascular risk and recommends
both lifestyle and pharmacologic treat-
ment for those with elevated LDL choles-
terol levels (319,320). Initial therapy
should be with a Step 2 AHA diet, which
restricts saturated fat to 7% of total calo-
ries and restricts dietary cholesterol to
200 mg/day. Data from randomized clin-
ical trials in children as young as 7
monthsofageindicatethatthisdietissafe
and does not interfere with normal
growth and development (321,322).
Neither long-term safety nor cardio-
vascular outcome efﬁcacy of statin ther-
apy has been established for children.
However, recent studies have shown
short-term safety equivalent to that seen
in adults, and efﬁcacy in lowering LDL
cholesterol levels, improving endothelial
function, and causing regression of ca-
rotid intimal thickening (323–325). No
statin is approved for use under the age of
10years,andstatintreatmentshouldgen-
erally not be used in children with type 1
diabetes prior to this age.
iv. Retinopathy
Recommendations
● The ﬁrst ophthalmologic examination
should be obtained once the child is 10
years of age and has had diabetes for
3–5 years. (E)
● After the initial examination, annual
routine follow-up is generally recom-
mended. Less frequent examinations
may be acceptable on the advice of an
eye care professional. (E)
Although retinopathy most commonly
occurs after the onset of puberty and after
5–10 years of diabetes duration, it has
been reported in prepubertal children
and with diabetes duration of only 1–2
years. Referrals should be made to eye
care professionals with expertise in dia-
betic retinopathy, an understanding of
the risk for retinopathy in the pediatric
population, and experience in counsel-
ing the pediatric patient and family on
the importance of early prevention/
intervention.
v. Celiac disease
Recommendations
● Children with type 1 diabetes should
be screened for celiac disease by mea-
suring tissue transglutaminase or
anti-endomysial antibodies, with
documentation of normal total serum
IgA levels, soon after the diagnosis of
diabetes. (E)
● Testing should be repeated in children
with growth failure, failure to gain
weight, weight loss, diarrhea, ﬂatu-
lence, abdominal pain, or signs of mal-
absorption, or in children with
frequent unexplained hypoglycemia or
deterioration in glycemic control. (E)
● Children with positive antibodies
should be referred to a gastroenterolo-
gist for evaluation with endoscopy and
biopsy. (E)
● Children with biopsy-conﬁrmed celiac
disease should be placed on a gluten-
free diet and have consultation with a
dietitian experienced in managing both
diabetes and celiac disease. (E)
Celiac disease is an immune-mediated
disorder that occurs with increased fre-
quency in patients with type 1 diabetes
(1–16% of individuals compared with
0.3–1% in the general population)
(326,327).Symptomsofceliacdiseasein-
cludediarrhea,weightlossorpoorweight
gain, growth failure, abdominal pain,
chronic fatigue, malnutrition due to mal-
absorption, other gastrointestinal prob-
lems, and unexplained hypoglycemia or
erratic blood glucose concentrations.
The advent of routine periodic
screeninghasledtothediagnosisofceliac
disease in asymptomatic children. While
several studies have documented short-
term beneﬁts of gluten restriction on
growth and bone mineral density in
asymptomatic children diagnosed with
celiac disease by routine screening, there
is little literature available regarding the
long-term beneﬁt of gluten-free diets in
this population.
vi. Hypothyroidism
Recommendations
● Childrenwithtype1diabetesshouldbe
screened for thyroid peroxidase and
thyroglobulin antibodies at diagnosis.
(E)
● TSH concentrations should be mea-
sured after metabolic control has been
established. If normal, they should be
re-checked every 1–2 years, or if the
patient develops symptoms of thyroid
dysfunction,thyromegaly,oranabnor-
mal growth rate. (E)
Auto-immune thyroid disease is the most
common autoimmune disorder associ-
ated with diabetes, occurring in 17–30%
ofpatientswithtype1diabetes(328).The
presence of thyroid auto-antibodies is
predictive of thyroid dysfunction, gener-
ally hypothyroidism but less commonly
hyperthyroidism (329). Subclinical hy-
pothyroidism may be associated with
increasedriskofsymptomatichypoglyce-
mia(330)andwithreducedlineargrowth
(331). Hyperthyroidism alters glucose
metabolism, potentially resulting in dete-
rioration of metabolic control.
c. Self-management
No matter how sound the medical regi-
men,itcanonlybeasgoodastheabilityof
thefamilyand/orindividualtoimplement
it. Family involvement in diabetes re-
mains an important component of opti-
mal diabetes management throughout
childhood and into adolescence. Health
care providers who care for children and
adolescents,therefore,mustbecapableof
evaluating the behavioral, emotional, and
psychosocial factors that interfere with
implementationandthenmustworkwith
the individual and family to resolve prob-
lems that occur and/or to modify goals as
appropriate.
d. School and day care
Becauseasizableportionofachild’sdayis
spent in school, close communication
with and cooperation of school or day
care personnel is essential for optimal di-
abetes management, safety, and maximal
academic opportunities. See the ADA po-
sition statement on Diabetes Care in the
SchoolandDayCareSetting(332)forfur-
ther discussion.
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As they approach the young adult years,
older adolescents are at increasing physi-
cal,behavioral,andotherrisks(333,334).
As they leave both their home and their
pediatric diabetes care providers, these
older teens may become disengaged from
thehealthcaresystem,leadingtolapsesin
medical care and deterioration in glyce-
mic control (335). Though scientiﬁc evi-
dence is limited to date, it is clear that
early and ongoing attention be given to
comprehensiveandcoordinatedplanning
for seamless transition of all youth from
pediatric to adult health care (336,337).
The National Diabetes Education Pro-
gram (NDEP) has materials available to
facilitate this transition process (http://
ndep.nih.gov/transitions/).
2. Type 2 diabetes
The incidence of type 2 diabetes in ado-
lescents is increasing, especially in ethnic
minority populations (21). Distinction
between type 1 and type 2 diabetes in
children can be difﬁcult, since the preva-
lence of overweight in children continues
to rise and since autoantigens and ketosis
maybepresentinasubstantialnumberof
patients with features of type 2 diabetes
(including obesity and acanthosis nigri-
cans). Such a distinction at the time of
diagnosis is critical since treatment regi-
mens, educational approaches, and di-
etary counsel will differ markedly
between the two diagnoses.
Type 2 diabetes has a signiﬁcant preva-
lenceofcomorbiditiesalreadypresentatthe
time of diagnosis (338). It is recommended
that blood pressure measurement, a fasting
lipidproﬁle,microalbuminuriaassessment,
and dilated eye examination be performed
atthetimeofdiagnosis.Thereafter,screen-
ing guidelines and treatment recommen-
dations for hypertension, dyslipidemia,
microalbuminuria, and retinopathy in
youth with type 2 diabetes are similar to
those for youth with type 1 diabetes. Ad-
ditionalproblemsthatmayneedtobead-
dressed include polycystic ovary disease
and the various comorbidities associated
with pediatric obesity such as sleep ap-
nea,hepaticsteatosis,orthopediccompli-
cations, and psychosocial concerns. The
ADA consensus statement on this subject
(23) provides guidance on the preven-
tion, screening, and treatment of type 2
diabetes and its comorbidities in young
people.
3. Monogenic diabetes syndromes
Monogenic forms of diabetes (neonatal
diabetes or maturity-onset diabetes of the
young) represent a small fraction of chil-
dren with diabetes (5%), but the ready
availability of commercial genetic testing
is now enabling a true genetic diagnosis
with increasing frequency. It is important
to correctly diagnose one of the mono-
genic forms of diabetes, as these children
may be incorrectly diagnosed with type 1
or type 2 diabetes, leading to nonoptimal
treatment regimens and delays in diag-
nosing other family members.
The diagnosis of monogenic diabetes
shouldbeconsideredinthefollowingset-
tings:diabetesdiagnosedwithintheﬁrst6
months of life; in children with strong
familyhistoryofdiabetesbutwithouttyp-
ical features of type 2 diabetes (nonobese,
low-risk ethnic group); in children with
mild fasting hyperglycemia (100–150
mg/dl [5.5–8.5 mmol]), especially if
young and nonobese; and in children
with diabetes but with negative auto-
antibodies without signs of obesity or in-
sulin resistance. A recent international
consensus document discusses in further
detail the diagnosis and management of
children with monogenic forms of diabe-
tes (339).
B. Preconception care
Recommendations
● A1C levels should be as close to normal
as possible (7%) in an individual pa-
tient before conception is attempted.
(B)
● Starting at puberty, preconception
counseling should be incorporated in
the routine diabetes clinic visit for all
women of child-bearing potential. (C)
● Womenwithdiabeteswhoarecontem-
plating pregnancy should be evaluated
and, if indicated, treated for diabetic
retinopathy,nephropathy,neuropathy,
and CVD. (E)
● Medications used by such women
should be evaluated prior to concep-
tion, since drugs commonly used to
treat diabetes and its complications
may be contraindicated or not recom-
mended in pregnancy, including st-
atins, ACE inhibitors, ARBs, and most
noninsulin therapies. (E)
● Since many pregnancies are un-
planned, consider the potential risks
and beneﬁts of medications that are
contraindicated in pregnancy in all
women of childbearing potential, and
counsel women using such medica-
tions accordingly. (E)
Major congenital malformations remain
the leading cause of mortality and serious
morbidity in infants of mothers with type
1andtype2diabetes.Observationalstud-
ies indicate that the risk of malformations
increases continuously with increasing
maternal glycemia during the ﬁrst 6–8
weeks of gestation, as deﬁned by ﬁrst-
trimesterA1Cconcentrations.Thereisno
threshold for A1C values below which
risk disappears entirely. However, mal-
formation rates above the 1–2% back-
ground rate of nondiabetic pregnancies
appear to be limited to pregnancies in
which ﬁrst-trimester A1C concentrations
are 1% above the normal range for a
nondiabetic pregnant woman.
Preconception care of diabetes ap-
pearstoreducetheriskofcongenitalmal-
formations. Five nonrandomized studies
comparedratesofmajormalformationsin
infants between women who participated
in preconception diabetes care programs
andwomenwhoinitiatedintensivediabe-
tes management after they were already
pregnant. The preconception care pro-
grams were multidisciplinary and de-
signed to train patients in diabetes self-
managementwithdiet,intensiﬁedinsulin
therapy, and SMBG. Goals were set to
achieve normal blood glucose concentra-
tions, and 80% of subjects achieved
normal A1C concentrations before they
became pregnant. In all ﬁve studies, the
incidence of major congenital malforma-
tions in women who participated in pre-
conception care (range 1.0–1.7% of
infants) was much lower than the inci-
dence in women who did not participate
(range 1.4–10.9% of infants) (78). One
limitation of these studies is that partici-
pation in preconception care was self-
selected rather than randomized. Thus, it
is impossible to be certain that the lower
malformation rates resulted fully from
improved diabetes care. Nonetheless, the
evidence supports the concept that mal-
formations can be reduced or prevented
by careful management of diabetes before
pregnancy.
Planned pregnancies greatly facili-
tate preconception diabetes care. Un-
fortunately, nearly two-thirds of
pregnanciesinwomenwithdiabetesare
unplanned, leading to a persistent ex-
cess of malformations in infants of dia-
betic mothers. To minimize the
occurrence of these devastating malfor-
mations, standard care for all women
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potential, beginning at the onset of pu-
berty or at diagnosis, should include 1)
education about the risk of malforma-
tions associated with unplanned preg-
nancies and poor metabolic control;
and 2) use of effective contraception at
all times, unless the patient has good
metabolic control and is actively trying
to conceive.
Women contemplating pregnancy
need to be seen frequently by a multi-
disciplinary team experienced in the
management of diabetes before and
during pregnancy. The goals of precon-
ception care are to 1) involve and em-
power the patient in the management of
her diabetes, 2) achieve the lowest A1C
test results possible without excessive
hypoglycemia, 3) assure effective con-
traception until stable and acceptable
glycemia is achieved, and 4) identify,
evaluate, and treat long-term diabetes
complications such as retinopathy, ne-
phropathy, neuropathy, hypertension,
and CHD (78).
Amongthedrugscommonlyusedin
the treatment of patients with diabetes,
a number may be relatively or abso-
lutely contraindicated during preg-
nancy. Statins are category X
(contraindicated for use in pregnancy)
and should be discontinued before con-
ception, as should ACE inhibitors
(340). ARBs are category C (risk cannot
be ruled out) in the ﬁrst trimester but
category D (positive evidence of risk) in
later pregnancy and should generally be
discontinued before pregnancy. Since
many pregnancies are unplanned,
health care professionals caring for any
womanofchildbearingpotentialshould
consider the potential risks and beneﬁts
of medications that are contraindicated
in pregnancy. Women using medica-
tions such as statins or ACE inhibitors
need ongoing family planning counsel-
ing. Among the oral antidiabetic agents,
metforminandacarboseareclassiﬁedas
category B (no evidence of risk in hu-
mans) and all others as category C. Po-
tential risks and beneﬁts of oral
antidiabeticagentsinthepreconception
period must be carefully weighed, rec-
ognizing that data are insufﬁcient to es-
tablish the safety of these agents in
pregnancy.
For further discussion of preconcep-
tion care, see the ADA’s consensus state-
ment on preexisting diabetes and
pregnancy (78) and the position state-
ment (341) on this subject.
C. Older adults
Recommendations
● Olderadultswhoarefunctional,cogni-
tively intact, and have signiﬁcant life
expectancyshouldreceivediabetescare
using goals developed for younger
adults. (E)
● Glycemic goals for older adults not
meeting the above criteria may be re-
laxed using individual criteria, but hy-
perglycemia leading to symptoms or
risk of acute hyperglycemic complica-
tions should be avoided in all patients.
(E)
● Other cardiovascular risk factors
should be treated in older adults with
consideration of the time frame of ben-
eﬁt and the individual patient. Treat-
ment of hypertension is indicated in
virtually all older adults, and lipid and
aspirin therapy may beneﬁt those with
lifeexpectancyatleastequaltothetime
frame of primary or secondary preven-
tion trials. (E)
● Screening for diabetes complications
should be individualized in older
adults, but particular attention should
be paid to complications that would
lead to functional impairment. (E)
Diabetes is an important health condition
for the aging population; at least 20% of
patients over the age of 65 years have di-
abetes, and this number can be expected
to grow rapidly in the coming decades.
Older individuals with diabetes have
higher rates of premature death, func-
tional disability, and coexisting illnesses
such as hypertension, CHD, and stroke
than those without diabetes. Older adults
with diabetes are also at greater risk than
otherolderadultsforseveralcommonge-
riatricsyndromes,suchaspolypharmacy,
depression, cognitive impairment, uri-
nary incontinence, injurious falls, and
persistent pain.
The American Geriatric Society’s
guidelines for improving the care of the
older person with diabetes (342) have in-
ﬂuenced the following discussion and
recommendations. The care of older
adults with diabetes is complicated by
their clinical and functional heterogene-
ity. Some older individuals developed di-
abetes years earlier and may have
signiﬁcant complications; others who are
newly diagnosed may have had years of
undiagnoseddiabeteswithresultantcom-
plications or may have few complications
from the disease. Some older adults with
diabetes are frail and have other underly-
ing chronic conditions, substantial diabe-
tes-related comorbidity, or limited
physical or cognitive functioning. Other
older individuals with diabetes have little
comorbidityandareactive.Lifeexpectan-
cies are highly variable for this popula-
tion, but often longer than clinicians
realize. Providers caring for older adults
withdiabetesmusttakethisheterogeneity
into consideration when setting and pri-
oritizing treatment goals.
There are few long-term studies in
older adults demonstrating the beneﬁts of
intensive glycemic, blood pressure, and
lipid control. Patients who can be expected
to live long enough to reap the beneﬁts of
long-term intensive diabetes management
and who are active, have good cognitive
function, and are willing should be pro-
vided with the needed education and skills
to do so and be treated using the goals for
younger adults with diabetes.
For patients with advanced diabetes
complications, life-limiting comorbid ill-
ness, or substantial cognitive or func-
tional impairment, it is reasonable to set
less-intensiveglycemictargetgoals.These
patients are less likely to beneﬁt from re-
ducing the risk of microvascular compli-
cations and more likely to suffer serious
adverse effects from hypoglycemia.
However, patients with poorly controlled
diabetes may be subject to acute compli-
cations of diabetes, including dehydra-
tion, poor wound healing, and
hyperglycemic hyperosmolar coma. Gly-
cemic goals at a minimum should avoid
these consequences.
Although control of hyperglycemia
may be important in older individuals
with diabetes, greater reductions in mor-
bidity and mortality may result from con-
trol of other cardiovascular risk factors
rather than from tight glycemic control
alone. There is strong evidence from clin-
ical trials of the value of treating hyper-
tension in the elderly (343,344). There is
less evidence for lipid-lowering and aspi-
rin therapy, although the beneﬁts of these
interventions for primary and secondary
prevention are likely to apply to older
adults whose life expectancies equal or
exceed the time frames seen in clinical
trials.
Special care is required in prescribing
andmonitoringpharmacologictherapyin
older adults. Metformin is often contrain-
dicated because of renal insufﬁciency or
signiﬁcant heart failure. TZDs can cause
ﬂuid retention, which may exacerbate or
lead to heart failure. They are contraindi-
cated in patients with CHF (New York
Standards of Medical Care
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and if used at all should be used very cau-
tiously in those with, or at risk for, milder
degrees of CHF. Sulfonylureas, other in-
sulinsecretagogues,andinsulincancause
hypoglycemia. Insulin use requires that
patients or caregivers have good visual
and motor skills and cognitive ability.
Drugsshouldbestartedatthelowestdose
and titrated up gradually until targets are
reached or side effects develop.
Screening for diabetes complications
in older adults also should be individual-
ized. Particular attention should be paid
to complications that can develop over
short periods of time and/or that would
signiﬁcantly impair functional status,
such as visual and lower-extremity com-
plications.
D. Cystic ﬁbrosis–related diabetes
Cystic ﬁbrosis–related diabetes (CFRD) is
themostcommoncomorbidityinpersons
with CF, occurring in about 20% of ado-
lescents and 40–50% of adults. The addi-
tional diagnosis of diabetes in this
populationisassociatedwithworsenutri-
tional status, more-severe inﬂammatory
lung disease, and greater mortality from
respiratory failure. For reasons that are
not well understood, women with CFRD
are particularly vulnerable to excess mor-
bidityandmortality.Insulininsufﬁciency
related to partial ﬁbrotic destruction of
the islet mass is the primary defect in
CFRD. Genetically determined function
of the remaining -cells and insulin resis-
tance associated with infection and in-
ﬂammation may also play a role.
Encouraging new data suggest that early
detection and aggressive insulin therapy
have narrowed the gap in mortality be-
tween CF patients with and without dia-
betes, and have eliminated the sex
difference in mortality.
A consensus conference on CFRD
was co-sponsored in 2009 by the Ameri-
can Diabetes Association, the Cystic Fi-
brosis Foundation, and the Pediatric
Endocrine Society. Recommendations for
the clinical management of CFRD can be
found in an ADA position statement
(344a).
VIII. DIABETES CARE IN SPECIFIC
SETTINGS
A. Diabetes care in the hospital
Recommendations
● All patients with diabetes admitted to
the hospital should have their diabetes
clearly identiﬁed in the medical record.
(E)
● All patients with diabetes should have
an order for blood glucose monitoring,
with results available to all members of
the health care team. (E)
● Goals for blood glucose levels:
● Critically ill patients: Insulin therapy
should be initiated for treatment of
persistenthyperglycemiastartingata
threshold of no greater than 180
mg/dl (10 mmol/l). Once insulin
therapy is started, a glucose range of
140–180 mg/dl (7.8–10 mmol/l) is
recommended for the majority of
critically ill patients. (A)
● More stringent goals, such as 110–
140 mg/dl (6.1–7.8 mmol/l) may be
appropriate for selected patients, as
long as this can be achieved without
signiﬁcant hypoglycemia. (C)
● Critically ill patients require an intra-
venous insulin protocol that has
demonstrated efﬁcacy and safety in
achieving the desired glucose range
without increasing risk for severe hy-
poglycemia. (E)
● Non–critically ill patients: There is
no clear evidence for speciﬁc blood
glucose goals. If treated with insulin,
the premeal blood glucose target
should generally be 140 mg/dl (7.8
mmol/l) with random blood glucose
180mg/dl(10.0mmol/l),provided
these targets can be safely achieved.
More stringent targets may be appro-
priateinstablepatientswithprevious
tight glycemic control. Less stringent
targets may be appropriate in those
with severe comorbidites. (E)
● Scheduled subcutaneous insulin with
basal, nutritional, and correction com-
ponents is the preferred method for
achieving and maintaining glucose
control in noncritically ill patients. (C)
Using correction dose or “supplemen-
tal” insulin to correct premeal hyper-
glycemia in addition to scheduled
prandial and basal insulin is recom-
mended. (E)
● Glucose monitoring should be initiated
in any patient not known to be diabetic
who receives therapy associated with
high risk for hyperglycemia, including
high-doseglucocorticoidtherapy,initi-
ation of enteral or parenteral nutrition,
or other medications such as octreotide
or immunosuppressive medications.
(B) If hyperglycemia is documented
and persistent, treatment is necessary.
Such patients should be treated to the
same glycemic goals as patients with
known diabetes. (E)
● A hypoglycemia management protocol
should be adopted and implemented
by each hospital or hospital system. A
plan for treating hypoglycemia should
be established for each patient. Epi-
sodes of hypoglycemia in the hospital
should be documented in the medial
record and tracked. (E)
● All patients with diabetes admitted to
the hospital should have an A1C ob-
tained if the result of testing in the pre-
vious 2–3 months is not available. (E)
● Patientswithhyperglycemiainthehos-
pital who do not have a diagnosis of
diabetes should have appropriate plans
for follow-up testing and care docu-
mented at discharge. (E)
Hyperglycemia in the hospital is exten-
sively reviewed in an ADA technical re-
view (345). A recent updated consensus
statement by the American Association of
ClinicalEndocrinologists(AACE)andthe
ADA (346) forms the basis for the discus-
sion and guidelines in this section.
The literature on hospitalized pa-
tients with hyperglycemia typically de-
scribes three categories:
1. Medical history of diabetes: diabetes
has been previously diagnosed and ac-
knowledged by the patient’s treating
physician.
2. Unrecognized diabetes: hyperglycemia
(fasting blood glucose 126 mg/dl or
random blood glucose 200 mg/dl)
occurring during hospitalization and
conﬁrmedasdiabetesafterhospitaliza-
tion by standard diagnostic criteria but
unrecognized as diabetes by the treat-
ing physician during hospitalization.
3. Hospital-related hyperglycemia: hy-
perglycemia (fasting blood glucose
126 mg/dl or random blood glucose
200 mg/dl) occurring during the
hospitalization that reverts to normal
after hospital discharge.
The management of hyperglycemia in the
hospital has often been considered sec-
ondary in importance to the condition
that prompted admission (345). How-
ever, a body of literature now supports
targeted glucose control in the hospital
setting for potential improved clinical
outcomes. Hyperglycemia in the hospital
may result from stress, decompensation
of type 1 or type 2 or other forms of dia-
betes, and/or may be iatrogenic due to
withholding of anti-hyperglycemic medi-
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mia-provoking agents such as
glucocorticoids or vasopressors.
People with diabetes are more likely
to be hospitalized and to have longer
lengths of stay than those without diabe-
tes.Arecentsurveyestimatedthat22%of
all hospital inpatient days were incurred
by people with diabetes and that hospital
inpatient care accounted for half of the
$174 billion total U.S. medical expendi-
tures for this disease (347). This is due, in
part, to the continued expansion of the
worldwide epidemic of type 2 diabetes.
While the costs of illness-related stress
hyperglycemia are not known, they are
likely to be signiﬁcant given the poor
prognosis of such patients (348–351).
There is substantial observational ev-
idence linking hyperglycemia in hospital-
izedpatients(withorwithoutdiabetes)to
poor outcomes. Cohort studies as well as
a few early randomized controlled trials
(RCTs)suggestedthatintensivetreatment
of hyperglycemia improved hospital out-
comes (345,350,351). In general, these
studies were heterogeneous in terms of
patient population, blood glucose targets
and insulin protocols, provision of nutri-
tional support, and the proportion of pa-
tients receiving insulin, which limits the
ability to make meaningful comparisons
among them. Recent trials in critically ill
patients have failed to show a signiﬁcant
improvement in mortality with intensive
glycemic control (352,353) or have even
shown increased mortality risk (354).
Moreover, these recent RCTs have high-
lighted the risk of severe hypoglycemia
resulting from such efforts (352–357).
The largest study to date, NICE-
SUGAR, a multicenter, multinational
RCT,comparedtheeffectofintensivegly-
cemic control (target 81–108 mg/dl,
mean blood glucose attained 115 mg/dl)
tostandardglycemiccontrol(target144–
180 mg/dl, mean blood glucose attained
144 mg/dl) on outcomes among 6,104
critically ill participants, the majority of
whom (95%) required mechanical ven-
tilation (354). Ninety-day mortality was
signiﬁcantlyhigherintheintensiveversus
the conventional group (78 more deaths;
27.5% vs. 24.9%, P  0.02) in both sur-
gicalandmedicalpatients.Mortalityfrom
cardiovascular causes was more common
in the intensive group (76 more deaths;
41.6% vs. 35.8%; P  0.02). Severe hy-
poglycemiawasalsomorecommoninthe
intensively treated group (6.8% vs. 0.5%;
P  0.001). The precise reason for the
increased mortality in the tightly con-
trolled group is unknown. The results of
this study lie in stark contrast to a famous
2001 single-center study that reported a
42% relative reduction in intensive-care
unit (ICU) mortality in critically ill surgi-
cal patients treated to a target blood glu-
coseof80–110mg/dl(350).Importantly,
the control group in NICE-SUGAR had
reasonably good blood glucose manage-
mentmaintainedatameanglucoseof144
mg/dl, only 29 mg/dl above the inten-
sively managed patients. Accordingly,
this study’s ﬁndings do not disprove the
notion that glycemic control in the ICU is
important. However, they do strongly
suggest that it is not necessary to target
blood glucose values 140 mg/dl, and
that a highly stringent target of 110
mg/dl may actually be dangerous.
In a recent meta-analysis of 26 trials
(N  13,567), which included the NICE-
SUGARdata,thepooledrelativerisk(RR)
of death with intensive insulin therapy
was 0.93 as compared with conventional
therapy (95% CI 0.83–1.04) (357). Ap-
proximately half of these trials reported
hypoglycemia, with a pooled RR of inten-
sivetherapyof6.0(95%CI4.5–8.0).The
speciﬁc ICU setting inﬂuenced the ﬁnd-
ings, with patients in surgical ICUs ap-
pearing to beneﬁt from intensive insulin
therapy (RR 0.63 [95% CI 0.44–0.91]),
while those in other critical care settings
did not (medical ICU, RR 1.0 [95% CI
0.78–1.28]; “mixed” ICU, RR 0.99 [95%
CI 0.86–1.12]). It was concluded that
overall, intensive insulin therapy in-
creased the risk of hypoglycemia but pro-
vided no overall beneﬁt on mortality in
the critically ill, although a possible mor-
tality beneﬁt to patients admitted to the
surgical ICU (RR 0.63 [95% CI 0.44–
0.91]) was suggested.
1. Glycemic targets in hospitalized
patients
Deﬁnition of glucose abnormalities
in the hospital setting
Hyperglycemia has been deﬁned as any
blood glucose level 140 mg/dl (7.8
mmol/l). Levels that are signiﬁcantly and
persistently above this may require treat-
ment in hospitalized patients. In patients
without a previous diagnosis of diabetes,
elevated blood glucose may be due to
“stress hyperglycemia,” a condition that
can be established by a review of prior
records or measurement of an A1C. A1C
values 6.5% suggest that diabetes pre-
ceded hospitalization (358). Hypoglyce-
miahasbeendeﬁnedasanybloodglucose
level 70 mg/dl (3.9 mmol/l). This is the
standard deﬁnition in outpatients and
correlateswiththeinitialthresholdforthe
release of counterregulatory hormones.
Severe hypoglycemia in hospitalized pa-
tients has been deﬁned by many as 40
mg/dl(2.2mmol/l),althoughthisislower
than the 50 mg/dl (2.8 mmol/l) level at
which cognitive impairment begins in
normal individuals (359). As with hyper-
glycemia, hypoglycemia among inpa-
tients is also associated with adverse
short-andlong-termoutcomes.Earlyrec-
ognition and treatment of mild to moder-
ate hypoglycemia (40 and 69 mg/dl) (2.2
and 3.8 mmol/l) can prevent deteriora-
tion to a more severe episode with poten-
tial adverse sequelae (346).
Critically ill patients
Based on the weight of the available evi-
dence, for the majority of critically ill pa-
tients in the ICU setting, insulin infusion
should be used to control hyperglycemia,
withastartingthresholdofnohigherthan
180 mg/dl (10.0 mmol/l). Once intrave-
nous insulin is started, the glucose level
should be maintained between 140 and
180mg/dl(7.8and10.0mmol/l).Greater
beneﬁt maybe realized at the lower end of
this range. Although strong evidence is
lacking, somewhat lower glucose targets
may be appropriate in selected patients.
However,targetslessthan110mg/dl(6.1
mmol/l) are not recommended. Use of in-
sulin infusion protocols with demon-
strated safety and efﬁcacy, resulting in
low rates of hypoglycemia, are highly rec-
ommended (346).
Noncritically ill patients
With no prospective RCT data to inform
speciﬁc glycemic targets in noncritically
ill patients, recommendations are based
on clinical experience and judgment. For
the majority of noncritically ill patients
treated with insulin, premeal glucose tar-
getsshouldgenerallybe140mg/dl(7.8
mmol/l) with random blood glucose lev-
els 180 mg/dl (10.0 mmol/l), as long as
these targets can be safely achieved. To
avoid hypoglycemia, consideration
should be given to reassessing the insulin
regimen if blood glucose levels fall below
100 mg/dl (5.6 mmol/l). Modiﬁcation of
the regimen is required when blood glu-
cose values are 70 mg/dl (3.9 mmol/l),
unless the event is easily explained by
other factors (such as a missed meal, etc.)
Occasional patients with a prior his-
toryofsuccessfultightglycemiccontrolin
the outpatient setting who are clinically
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range below the above cut points. Con-
versely, higher glucose ranges may be ac-
ceptable in terminally ill patients or in
patients with severe comorbidities, as
well as in those in patient-care settings
where frequent glucose monitoring or
close nursing supervision is not feasible.
Clinical judgment, combined with
ongoing assessment of the patient’s clini-
calstatus,includingchangesinthetrajec-
tory of glucose measures, the severity of
illness, nutritional status, or concurrent
use of medications that might affect glu-
cose levels (e.g., steroids, octreotide)
must be incorporated into the day-to-day
decisions regarding insulin dosing (346).
2. Anti-hyperglycemic agents in
hospitalized patients
In the hospital setting, insulin therapy is
the preferred method of glycemic control
in majority of clinical situations (346). In
the ICU, intravenous infusion is the pre-
ferred route of insulin administration.
When the patient is transitioned off intra-
venous insulin to subcutaneous therapy,
precautions should be taken to prevent
hyperglycemiaescape(360,361).Outside
of critical care units, scheduled subcuta-
neous insulin which delivers basal, nutri-
tional, and correction (supplemental)
components is preferred. Prolonged ther-
apy with sliding scale insulin (SSI) as the
sole regimen is ineffective in the majority
of patients, increases risk of both hypo-
glycemia and hyperglycemia, and has re-
cently been shown to be associated with
adverse outcomes in general surgery pa-
tients with type 2 diabetes (362). SSI is
potentially dangerous in type 1 diabetes
(346). The reader is referred to several
recent publications and reviews that de-
scribecurrentlyavailableinsulinprepara-
tions and protocols and provide guidance
in use of insulin therapy in speciﬁc clini-
cal settings including parenteral nutrition
(363), enteral tube feedings, and with
high-dose glucocorticoid therapy (346).
There are no data on the safety and
efﬁcacy of oral agents and injectable non-
insulin therapies such as GLP1 analogs
and pramlintide in the hospital. They are
generallyconsideredtohavealimitedrole
in the management of hyperglycemia in
conjunction with acute illness. Continua-
tionoftheseagentsmaybeappropriatein
selected stable patients who are expected
to consume meals at regular intervals and
theymaybeinitiatedorresumedinantic-
ipation of discharge once the patient is
clinically stable. Speciﬁc caution is re-
quired with metformin, due to the possi-
bilitythatacontraindicationmaydevelop
during the hospitalization, such as renal
insufﬁciency,unstablehemodynamicsta-
tus, or need for an imaging study that re-
quires a radio-contrast dye.
3. Preventing hypoglycemia
Hypoglycemia, especially in insulin-
treated patients, is the leading limiting
factor in the glycemic management of
type 1 and type 2 diabetes (173). In the
hospital, multiple additional risk factors
for hypoglycemia are present. Patients
with or without diabetes may experience
hypoglycemia in the hospital in associa-
tion with altered nutritional state, heart
failure, renal or liver disease, malignancy,
infection, or sepsis. Additional triggering
eventsleadingtoiatrogenichypoglycemia
include sudden reduction of corticoste-
roid dose, altered ability of the patient to
report symptoms, reduction of oral in-
take, emesis, new NPO status, inappro-
priate timing of short- or rapid-acting
insulin in relation to meals, reduction of
rate of administration of intravenous dex-
trose, and unexpected interruption of en-
teral feedings or parenteral nutrition.
Despite the preventable nature of
many inpatient episodes of hypoglyce-
mia, institutions are more likely to have
nursing protocols for the treatment of hy-
poglycemia than for its prevention.
Tracking such episodes and analyzing
their causes are important quality im-
provement activities (346).
4. Diabetes care providers in the
hospital
Inpatient diabetes management may be
effectively championed and/or provided
by primary care physicians, endocrinolo-
gists, intensivists, or hospitalists. Involve-
ment of appropriately trained specialists
or specialty teams may reduce length of
stay, improve glycemic control, and im-
prove outcomes (346). In the care of dia-
betes, implementation of standardized
order sets for scheduled and correction-
dose insulin may reduce reliance on slid-
ing-scalemanagement.Ashospitalsmove
to comply with “meaningful use” regula-
tions for electronic health records, as
mandated by the Health Information
Technology Act, efforts should be made to
assurethatallcomponentsofstructuredin-
sulin order sets are incorporated into elec-
tronic insulin order sets (364,365).
A team approach is needed to estab-
lish hospital pathways. To achieve glyce-
mic targets associated with improved
hospital outcomes, hospitals will need
multidisciplinary support to develop in-
sulin management protocols that effec-
tively and safely enable achievement of
glycemic targets (366).
5. Self-management in the hospital
Self-management of diabetes in the hos-
pital may be appropriate for competent
adult patients who: have a stable level of
consciousness, have reasonably stable
daily insulin requirements, successfully
conduct self-management of diabetes at
home, have physical skills needed to suc-
cessfully self-administer insulin and per-
form SMBG, have adequate oral intake,
and are proﬁcient in carbohydrate count-
ing, use of multiple daily insulin injec-
tions or insulin pump therapy, and sick-
day management. The patient and
physician, in consultation with nursing
staff, must agree that patient self-
management is appropriate under the
conditions of hospitalization.
Patients who use CSII pump therapy
intheoutpatientsettingcanbecandidates
for diabetes self-management in the hos-
pital, provided that they have the mental
and physical capacity to do so (346). A
hospital policy and procedures delineat-
ing inpatient guidelines for CSII pump
therapy are advisable. The availability of
hospital personnel with expertise in CSII
therapy is essential. It is important that
nursing personnel document basal rates
and bolus doses taken on a regular basis
(at least daily).
6. DSME in the hospital
Teaching diabetes self-management to
patients in hospitals is a challenging task.
Patients are ill, under increased stress re-
lated to their hospitalization and diagno-
sis, and in an environment not conducive
to learning. Ideally, people with diabetes
should be taught at a time and place con-
ducive to learning—as an outpatient in a
recognized program of diabetes educa-
tion.
For the hospitalized patient, diabetes
“survival skills” education is generally a
feasible approach. Patients and/or family
members receive sufﬁcient information
and training to enable safe care at home.
Those newly diagnosed with diabetes or
who are new to insulin and/or blood glu-
cose monitoring need to be instructed
beforedischarge.Thosepatientshospital-
ized because of a crisis related to diabetes
management or poor care at home need
educationtopreventsubsequentepisodes
of hospitalization. An assessment of the
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to an outpatient diabetes education pro-
gram should be part of discharge plan-
ning for all patients.
7. MNT in the hospital
The goals of MNT are to optimize glyce-
mic control, to provide adequate calories
to meet metabolic demands, and to create
a discharge plan for follow-up care
(345,367). ADA does not endorse any
single meal plan or speciﬁed percentages
of macronutrients, and the term “ADA
diet” should no longer be used. Current
nutrition recommendations advise indi-
vidualization based on treatment goals,
physiologic parameters, and medication
usage. Consistent carbohydrate meal
plans are preferred by many hospitals
sincetheyfacilitatematchingtheprandial
insulin dose to the amount of carbohy-
drate consumed (368). Because of the
complexity of nutrition issues in the hos-
pital, a registered dietitian, knowledge-
able and skilled in MNT, should serve as
an inpatient team member. The dietitian
is responsible for integrating information
about the patient’s clinical condition, eat-
ing, and lifestyle habits and for establish-
ing treatment goals in order to determine
a realistic plan for nutrition therapy
(369,370).
8. Bedside blood glucose monitoring
Point-of-care (POC) blood glucose moni-
toring performed at the bedside is used to
guideinsulindosing.Inthepatientwhois
receiving nutrition, the timing of glucose
monitoring should match carbohydrate
exposure.Inthepatientwhoisnotreceiv-
ing nutrition, glucose monitoring is per-
formed every 4 to 6 h (371,372). More
frequent blood glucose testing ranging
fromevery30mintoevery2hisrequired
for patients on intravenous insulin infu-
sions.
Safety standards should be estab-
lished for blood glucose monitoring, pro-
hibiting sharing of ﬁngerstick lancing
devices,lancets,andneedlestoreducethe
risk of transmission of blood borne dis-
eases. Shared lancing devices carry essen-
tially the same risk as shared syringes and
needles (373).
Accuracy of blood glucose measure-
ments using POC meters has limitations
that must be considered. Although the
FDA allows a 20% error for blood glu-
cose meters, questions about the appro-
priateness of these criteria have been
raised (388). Glucose measures differ sig-
niﬁcantly between plasma and whole
blood, terms that are often used inter-
changeably and can lead to misinterpre-
tation. Most commercially available
capillary blood glucose meters introduce
a correction factor of 1.12 to report a
“plasma adjusted” value (374).
Signiﬁcant discrepancies between
capillary, venous, and arterial plasma
samples have been observed in patients
with low or high hemoglobin concentra-
tions, hypoperfusion, and the presence of
interfering substances particularly mal-
tose, as contained in immunoglobulins
(375). Analytical variability has been de-
scribed with several POC meters (376).
Increasingly, newer generation POC
blood glucose meters correct for variation
in hematocrit and for interfering sub-
stances. Any glucose result that does not
correlate with the patient’s status should
be conﬁrmed through conventional labo-
ratory sampling of plasma glucose. The
FDA has become increasingly concerned
about the use of POC blood glucose
meters in the hospital and is presently re-
viewing matters related to their use.
9. Discharge planning
Transition from the acute care setting is a
high-risk time for all patients, not just
those with diabetes or new hyperglyce-
mia. Although there is an extensive liter-
ature concerning safe transition within
andfromthehospital,littleofitisspeciﬁc
to diabetes (377). It is important to re-
member that diabetes discharge planning
is not a separate entity, but part of an
overalldischargeplan.Assuch,discharge
planning begins at admission to the hos-
pital and is updated as projected patient
needs change.
Inpatients may be discharged to var-
ied settings, including home (with or
without visiting nurse services), assisted
living, rehabilitation, or skilled nursing
facilities. The latter two sites are generally
staffed by health professionals; therefore
diabetes discharge planning will be lim-
ited to communication of medication and
diet orders. For the patient who is dis-
charged to assisted living or to home, the
optimalprogramwillneedtoconsiderthe
typeandseverityofdiabetes,theeffectsof
the patient’s illness on blood glucose lev-
els, and the capacities and desires of the
patient. Smooth transition to outpatient
care should be ensured. The Agency for
Healthcare Research and Quality recom-
mends that at a minimum, discharge
plans include:
● Medication reconciliation: The pa-
tient’s medications must be cross-
checked to ensure that no chronic
medications were stopped and to en-
sure the safety of new prescriptions.
Whenever possible, prescriptions for
new or changed medication should be
ﬁlledandreviewedwiththepatientand
family at or before discharge
● Structured discharge communication:
Information on medication changes,
pending tests and studies, and fol-
low-up needs must be accurately and
promptly communicated to outpatient
physicians,assoonaspossibleafterdis-
charge.
Ideally the inpatient care providers or
case managers/discharge planners will
schedule follow-up visit(s) with the ap-
propriate professionals, including pri-
mary care provider, endocrinologist, and
diabetes educator (378).
Anoutpatientfollow-upvisitwiththe
primary care provider, endocrinologist,
or diabetes educator within 1 month of
dischargeisadvisedforallpatientshaving
hyperglycemiainthehospital.Clearcom-
munication with outpatient providers ei-
ther directly or via hospital discharge
summaries facilitates safe transitions to
outpatientcare.Providinginformationre-
garding the cause or the plan for deter-
mining the cause of hyperglycemia,
related complications and comorbidities,
and recommended treatments can assist
outpatient providers as they assume on-
going care.
It is important that patients be pro-
vided with appropriate durable medical
equipment, medication, supplies, and
prescriptions at the time of discharge in
order to avoid a potentially dangerous hi-
atus in care. These supplies/prescriptions
should include:
● Insulin (vials or pens) (if needed)
● Syringes or pen needles (if needed)
● Oral medications (if needed)
● Blood glucose meter and strips
● Lancets and lancing device
● Urine ketone strips (type 1)
● Glucagon emergency kit (insulin-
treated)
● Medical alert application/charm
IX. STRATEGIES FOR
IMPROVING DIABETES
CARE— There has been steady im-
provement in the proportion of diabetic
patientsachievingrecommendedlevelsof
A1C,bloodpressure,andLDLcholesterol
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settings and in endocrinology practices.
Mean A1C nationally has declined from
7.82% in 1999–2000 to 7.18% in 2004
based on National Health and Nutrition
Examination Survey (NHANES) data
(379). This has been accompanied by im-
provements in lipids and blood pressure
control and led to substantial reductions
in end-stage microvascular complications
in those with diabetes (380). Neverthe-
less, in some studies only 57.1% of adults
with diagnosed diabetes achieved an A1C
of7%,only45.5%hadabloodpressure
130/80 mmHg, and just 46.5% had a
total cholesterol 200 mg/dl, with only
12.2% of people with diabetes achieving
allthreetreatmentgoals(381).Moreover,
there is persistent variation in quality of
diabetes care across providers and across
practice settings even after adjusting for
patient factors that indicates the potential
for substantial further improvements in
diabetes care.
While numerous interventions to im-
prove adherence to the recommended
standards have been implemented, a ma-
jor contributor to suboptimal care is a de-
liverysystemthattoooftenisfragmented,
lacks clinical information capabilities, of-
ten duplicates services, and is poorly de-
signed for the delivery of chronic care.
The Chronic Care Model (CCM) includes
six core elements for the provision of op-
timal care of patients with chronic dis-
ease: 1) delivery system design (moving
from a reactive to a proactive care delivery
system, where planned visits are coordi-
nated through a team-based approach; 2)
self-management support; 3) decision
support (basing care on consistent, effec-
tive care guidelines); 4) clinical informa-
tion systems (using registries that can
provide patient-speciﬁc and population-
based support to the care team); 5)
community resources and policies (iden-
tifyingordevelopingresourcestosupport
healthy lifestyles); and 6) health systems
(to create a quality-oriented culture). Al-
terations in reimbursement that reward
theprovisionofqualitycare,asdeﬁnedby
the attainment of evidence-based quality
measures, will also be required to achieve
desiredoutcomegoals.Redeﬁnitionofthe
rolesoftheclinicstaffandpromotingself-
managementonthepartofthepatientare
fundamental to the successful implemen-
tation of the CCM (382). Collaborative,
multidisciplinary teams are best suited to
providesuchcareforpeoplewithchronic
conditions like diabetes and to facilitate
patients’ performance of appropriate self-
management.
A rapidly evolving literature suggests
that there are three major strategies to
successfully improve the quality of diabe-
tes care delivered by a team of providers.
NDEP maintains an online resource
(www.betterdiabetescare.nih.gov)tohelp
health care professionals design and im-
plement more effective health care deliv-
ery systems for those with diabetes.
Three speciﬁc objectives, with refer-
ences to literature that outlines practical
strategiestoachieveeach,areoutlinedbe-
low.
Objective 1
Provider and team behavior change: Fa-
cilitatetimelyandappropriateintensiﬁca-
tion of lifestyle and/or pharmaceutical
therapyofpatientswhohavenotachieved
beneﬁcial levels of blood pressure, lipid,
or glucose control.
● Clinical information systems including
registries that can prospectively iden-
tify and track those requiring assess-
ments and/or treatment modiﬁcations
by the team.
● Electronic medical record-based clini-
caldecisionsupportatthepointofcare,
both personalize and standardize care
and can be used by multiple providers
(383).
● Useofchecklistsand/orﬂowsheetsthat
mirror guidelines.
● Detailed treatment algorithms enabling
multiple team members to “treat to tar-
get” and appropriately intensify ther-
apy.
● Availability of care or disease manage-
mentservices(384)bynurses,pharma-
cists, and other providers using
detailed algorithms often catalyzing re-
duction in A1C, blood pressure, and
LDL cholesterol (385,386).
Objective 2
Patient behavior change: Implement a
systematic approach to support patients’
behavior change efforts as needed includ-
ing 1) healthy lifestyle (physical activity,
healthy eating, nonuse of tobacco, weight
management, effective coping, medica-
tion taking and management); 2) preven-
tion of diabetes complications (screening
foreye,foot,andrenalcomplications;im-
munizations); and 3) achievement of ap-
propriate blood pressure, lipid, and
glucose goals.
● Delivery of high-quality DSME, which
hasbeenshowntoimprovepatientself-
management, satisfaction, and glucose
control (115,387).
● Delivery of ongoing diabetes self-
managementsupport(DSMS)toensure
that gains achieved during DSME are
sustained (128–129). National DSME
standards call for an integrated ap-
proach that includes clinical content
and skills, behavioral strategies (goal-
setting, problem solving), and address-
ing emotional concerns in each needed
curriculum content area. Provision of
continuing education and support
(DSMS)improvesmaintenanceofgains
regardlessoftheeducationalmethodol-
ogy (89).
● Provision of automated reminders via
multiple communication channels to
various subgroups of diabetic patients
(96).
Objective 3
Change the system of care: Research on
the comprehensive CCM suggests addi-
tional strategies to improve diabetes care,
including the following:
● Basing care on consistent, evidence-
based care guidelines
● Redeﬁning and expanding the roles of
the clinic staff (382)
● Collaborative, multidisciplinary teams
to provide high-quality care and sup-
port patients’ appropriate self-
management
● Audit and feedback of process and out-
come data to providers to encourage
population-based care improvement
strategies
● Care management, one of the most ef-
fective diabetes quality improvement
strategies to improve glycemic control
(384).
● Identifying and/or developing commu-
nity resources and public policy that
support healthy lifestyles
● Alterations in reimbursement that re-
ward the provision of appropriate and
high-qualitycareandaccommodatethe
need to personalize care goals, provid-
ingadditionalincentivestoimprovedi-
abetes care (382,388–392)
The most successful practices have an in-
stitutional priority for quality of care, ex-
panding the role of teams and staff,
redesigning their delivery system, activat-
ing and educating their patients, and us-
ing electronic health record tools
(393,394). Recent initiatives such as the
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promise in improving outcomes through
coordinated primary care and offer new
opportunitiesforteam-basedchronicdis-
ease care (395).
It is clear that optimal diabetes man-
agement requires an organized, system-
atic approach and involvement of a
coordinatedteamofdedicatedhealthcare
professionals working in an environment
where patient-centered high-quality care
is a priority.
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